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ABSTRACT 
 
 Aging affects the reproductive efficiency of females. In rodent models, injection 
of mesenchymal stem cells (MSCs) improves function and induces trophic mRNA 
expression in ovaries compromised by chemotherapy. However, little information is 
available on the effect of MSCs in the aging ovary, an application which if effective in 
increasing fertility, would have an impact in both human and equine reproduction. The 
aim of the research outlined in this dissertation was to investigate this area. We 
hypothesized that injection of MSCs into the ovaries of old mares would increase follicle 
numbers and increase expression of genes related to follicle growth. We examined for 
the first time the use of fluorescent quantum dots (QDs) to label equine MSCs, to see if 
this would allow them to be tracked after injection. We found that QD-labeled MSCs 
retain their ability to proliferate and differentiate. The QDs were maintained in MSCs 
induced to differentiate into chondrocytes (non-proliferating), but the percentage of 
labeled cells and the fluorescence intensity decreased to essentially non-detectable 
within 3 to 5 days in rapidly proliferating cells. Co-culture of equine ovarian tissue with 
MSCs was not effective due to tissue degradation in culture; however, we used this trial 
to develop effective methods for isolation of RNA from the extremely fibrous equine 
ovarian tissue. In a preliminary study on intra-ovarian MSC injection, there was an 
apparent increase in follicle numbers 4 weeks after injection in 2 randomly-selected 
young mares. Based on these results, a more comprehensive study was performed on old 
and young mares to determine if MSC injection affects ovarian function. There was no 
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significant increase in follicle numbers after MSC injection in either old or young mares, 
nor was there an increase in serum levels of anti-Müllerian hormone, a marker for 
numbers of growing follicles. Results of RNA sequencing of ovarian tissue showed that 
injection of MSCs in old mares was associated with a minor increase in gene expression 
of factors that might relate to ovarian function.  
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CHAPTER I 
 INTRODUCTION  
 
 Aging affects female reproductive efficiency. While neuroendocrine and uterine 
and/or oviductal factors may affect fertility, a decrease in oocyte quality and exhaustion 
of ovarian follicle stores are the major causes of age-related reproductive failure [1]. 
This is especially relevant to human medicine as each year millions of women undergo 
fertility treatments due to age-related loss of fertility. In women, ovarian senescence 
begins as early as 31 to 35 yr of age; the proportion of women who remain fertile rapidly 
declines afterward, from 50% at age 40, to 15% by age 45 [2].  
 The mare may serve as an excellent model for reproductive aging. In mares, 
reproductive senescence begins around 20 yr of age, and it is estimated that only 37% of 
mares older than 24 yr of age display any ovarian activity [3]. Most research on 
reproductive aging has been performed with rodent models, which have ovarian function 
and senescence timelines that differ in many aspects from that in women.  
 Each year millions of women are rendered sterile by chemotherapy-associated 
oocyte loss. Interestingly, there have been reports showing an unexpected return of 
ovarian function and fertility after chemotherapy in women who underwent bone 
marrow transplantation as a component of their therapy [4-7]. Several animal studies 
have been conducted to try to explain this phenomenon. Studies performed on mice, rats 
and rabbits indicate that systemic or intra-ovarian injection of bone marrow-derived 
mesenchymal stem cells (MSCs) increases ovarian follicle numbers and induces mRNA 
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and protein expression of genes that may improve the function of ovaries compromised 
by chemotherapy [8-14]. However, little information is available on the effect of MSC 
injection on the aging ovary, an understanding of which would have a potential impact 
on millions of women undergoing assisted reproduction because of age-related 
infertility. Furthermore, considerable interest exists in the equine industry to establish 
pregnancies from older, valuable mares. Thus, the mare offers a useful model to explore 
the possibility that bone marrow-derived MSCs could restore ovarian function in aging 
females. 
 The studies in this dissertation aim to determine 1) the effects of intra-ovarian 
injections of bone marrow-derived MSCs on the ovarian function of old and young 
mares; 2) if MSCs persist in the ovaries after injection, and 3) the effects of bone 
marrow-derived MSCs on equine ovarian gene expression.  
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CHAPTER II 
 LITERATURE REVIEW  
 
DEVELOPMENT OF THE OOCYTE AND FOLLICLE AND FACTORS 
AFFECTING OOCYTE QUALITY 
Introduction 
 Normal fertility depends on complex biological processes including the 
production of gametes, the fertilization process, the initial growth of the embryo, the 
transition from embryo to fetus, and the growth of the fetus. Aging affects female 
reproductive efficiency [1, 15, 16]. Ovarian aging in women is characterized by a 
reduction in follicle and oocyte numbers, failure of follicular growth, and a decrease in 
oocyte developmental competency [16, 17]. While there are neuroendocrine and uterine 
and/or oviductal factors that affect fertility, the decrease in oocyte quality and exhaustion 
of ovarian follicle stores appear to be the major causes of age-related reproductive 
failure. This has been clearly demonstrated by the ability of women well past 
reproductive age to become pregnant and carry successfully to term when embryos 
produced from young donor oocytes are transferred to their uteri [17-20]. Similarly, in 
mares, oocytes from young donors transferred to the oviducts of inseminated recipients 
have higher developmental rates than those from old donors, suggesting that oocytes 
from old mares have lower or impaired developmental competence [21].  
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Folliculogenesis and Follicle Number 
 In mammals, oocyte precursors are produced during embryogenesis. Primordial 
germ cells arise extra-gonadally and migrate from the yolk sac through the hindgut 
endoderm up the dorsal mesentery and into the genital ridges where, after undergoing 
several mitotic divisions, they form oogonia, the population of cells from which all 
future gametes will arise. Oogonia resulting from the rapid mitotic proliferation of 
primordial germ cells become primary oocytes when they enter prophase of meiosis; 
thereafter they are incapable of further mitotic division. Meiosis begins between late 
intra-uterine and early post-natal life, the timing varying among species. At the time the 
primary oocytes become arrested in prophase of the first meiotic division they are 
enclosed by pre-granulosa cells to form primordial follicles [15, 22]. This meiotic arrest 
lasts the lifetime of the oocyte, except in those rare oocytes destined to ovulate. Follicles 
grow in pre-pubertal females; however, no nuclear progression occurs in oocytes until 
they are in antral follicles stimulated by the preovulatory LH surge. Thus, since women 
can ovulate into their fifties, the oocytes ovulated at that time remained arrested for 50 yr 
or more at the same stage of meiosis that they entered before birth.  
 In female rats, the total population of germ cells peaks 4 days before birth (i.e. 
the 18th day of gestation) and rapidly declines so that only about 30% of germ cells 
(now oogonia) survive to 2 days after birth [23]. In humans, it is estimated that by 20 
weeks of gestation each fetal ovary contains 5 to 7 million primordial follicles and this 
number decreases to about 1 million at birth [22]. The rise in the population of germ 
cells is associated with high mitotic activity whereas the subsequent decline is due to the 
 5 
 
spontaneous degeneration (i.e., apoptosis) of germ cells, especially of oogonia that do 
not become surrounded by follicle cells. Germ cell apoptosis is regulated by opposing 
functions of members of the B-cell lymphoma/leukemia (BCL) protein family [24]. The 
BCL2 and BCLX proteins are antiapoptotic, whereas BAX promotes cell death. In mice, 
deletion of BCL2 results in fewer oocytes and primordial follicles, but no differences in 
the number of primary and preantral follicles [25], whereas loss of BAX increases the 
number of germ cells [26].  The involvement of caspases (proteases that upon activation 
cleave cellular proteins leading to apoptosis) in follicle atresia was shown by targeted 
disruption of the caspase 2 gene (Casp2); loss of Casp2 results in significantly more 
primordial follicles and resistance to the chemotherapeutic agent doxorubicin in mice 
[27]. Thus, during fetal development and in the perinatal period, apoptosis is important 
in reducing the primordial follicle pool.  
 Between birth and puberty, there is continued recruitment of follicles from the 
primordial pool, but all growing follicles undergo atresia due to lack of gonadotropin 
support. Because of this, in humans the numbers of primordial follicles decline to about 
25% of the numbers at birth during the years before puberty [15, 16]. After puberty, 
those follicles that leave the primordial pool but do not reach ovulatory maturity (the 
majority of follicles that leave the pool), estimated to be around 400 follicles for each 
one that ovulates [28], undergo atresia. Because of both pre-pubertal loss and loss of the 
vast majority of follicles leaving the primordial pool after puberty, fewer than 0.1% of 
the oocytes present at birth will actually be ovulated during a woman’s reproductive life 
[29].  
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 In mammals, granulosa cells are the major cell type of the follicle, and they 
undergo apoptosis during atresia. Evaluation of apoptosis using the TUNEL 
histochemical assay or DNA laddering in atretic follicles of pig [30, 31], rat [32, 33], 
human [34], horse [35], and sheep [36] ovaries revealed DNA fragmentation and ladder 
formation in granulosa cells, indicating that apoptosis is involved in follicular atresia. 
There is an inevitable decline in the numbers of oocytes with age because the numbers of 
oocytes within the ovary are fixed at birth; once the oogonia have committed to meiosis, 
there is no mechanism for producing more of them [22]. Recently, the dogma of a non-
renewable pool of primordial follicles that declines with age has been challenged by a 
claim that neo-oogenesis from female germline stem cells (“oogonial stem cells”) 
present in the ovarian surface epithelium can occur in the adult ovary of mice [14]; this 
will be discussed more thoroughly below. 
 Follicle recruitment is the process by which a primordial follicle makes an 
irreversible commitment to growth. Once this process has started, follicle growth 
continues until the follicle undergoes atresia or, in a minority of cases, ovulates. Many 
follicles are recruited each month but only one reaches ovulatory maturity in 
monoovulatory species. In women, follicles are recruited continuously until the original 
store is exhausted, shortly after menopause. The number of follicles that begin growing 
each day depends on the number of primordial follicles remaining in the ovary and, 
therefore, decreases with age [22].   
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Primordial Follicle Recruitment and Activation 
 Although the trigger and molecular mechanisms that promote growth in some 
follicles while the rest remain in primordial stage is unclear in humans, studies using 
genetically-modified mouse models have identified signaling pathways and transcription 
factors involved in the regulation of follicular activation (i.e., transition from primordial 
to primary follicle) and survival. Mice with mutations at the white spotting (Kit) or steel 
loci (Kit ligand) lack germ cells in their gonads [37-39]. Interactions between Kit ligand 
and the KIT tyrosine receptor appear to be critical in early folliculogenesis. During 
postnatal ovarian development, Kit is expressed in oocytes and Kit ligand is expressed in 
pre-granulosa and granulosa cells throughout folliculogenesis [40-44]. Kit/Kit ligand 
interactions have been implicated during follicular growth from the primordial pool. 
Newborn mice injected with an antibody to Kit (ACK2) that blocks its interaction with 
Kit ligand exhibit restricted progression of primordial follicles to primary follicles [44]. 
Conversely, treatment of neonatal rat ovaries with recombinant Kit ligand accelerates 
follicular activation, resulting in an increased number of growing follicles [45]. 
Although these studies suggest that Kit signaling is necessary during follicular 
development and follicular activation, the mechanisms by which Kit signaling 
contributes to the primordial-to-primary transition are not entirely known; however, 
there is evidence suggesting that the Kit/Kit ligand pathway induces the PI3K 
(phosphatidylinositol 3-kinase)/AKT (protein kinase B) pathway, leading to 
phosphorylation and thus inactivation of forkhead box O3 (Foxo3), an inhibitor of 
primordial follicle activation [46]. The conversion of the membrane phospholipid PIP2 
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(phosphatidylinositol 4,5-bisphosphate) to the second messenger PIP3 
(phosphatidylinositol 3,4,5-trisphosphate) is catalyzed by PI3K, which leads to AKT 
activation. Foxo3 is a member of the FOXO subfamily of forkhead transcription factors, 
which are downstream targets of AKT; activation of AKT phosphorylates and 
functionally suppresses FOXO transcription factors by causing their nuclear exclusion 
[46]. When mouse or rat oocytes are treated with Kit ligand, Foxo3 is phosphorylated in 
a PI3K/AKT-dependent manner; treatment with a PI3K inhibitor prevents AKT 
activation and subsequent Foxo3 phosphorylation [47].  
 Additional genetic studies support a critical role for the PI3K/AKT pathway in 
regulation of Foxo3. Oocyte-specific deletion of Pten (phosphatase and tensin homolog 
deleted on chromosome 10), which opposes the actions of PI3K by converting PIP3 to 
PIP2, causes premature activation of primordial follicles, with an ovarian phenotype 
nearly identical to Foxo3 deletion (i.e., enlarged ovaries, marked increase in growing 
and atretic follicles, and absence of primordial follicles) [48-50]. Loss of Pten in oocytes 
results in enhanced PI3K activity, AKT hyperactivation, and functional suppression of 
FOXO3 secondary to hyperphosphorylation, resulting in follicle activation. Concurrent 
loss of Pten and Foxo3 in oocytes does not have a synergistic effect on follicle 
activation, indicating that phosphorylation of FOXO3 is the main regulator of its activity 
[50]. The PI3K inhibitor LY294002 suppressed primordial follicle activation in ovaries 
with Pten-deficient oocytes but had no effect in Foxo3 null mutant ovaries, suggesting a 
linear PTEN-PI3K-AKT-FOXO3 pathway [49]. It is unknown whether Kit is an 
upstream modulator of this pathway in vivo, or at least one of the many receptor tyrosine 
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kinases that might initiate this signaling cascade to promote primordial follicle 
recruitment; however, in female mice with a mutated KIT receptor that prevents 
activation of PI3K, folliculogenesis is impeded beyond the primary stages of 
development [51], similar to mice with constitutively active Foxo3, which are infertile 
due to impeded follicular development beyond primary follicles [52]. The mechanisms 
by which nuclear Foxo3 prevents primordial follicle activation and arrest at the primary 
follicle stage remain unknown [53].   
 Whereas Foxo3 is the key oocyte factor critical for suppressing primordial 
follicle activation, forkhead box L2 (Foxl2), another forkhead domain transcription 
factor, is crucial in maintaining granulosa cell identity through the repression of testis-
specific genes [54]. Foxl2 also has a role in modulating the transition from squamous to 
cuboidal granulosa cells that occurs during the primordial-to-primary follicle transition. 
Non-functional mutations in Foxl2 cause type I blepharophimosis/ptosis/epicanthus 
inversus syndrome (BPES) which is associated with premature ovarian failure. In the 
ovary, Foxl2 is expressed in pre-granulosa cells surrounding primordial follicles, and in 
granulosa cells throughout folliculogenesis. Foxl2 knock-out mice form primordial 
follicles, but differentiation of granulosa cells from the squamous to cuboidal state is 
blocked, and granulosa cell proliferation is interrupted [55, 56]. Unexpectedly, however, 
at 2 weeks of age, most primordial follicles are activated in the ovaries of Foxl2 knock-
out mice, as demonstrated by expression of transforming growth factor beta family 
member (TGFβ) Gdf9 (growth differentiation factor 9), a marker of oocyte activation. 
This activation is accompanied by widespread follicular atresia and a near absence of 
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primordial follicles by 8 weeks of age because the defective granulosa cells fail to 
progress along the follicular growth pathway and fail to support growing oocytes [55].  
 As noted above, Gdf9 is a member of the TGFβ family associated with oocyte 
activation; however, another TGFβ family member, AMH (anti-Müllerian hormone), 
produced by granulosa cells of growing follicles, appears to suppress primordial follicle 
recruitment. In the rodent and human ovary, AMH and its type II receptor, AMHR2, are 
expressed in granulosa cells of primary and growing pre-antral follicles; type II receptors 
phosphorylate and activate type I receptors, which then bind and activate transcriptional 
regulators [57]. Although female mice lacking AMH are fertile, juveniles show an 
increase in growing follicles, and by 4 months this increase is reflected in a reduction of 
primordial follicles compared to wild-type litter-mates. By 13 months of age, AMH 
knock-out females have few remaining primordial follicles [58]. These in vivo findings 
are supported by in vitro studies showing that neonatal ovaries cultured in the presence 
of recombinant AMH show fewer growing follicles [59]. Thus, AMH appears to inhibit 
the recruitment of primordial follicles, and in its absence, there is a faster depletion of 
primordial follicles [58, 59]. The mechanism by which AMH inhibits primordial follicle 
recruitment has not been elucidated [60]. Although no information is available that 
clearly demonstrates AMH type II receptor expression in primordial follicles, a direct 
effect of AMH on the primordial follicles themselves cannot be excluded. Alternatively, 
the primary action of AMH may be autocrine in nature, as granulosa cells of small 
follicles express both AMH and its type II receptor. The small follicles may be 
stimulated by AMH to produce factors that act on the primordial follicles [58]. Since 
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AMH null mice have low levels of FSH (follicle-stimulating hormone), and yet greater 
numbers of growing follicles, it has also been hypothesized that follicles are more 
sensitive to FSH in the absence of AMH. The possible inhibitory effect of AMH on 
follicular sensitivity could play a role in the process of follicular selection. Diminished 
expression of AMH within the growing follicles would reduce the threshold level for 
FSH, allowing follicles to continue growing and to ovulate in the next cycle. Another 
theory suggests a role of AMH in modulating the function of FSH; treatment with AMH 
decreases FSH-stimulated aromatase expression in human granulosa cells [61, 62] and 
decreases FSH receptor expression [62], thus showing a relevant effect of AMH in 
modulating ovarian follicular responses to gonadotropins.  
   The heterodimeric complex made by TSC1 and TSC2 (tuberous sclerosis 
complex 1 and 2, respectively) is the most important regulator of mTORC1 (mammalian 
target of rapamycin complex 1) [63, 64]. TSC1 and TSC2 are products of two distinct 
tumor suppressor genes, Tsc1 and Tsc2, respectively. It has been shown that oocyte-
specific deletion of Tsc1 [65] or Tsc2 [66] leads to a global activation of all primordial 
follicles, causing follicular depletion and premature ovarian failure in mice. The driving 
force underlying the overactivation of primordial follicles in the ovaries of these knock-
out mice is elevated mTORC1 activity, suggesting that suppression of mTORC1 activity 
by the TSC1-TSC2 complex in oocytes is required for maintenance of the quiescent state 
of primordial follicles. At the same time, these findings also indicate that elevated 
mTORC1 activity in the oocyte is required for follicular activation [65, 66].   
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 The results from the above genetic mouse models suggest that the PTEN-PI3K-
AKT-FOXO3 signaling pathway, AMH activity, and suppression of mTORC1 activity, 
and likely other pathways yet to be identified, converge to repress primordial follicle 
recruitment, and this inhibitory effect must be overcome for follicles to leave the 
primordial pool.  
 
Oocyte Quality  
 Oocyte quality deteriorates with age [17]. In women, the importance of decreased 
oocyte quality in age-related decline of fertility was confirmed by studies that showed 
that after receipt of embryos produced from oocytes from young donors, women > 40 yr 
of age were able to conceive, carry, and give birth with success rates similar to young 
women [17-20]. Meiosis in oocytes consists of 2 divisions and of 2 different stages of 
temporary arrest. As mentioned above, meiosis starts in oogonia in the human fetal 
ovary at 11 to 12 weeks of gestation. During this time, the oogonia enter prophase and 
become oocytes; the chromosomes replicate and the homologous chromosomes undergo 
pairing. An exchange of material between the chromatids of different homologs occurs 
via the formation of chiasmata in a process known as recombination or crossing over 
[67]. The oocytes then progress to the diplotene stage of prophase and enter meiotic 
arrest. They remain at this stage until ovulation, which may occur much later (10 to 50 
yr in women). At the time of or soon after the oogonia initially enter meiosis, the oocytes 
become surrounded by pre-granulosa cells, forming primordial follicles. When 
primordial follicles leave the pool, the oocyte remains arrested in prophase I during 
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follicle growth. It is not until the oocyte is within a dominant preovulatory follicle in a 
sexually mature female, in response to the luteinizing hormone (LH) surge, that the 
oocyte resumes meiosis. At this time, the nuclear membrane breaks down and the 
chromosomes condense and line up on the first metaphase plate (MI). During anaphase, 
the bivalents separate, each moving to the opposite poles of the meiotic spindle. Thus, in 
humans, 23 bivalents, each composed of two sister chromatids, enter the polar body 
while the remaining 23 remain within the oocyte. After this, a second meiotic spindle 
and metaphase plate (MII) form immediately. The remaining chromosomes align and the 
cell cycle arrests again until fertilization, when fusion with the sperm triggers the 
resumption of meiosis and release of the oocyte from MII [68]. The sister chromatids 
separate; half are extruded as the second polar body and half are retained within the 
oocyte as its 1n chromosome complement. Thus, meiosis in the oocyte takes a long 
period of time to be completed, since this process starts during fetal life and is completed 
only in matured oocytes that undergo fertilization.   
 Alterations during the process described above can lead to aneuploidy (an 
abnormal number of chromosomes) through two main mechanisms: 1) nondisjunction 
(failure of homologous chromosomes or sister chromatids to separate and segregate 
normally) during the first or second meiotic divisions or 2) premature separation of sister 
chromatids [69]. Although aging does not appear to affect the ability of oocytes to 
become fertilized in vitro, maternal age in women has been associated with an increased 
incidence of aneuploidy. In women < 25 yr of age, the expected aneuploidy rate is 5%, 
while this is nearly 60% in oocytes of women > 43 yr of age [70].  
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 Many factors in addition to aneuploidy affect the quality of oocytes in aging 
females. Oocyte cytoplasmic factors and mitochondrial abnormalities also affect oocyte 
quality, as does the quality of the cells making up the follicle and supporting the oocyte 
in its growth. Recent work suggests that patterns of gene expression of cumulus cells 
(CCs) and the metabolites present in follicular fluid (FF) have the potential to be used as 
markers of oocyte quality; these are reviewed below.  
 
Follicle-Stimulating Hormone 
 Elevated FSH levels in older women are one of the first signs of reproductive 
aging [71], and increased levels of FSH have been hypothesized as a possible cause of 
increased aneuploidy [72, 73]. In mouse models, repeated ovarian stimulation with FSH 
results in an increased number of MII oocytes with spindle malformations [74]. Studies 
in mouse cumulus-oocyte complexes cultured in increasing concentrations of FSH have 
shown that exposure to high levels of FSH accelerates the timing of nuclear maturation 
and induces chromosomal abnormalities [75]. Oocytes with aneuploidy are associated 
with follicles with increased follicular-fluid FSH levels [76]; these findings are 
supported by in vitro studies showing that high FSH levels in the in vitro fertilization 
(IVF) medium during in vitro oocyte maturation significantly increase aneuploidy rates 
[77]; however, the mechanisms by which elevated FSH appears to cause oocyte 
aneuploidy remain unknown [73, 77].   
 The integrity of bivalents is crucial for accurate chromosome segregation. 
However, there is a high proportion of bivalents that are disintegrated in the oocytes of 
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older women [78-81]. Sister chromatids in mouse and human oocytes lose cohesion with 
age, which may lead to incorrect alignment of bivalents on the meiotic spindle and 
segregation errors during meiosis [78-84]. Cohesion along crossover sites keeps 
bivalents intact in MI and centromere cohesion holds sister chromatids together during 
all stages of meiosis until MII. A defect in cohesion distal to crossover sites may result 
in a shift of chiasmata placement or premature separation of bivalents in MI, whereas 
reduced centromere cohesion may result in premature separation of sister chromatids in 
MII [85]. Studies in mice have identified cohesion loss as a major contributor to age-
related aneuploidy [83, 86-88]. Cohesin complexes in mouse oocytes are already present 
during DNA replication in the early stages of meiosis. Therefore, cohesin complexes 
must remain in place and functional throughout the period of oocyte arrest to ensure 
correct chromosome segregation in meiosis. The levels of Rec8, a subunits that forms 
the cohesin complex, are markedly decreased on the bivalents of oocytes from aged mice 
[82, 83] and these oocytes show an increase in segregation errors [83]. Human oocytes 
from aged females show age-related structural changes similar to those observed in mice 
[78-81]; however, the molecular mechanisms that cause these age-related changes in 
chromosome architecture in human oocytes remain unknown [79].  
 
Mitochondrial Dysfunction 
 Mitochondrial dysfunction is another factor that affects oocyte quality. The 
theory of ovarian aging, first proposed by Tarin [89], implies a reduced ability of 
oocytes and granulosa cells to counteract reactive oxygen species (ROS), which are 
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among the most important physiological inducers of cellular injury associated with 
aging. Mitochondria are major generators of ROS and abnormal accumulation of intra-
mitochondrial ROS can result in mitochondrial DNA (mtDNA) mutations [90]. ROS-
induced mtDNA mutations lead to the production of inefficient proteins that increase the 
mitochondrial production of ROS, creating a vicious cycle [91]. Animal models with 
accelerated mtDNA mutations show significantly reduced longevity, and exhibit a 
phenotype consistent with human aging, including reduced fertility [92, 93]. When 
nuclei from mouse oocytes with induced oxidative mitochondrial damage are transferred 
into healthy enucleated ooplasts, nuclear function is rescued, leading to an increase in 
normal meiosis, fertilization, and blastocyst formation [94]. Alterations in mtDNA copy 
number and mutation load and in mitochondrial function have been demonstrated in 
aged mammalian oocytes and are thought to be either a contributing factor or a hallmark 
of oocyte aging [95-100]. In aged mice, mitochondria of primary follicle-enclosed 
oocytes are smaller than those of young mice. Mature MII oocytes from old mice have 
significantly less mtDNA and have elevated expression of mitochondrial unfolded 
protein response gene Hspd (heat shock protein family D), compared to oocytes from 
young mice. Aged mature oocytes also have higher ROS levels than do mature oocytes 
from young mice [101].  
 Human and mouse oocytes from females of advanced age also have abnormal 
mitochondria with large vacuoles [98] and have increased mitochondrial aggregates, 
which are correlated with poor-quality oocytes and decreased fertilization [102]. 
Additionally, mouse, hamster, and human oocytes from old females have decreased ATP 
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content, correlated with a similar decrease in mtDNA copy number and number of 
mitochondria [98]. Oocytes from older women, compared to those from younger 
women, also have upregulation of proapoptotic genes including CD40 ligand (CD40), 
and tumor necrosis factor receptor superfamily members 10a and 21 (Tnfrsf10a, 
Tnfrsf21). Oocytes from old females also show downregulation of antiapoptotic genes 
including Bcl2 and caspase 8-and-fas-associated death domain-like apoptosis regulator 
(Cflar); these findings suggest that aging initiates apoptosis in oocytes [103]. 
 Mitochondrial dysfunction can also affect formation of the meiotic spindle. In 
mice, a decrease in mitochondria-derived ATP induced by oxidative stress causes 
disassembly of MII spindles [104]. And in human germinal-vesicle stage oocytes, ROS 
production induced by mitochondrial stress also disrupts subsequent spindle formation 
and size [105]. Thus, it is possible that oxidative damage from increased ROS 
production by dysfunctional mitochondria of aged oocytes could lead to segregation 
errors and aneuploidy as a consequence of abnormal spindle function.  
 
Cumulus Cells 
 Cumulus cells (CCs) are a highly specialized cell type that surround the 
mammalian oocyte from antrum formation through the early stages of embryo 
development in the oviduct. During this period of close contact, CCs maintain paracrine 
and bidirectional cell-to-cell communications with the oocyte and appear to be 
indispensable for acquisition of oocyte developmental competence; the early removal of 
CCs significantly reduces blastocyst rates [106]. Furthermore, the properties and 
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functions of CCs are regulated by the oocyte itself and reflect the degree of maturation 
of the oocyte [107, 108]. Oocyte competence can be divided into 2 levels: meiotic 
competence, the ability of the oocyte to complete meiosis to MII, and developmental 
competence, the ability of the oocyte to be fertilized, and to produce blastocysts able to 
produce viable and healthy progeny [109-112].  
 Because of their relationship with oocyte competence, CCs are increasingly 
being investigated as potential markers to predict oocyte quality, an application which 
could lead to greater ability to select oocytes with increased fertilization, implantation 
and pregnancy rates during IVF treatments. Despite the improvement in our 
understanding of events occurring during oocyte maturation, accurate selection of good-
quality oocytes remains challenging. In women and cattle, morphological criteria 
associated with the oocyte (ooplasm transparency, diameter), the CCs (number of layers, 
compactness), the follicle (follicle size, follicular vascularization), and the early embryo 
(fragmentation, number of blastomeres, multinucleation) are often used to predict 
developmental and implantation competence [113-117]; however, these criteria are 
subjective and lack the required precision to select highly-competent oocytes or 
embryos. Thus, several groups have focused their research on the analysis of CC gene 
expression to identify markers that represent quantitative and non-invasive (once the 
cumulus-oocyte-complex has already been removed from the follicle for IVF) tools for 
the assessment of oocyte developmental competence in humans [118-124].  
 In a study applying a microarray approach, new potential regulators and marker 
genes involved in human oocyte maturation and CC function were identified; these 
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genes, suggested as potential marker of oocyte competence, included Bard1 (BRCA1 
associated RING domain 1), Rbl2 (RB transcriptional corepressor like 2), Rbbp7 (RB 
binding protein 7), Bub3 (budding uninhibited by benzimidazoles 3) and Bub1b 
(budding uninhibited by benzimidazoles 1 homolog beta) [118]. In a later study, this 
same group demonstrated that morphologically-normal oocytes from patients with 
recurrent fertilization failure display abnormal patterns of gene expression, especially of 
those genes involved in meiosis, cell growth and apoptosis [119]. Alterations in gene 
expression have also been reported in morphologically abnormal embryos [120]. 
Patterns of CC gene expression on microarray evaluation significantly associated with 
embryo morphology and pregnancy outcome have also been reported; these include the 
up-regulation of Bcl2l11 (BCL2-like 11 involved in apoptosis) and Pck1 
(phophoenolpyruvate carboxykinase 1 involved in gluconeogenesis) and down-
regulation of transcription factor Nfib (nuclear factor 1 b) [121]. Using real-time PCR, 
transcription of 5 genes in CCs, previously shown to be affected by the preovulatory LH-
surge, was shown to be associated with oocyte competence [122]. Nuclear maturation of 
the oocyte was associated with increased expression of Star (steroidogenic acute 
regulator), Cox2 (cyclooxygenase 2), Areg (amphiregulin), Scd1 (stearoyl-CoA 
desaturase 1) and Scd5 in CCs; the expression of Star, Cox2 and Areg is induced by the 
preovulatory LH peak while Scd1 and Scd5 are involved in oocyte lipid metabolism. 
[122]. Real-time PCR has also been used to correlate CC gene expression with 
subsequent embryo development; CCs isolated from oocytes which produced high 
quality Day-3 embryos were found to have higher transcript levels of Cox2, Has2 
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(hyaluronan synthase 2), and Grem1 (gremlin 1) than those detected in CCs from 
oocytes that developed into poor-quality embryos [123, 124]. Thus, measurement of 
transcripts of these genes in CCs could complement morphological evaluation of the 
cumulus-oocyte complex and provide a useful tool for selecting oocytes with higher 
potential of fertilization and development in vitro. A further set of 6 genomic markers 
differentially expressed in CCs of human oocytes in association with successful 
pregnancies has been identified using 2 different microarray platforms, and validated by 
real-time PCR [125]. These include Ar (androgen receptor), which acts as an 
intracellular transducer signal and/or a transcription factor that interacts with 
transcription regulators and is also involved in CC steroidogenesis [126]; Calu 
(calumenin) and Calm1 (calmodulin 1), two ubiquitous calcium-binding proteins shown 
to be important for the calcium pathway which has been reported to interact with 
progesterone, PKA and PI3K which in addition to other actions induce a chemical 
attraction of the spermatozoa to the oocyte during fertilization [127]; Ubqln1 (ubiquilin 
1), Casp9 (caspase 9) and Tom1 (target of Myb1 membrane trafficking protein), which 
are associated with catabolic and proteasome activities shown to be required for oocyte 
maturation, CC expansion, ovulation, and fertilization [128-131].     
 Current studies on the CC transcriptome are focusing on explaining the 
mechanisms by which differences in CC gene expression are associated with altered 
oocyte competence as well as on linking the different potential pathways involved. 
Recently it has been reported that activation of the EGF (epidermal growth factor) 
pathway by Areg, an EGF-related ligand, in CCs stimulates PI3K/AKT signaling in 
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mouse oocytes [132, 133]. As mentioned above, Areg is induced by the LH surge and 
has been shown to promote oocyte maturation and developmental competence during in 
vitro maturation [122]. Activation of PI3K/AKT cascade results in an increased 
translation of maternal mRNAs and an increase in corresponding protein accumulation 
in mouse oocytes; this increase in protein levels is associated with increased fertilization 
rate and improved embryo development [132, 133]. The increase in protein translation 
also promotes the release of factors such as GDF9, BMP15 (bone morphogenic protein 
15), and IL7 (interleukin 7) from oocytes, which act on CCs, regulating their function, 
thus completing a feedback regulatory loop [134]. This timed secretion before ovulation 
likely modulates molecular events in CCs that are necessary for the development of a 
competent oocyte.  
 These studies highlight the importance of the bidirectional communication 
between the oocyte and CCs and highlight gene expression of CCs as a potential tool to 
assess oocyte quality. 
  
Follicular Fluid 
 Follicular fluid (FF) provides an important microenvironment for the 
development of oocytes. Follicular fluid is a product of both the transfer of blood plasma 
constituents that cross the blood-follicle barrier and of the secretory activity of granulosa 
and thecal cells [135]. It has been suggested that the biochemical characteristics of the 
FF surrounding the oocyte may play a role in determining oocyte quality and the 
subsequent potential to achieve fertilization and embryo development, or at least reflect 
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the status of the oocyte [136-141]. In cows, differential abundance of 8 proteins in the 
follicular fluid has been found in less fertile cows (i.e., cows that fail to conceive 
following six inseminations) compared to control cows; these proteins include 
SERPINA1 (serpin family A member1), TIMP2 (tissue inhibitor of metalloproteinases 
2), ITIH1 (inter-alpha-trypsin inhibitor heavy chain 1), HSPG2 (heparin sulfate 
proteoglycan 2), C8A (complement C8 alpha chain), COL1A2 (collagen type 1 alpha 2 
chain), F2 (coagulation factor II, thrombin), and IL1RAP (interleukin 1 receptor 
accessory protein) [137]. Although the specific role of each protein has yet to be 
determined, it is possible that they could influence (or reflect) follicular function and 
oocyte quality. Recent research has focused on protein analysis and metabolomics, i.e., 
the analysis of all low molecular-weight substances contained in FF at a given time. This 
approach could be more useful than the direct study of gene expression, mRNAs or 
proteins because metabolites can reveal the response of the follicle to all influences 
affecting its development, and more than one metabolite are likely to be involved in 
determining oocyte quality [142]. In mice, oocytes able to absorb larger amounts of 
glucose and actively convert it into lactate show the highest fertilization potential [136]. 
Follicular fluid from aged women (> 40 yr) and aged cows (≥ 10 yr) has been reported to 
contain high concentrations of advanced glycation end-products (AGEs) [138, 139]. 
Glycation is the non-enzymatic reaction between reducing sugars and proteins, lipids or 
nuclei acids. Electrophilic carbonyl groups of reactive sugars react with free amino 
groups of amino acids forming a non-stable Schiff base. Further rearrangement leads to 
formation of a more stable ketoamine. Schiff bases and ketoamines are reversible 
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reaction products; however, they can react irreversibly with amino acid residues of 
peptides to form protein crosslinks. They can also undergo further oxidation, 
dehydration, polymerization and oxidative breakdown reactions which give rise to 
AGEs. AGEs are glycated proteins or lipids that form as a result of glycation during 
normal metabolic processes [143]. The accumulation of AGEs in FF of aged women was 
negatively correlated with follicular growth, fertilization and embryonic development, 
while in cows, supplementation of in vitro maturation medium with FF from aged cows 
decreased oocyte fertilization and embryo development rates and increased oocyte ROS 
levels [139]. AGEs induce apoptosis through the production of ROS in human epithelial 
cells [144]. Maturation medium of mouse oocytes containing MG (methylglyoxal), an 
AGE precursor, induces oxidative stress which leads to DNA damage, meiotic delay and 
spindle aberrations, and the sensitivity to oxidative stress by MG increases with maternal 
age [140, 141].  Furthermore, expression of AGE receptor in human ovarian granulosa 
cells is correlated with age [145, 146] and may be responsible for decreased glucose 
uptake by granulosa cells leading to altered follicular growth [146]. These studies 
suggest that soluble AGEs may play a role in the decline of ovarian function and oocyte 
quality during aging; however, further studies are needed to determine what other factors 
present in FF may affect oocyte competence.  
 The results from the CC and FF studies suggest that non-invasive biomarkers 
may be prognostic of the quality of an oocyte to develop into an embryo that 
successfully implants and sustains pregnancy. However, further studies are needed to 
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determine if these markers can be used as a clinical tool to select the most competent 
oocytes in assisted reproductive technologies.  
 
Ovarian Stem Cells 
 Recently, Johnson et al., [14] proposed the existence of oocyte-generating stem 
cells in mouse adult ovaries. This finding remains controversial. These “oogonial stem 
cells” have been implied as being present via immunohistochemical and grafting 
experiments in that report and in subsequent studies. The main findings from Johnson et 
al., and subsequent reports from the same laboratory were that histological analysis of 
adult mouse ovaries revealed the presence of large ovoid cells, resembling germ cells of 
fetal mouse ovaries; however, these cells were in the surface epithelial cell layer 
covering the ovary and not associated with any cells in any type of structure resembling 
a follicle [14]. Immunohistochemical staining for DEAD box polypeptide 4 (Ddx4), a 
gene thought to be expressed exclusively in germ cells [147], was positive, suggesting 
that the ovoid cells were of a germline lineage [14]. Expression of synaptonemal 
complex protein 3 (SCP3), a meiosis-specific protein structure that is essential for 
synapsis of homologous chromosomes, was examined in adult mouse ovaries. 
Immunohistochemical localization of SCP3 revealed individual immunoreactive cells in 
the surface of the ovary; however, minimal to no expression of this protein was observed 
in non-gonadal tissues [14]. Finally, ovarian fragments harvested from normal adult 
mice were grafted onto the ovaries of transgenic females expressing green fluorescent 
protein (GFP). After 3 to 4 weeks, the ovarian fragments were collected and examined. 
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Confocal microscopic analysis revealed follicle-enclosed, GFP-positive cells surrounded 
by GFP-negative granulosa cells in the fragments. The authors suggest that germ cells 
from the host transgenic mouse infiltrated the grafted tissue and initiated folliculogenesis 
[14]. However, it is not clear whether the GFP-positive cells were in fact normal oocytes 
as their developmental potential was not tested.  
 White et al., [148] described a fluorescent-activated cell sorting-based protocol 
that was used with adult human ovarian cortical tissue to isolate mitotically-active cells 
having a gene expression pattern consistent with germ cells. The isolated cells expressed 
germline markers including PR domain containing 1 (Prdm1), developmental 
pluripotency-associated 3 (Dppa3), interferon-induced transmembrane protein 3 (Ifitm3), 
telomerase reverse transcriptase (Tert), and Ddx4; and lacked expression of 
differentiated oocyte markers including NOBOX oogenesis homeobox (Nobox), zona 
pellucida glycoprotein 3 (Zp3) and Gdf9. Injection of the isolated cells, engineered to 
express GFP, into human ovarian cortical biopsy tissue led to the formation of follicle-
like structures containing GFP-positive cells 1 to 2 weeks after xenotransplantation of 
the cortical tissue into immunodeficient female mice; when the cortical tissue was 
removed from the mice, these structures remained detectable through 72 h of culture. 
The authors suggest that their findings provide evidence that GFP-expressing human 
oogonial stem cells spontaneously generated germline cells that became enclosed by 
granulosa cells that were present in the adult human biopsy tissue [148]. However, as for 
the previous study, the authors in this study did not test for function of the structures that 
they called follicles and oocytes. Thus, the existence of oogonial stem cells remains 
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controversial and it is still unclear whether, if these stem cells do exist, they are in fact 
capable of oogenesis and folliculogenesis, and if they exist in other species.  
 
The Mare as a Model for Reproductive Aging 
 All of the age-related changes discussed above result in reduced fertility. 
Reproductive aging is especially relevant to human medicine, as each year millions of 
women undergo fertility treatments due to age-related loss of fertility [149]. Female 
fertility is defined as the ability to achieve a successful pregnancy after 12 months or 
more of attempted conception [150]. In women, ovarian senescence begins as early as 31 
to 35 yr of age; the proportion of women who remain fertile declines rapidly afterward, 
from 50% at age 40, to 15% by age 45 [2]. In the United States, of all the assisted 
reproductive technology procedures performed in 2013, 57% were performed on women 
between 35 and 44 yr of age [151].  
 Most research on reproductive aging has been performed with rodent models, but 
the ovarian function and senescence timelines in these species differ in many aspects 
from that in women. The mare offers advantages as a model for women, as in both 
species, oocytes are maintained in meiotic arrest for decades, and follicle development 
and ovulation timing are similar, suggesting a comparable sequence of events. For 
instance, the cycle length is similar (3 weeks in mares vs 4 weeks in women), only 1 
follicle ovulates per cycle, and, as noted above, decreased oocyte quality has been 
identified in both species as the main factor in age-related infertility [1, 21]. Trans-
vaginal follicle aspiration can be performed in mares as in women, allowing simple and 
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repeatable non-terminal evaluation of follicle cells, fluid and oocytes. In addition, 
considerable interest exists in the equine industry to establish pregnancies from older, 
valuable mares. These mares may be kept by breeders until they start to show age-related 
infertility and thus older mares are typically readily available for study. This allows us to 
perform research on individuals that may more accurately reflect the changes present 
during ovarian aging in women. 
 As in women, characteristic reproductive changes occur in aging mares. In 
mares, reproductive senescence begins around 20 yr of age, and it is estimated that only 
50% of mares older than 20 yr of age and 37% of mares older than 24 yr of age display 
normal ovarian activity [3, 152-155]. When they do cycle, aged mares have a delayed 
entry into the breeding season and have longer estrous cycles [3, 156]. Carnevale et al., 
[21] reported lower pregnancy rates after artificial insemination in old mares (20 to 26 
yr) compared to young mares (31% vs. 83%, respectively). Carnevale et al., [157] also 
reported lower pregnancy rates in a retrospective analysis of a commercial oocyte 
transfer program; oocyte transfers from donors < 15 yr resulted in a 50% pregnancy rate, 
while oocyte transfers from donors > 23 yr resulted in a 16% pregnancy rate. 
Additionally, lower foaling rates (53%) have been reported for old mares (≥ 20 yr) 
compared to young mares (85%), and to produce a foal, old mares have been reported to 
be bred 2.3 more cycles than young mares [3]. Ovarian inactivity, characterized by the 
presence of small, hard ovaries with no visible follicles, is also associated with increased 
age in mares, as reported in a slaughterhouse survey [158].  
 As seen in women, a decrease in follicle numbers and failure of follicular growth 
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are also found in the older mare. Old mares (≥ 20 yr) have longer interovulatory 
intervals than young mares due to a lengthened follicular phase; the growth rate of the 
ovulatory follicle in old mares is slower than that for young mares, and old mares also 
ovulate smaller follicles than young mares [156]. The decreased follicular development 
in old mares, like that in women, is also likely related to follicle depletion, as FSH is 
elevated in old mares suggesting decreased negative feedback from follicular inhibin due 
to lack of follicle activity [152]. The number of antral follicles that can be imaged by 
ultrasonography in old mares is decreased compared to that of young mares [159].  
 As in women, in addition to a decrease in follicle numbers, a decline in oocyte 
quality has also been documented in older mares. Oocyte transfers from young donors (6 
to 10 yr) to young recipients had higher embryo development rates (92%) than did 
oocyte transfers from old donors (20 to 26 yr) to young recipients (31%) [21]. Day-3 
oviductal embryos from old mares have fewer cells and more morphological 
abnormalities than do embryos from young mares [156]. The results from these studies 
suggest that there is an age-related decline in oocyte quality which affects embryo 
development. In a study using light and electron microscopy, more oocytes from old 
mares (> 19 yr) than young mares (3 to 10 yr) had morphological abnormalities 
including fragmentation, large vesicles in the ooplasm, atypical shapes, areas of ooplasm 
without organelles, and sections of oolemma with scarce microvilli [160]. Altermatt et 
al., [161] evaluated oocytes collected from preovulatory follicles of young (4 to 9 yr) 
and old (≥ 20 yr) mares by light microscopy to determine morphological measurements. 
In old mares, the zona pellucida (ZP) was thinner than that in young mares, and the 
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perivitelline space and inner ZP volume were larger and associated with oocytes that 
failed to develop after intracytoplasmic sperm injection; the authors suggested that 
during natural fertilization these changes could constitute a functional impairment 
associated with sperm binding or penetration of the ZP. The results from these studies 
indicate that oocytes from old mares undergo degenerative changes. Ruggeri et al., [162] 
showed the presence of actin vesicles in oocytes collected from old (20 to 25 yr) mares. 
Actin is a major cytoskeletal component and plays a key role in the migration of the 
meiotic spindle in mouse oocytes [163, 164]. Actin vesicles are spherical filamentous 
actin structures which act as pushing forces and are part of the actinomyosin contractile 
forces during oocyte maturation [165-167]. Actin cytoskeleton remodeling and 
localization is involved in human oocyte maturation, and in vitro maturation affects the 
actin network and amount of actin present before fertilization [167]. Although the role of 
actin in equine oocyte maturation and fertilization has not been studied, the presence of 
actin vesicles in oocytes from old mares could suggest abnormal remodeling of the 
cytoskeleton of those oocytes [162]. 
 As mentioned above, mitochondrial damage and low mtDNA copy numbers also 
negatively influence oocyte developmental competence and contribute to decreased 
fertility in women [94, 98, 101, 102]. Oocytes of aged mares, like those of aged women, 
have a lower mtDNA copy number [99, 168] and a higher prevalence of morphological 
mitochondrial abnormalities; oocyte mitochondria from aged mares are often enlarged 
with damaged cristae [99]. Thus, mitochondrial dysfunction and degeneration also 
appears to be associated with aging in mares.   
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 As reviewed above, the composition of FF has been suggested as a possible 
marker of oocyte quality. In mares, analysis of FF revealed the presence of microvesicles 
and exosomes which contain microRNAs (miRNAs) [169]. Bioinformatics analysis 
revealed that three miRNAs were significantly higher in FF from old mares compared to 
that of young mares. The main pathway targeted by these three miRNAs is TGFβ 
signaling which, as discussed above, is critical for proper follicular development and 
growth. These findings suggest that in old mares, miRNAs present in FF could suppress 
this pathway leading to decreased oocyte competence [169]. In support of these results, 
another study from the same group evaluated gene expression of selected TGFβ family 
targets/components in granulosa cells from young and old (20 to 26 yr) mares [170]. 
Analysis revealed significant differences of Il6 (interleukin 6) and Col1a2 in young 
mares, and Id2 (inhibitor of DNA binding 2), Stat1 (signal transducer and activator of 
transcription 1) and Cdc25a (cell division cycle 25A) in old mares; the expression level 
of these 5 genes was altered after induction of follicular maturation. Col1a2 is involved 
in cell proliferation and regulation of the cell cycle, and decreased levels of this gene in 
old mares further supports the possibility of downregulation of TGFβ signaling as a 
factor in the age-related decrease in oocyte quality [170]. Differences in gene expression 
in granulosa cells [168, 171], CCs and oocytes from old and young mares after 
administration of equine recombinant LH have also been evaluated [168]. In these 
studies, levels of LHr (luteinizing hormone receptor) in granulosa cells of young mares 
declined (this decline is caused by exogenous LH or the preovulatory LH surge and lasts 
until cells luteinize and the CL forms after which levels of LHr increase), but there was 
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no time effect in old mares, suggesting an age-related delay in response to LH by 
follicular cells and oocytes. Granulosa cells of old mares also had higher expression 
levels of Areg and Ereg (epiregulin; an EGR-related ligand) [168] which, as reviewed 
above, activate the EGF pathway to stimulate PI3K/AKT signaling in CCs; Star, Tpa 
(tissue-type plasminogen activator), and Txn2 (thioredoxin-2) [171]. These age-related 
changes in metabolic, steroidogenic and inflammatory genes could mark alterations in 
follicular functions of old mares. Cumulus cells from old mares also had higher 
expression levels of phosphodiesterases (PDEs) Pde4d and Pde3a. These PDEs are 
essential for oocyte maturation as they regulate cAMP (cyclic adenosine 
monophosphate; a second messenger involved in intracellular signal transduction and of 
major importance in resumption of meiosis in preovulatory oocytes) in response to 
gonadotropins; these results suggest the possibility of premature oocyte maturation in 
aged mares, which could affect their reproductive success [172].  Finally, oocytes from 
old mares had lower expression levels of Gdf9 and Bmp15, which, as described above, 
regulate the function of CCs; these lower levels of oocyte-secreted factors could 
contribute to the decreased developmental competence observed in oocytes from old 
mares [168].  
 In summary, aging causes a decrease in female reproductive efficiency. In both 
women and mares, a decrease in follicle numbers and oocyte quality is the major cause 
of age-related infertility. Factors that affect the oocyte quality in aging women and 
mares include aneuploidy, oocyte cytoplasmic factors, and mitochondrial abnormalities. 
Therefore, the mare offers an excellent model for reproductive aging.  
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MESENCHYMAL STEM CELLS 
 Stem cells are distinguished from other cell types by their ability to self-renew 
through cell division and to differentiate into multiple lineages during early life and 
growth [173]. When a stem cell divides, each new cell has the potential to either remain 
a stem cell or become another type of cell with a more specialized function. In addition, 
in many tissues they serve as an internal repair system, dividing to replenish other cells 
as long as the organism is alive [174].  
 Adult stem cells are undifferentiated cells found in many organs and 
differentiated tissues with a limited capacity for self-renewal and differentiation. The 
differentiation capacity of these cells, under certain physiologic or experimental 
conditions, is usually limited to cell types in the organ of origin. The main function of 
adult stem cells in a living organism is to maintain and repair the tissue in which they are 
found [174]. Bone marrow contains two kinds of stem cells: 1) hematopoietic stem cells, 
which give rise to all types of blood cells in the body, and 2) mesenchymal stem cells 
(MSCs; also called bone marrow stromal cells), which can differentiate into osteoblasts 
[175], chondrocytes [176], and adipocytes [177]. Mesenchymal stem cells also exist in 
other tissues such as umbilical cord blood [178], adipose tissue, and muscle [179].  
 Mesenchymal stem cells, particularly those derived from bone marrow (BM-
MSCs), are increasingly being used in regenerative therapies because of their capacity to 
repair tissue damages due to injury and disease. In horses, BM-MSCs have been shown 
to enhance early chondrogenesis in articular defects [180], as well as to improve the 
biomechanical, morphological and compositional parameters in naturally-occurring 
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[181] and experimentally-induced [182] tendon injuries. Wilke et al., [180] examined 
the effects of BM-MSC implantation on cartilage healing characteristics in horses. 
Twelve full-thickness cartilage lesions in the femoropatellar articulations of six horses 
were treated by injection of a fibrin vehicle with MSCs or fibrin vehicle alone in control 
joints. One month after injection, arthroscopic assessments and defect biopsies were 
performed, and 8 months after injection the animals were euthanized. Cartilage repair 
was evaluated by histology, histochemistry, collagen type I and type II 
immunohistochemistry, collagen type II in situ hybridization, and matrix biochemical 
assays. In the full-thickness articular defects, MSC grafting resulted in early 
improvement of defect healing. However, this was not sustained over the course of the 
8-month study. Arthroscopic assessments and biopsies at 1 month showed improved 
tissue filling of MSC-grafted defects; however, biochemical and morphologic 
assessment at 8 months showed few differences between MSC-implanted defects and 
those implanted with fibrin vehicle without MSCs [180]. Smith et al., [181] studied the 
effects of BM-MSCs in the treatment of naturally-occurring superficial digital flexor 
injuries in 12 horses. Horses were randomly assigned to receive MSCs or saline, then 
after a 6-month exercise program the horses were euthanized and their tendons assessed 
for structural stiffness, appearance and molecular composition. Tendons treated with 
MSCs exhibited statistically significant improvements in the key parameters examined 
compared to the saline-injected control tendons. Injections of MSCs resulted in the 
formation of tissue resembling normal tendon matrix rather than the fibrous scar tissue 
formed after natural inflammation and repair. Schnabel et al., [182] examined the effects 
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of BM-MSCs in collagenase-induced tendinitis lesions created in the superficial digital 
flexor tendon of horses. Horses were euthanized 8 weeks after MSC injection and their 
tendons were mechanically tested and evaluated for biochemical composition and 
histologic characteristics. Similar to the findings of Smith et al., in naturally-occurring 
tendon injuries [181], the results from this study showed that MSC injections into 
tendinitis core lesions resulted in significant histological tendon healing and a trend 
towards improved biomechanical characteristics of healing tendon [182].  
 Mesenchymal stem cells have also been successfully used in models of injury in 
other species, typically with the proposed mechanism of stimulating endogenous repair 
pathways. They have been used in rat models of kidney disease to accelerate glomerular 
recovery damage to mesangial cells, important structural and functional cells in the 
glomeruli, by releasing paracrine growth factors [183], mouse models of diabetes 
mellitus to decrease mesangial thickening and macrophage infiltration and to enhance 
insulin secretion by increasing proliferation, migration and differentiation of endogenous 
cells [184], mouse, sheep, canine, and swine models to restore ventricular function after 
acute myocardial infarction by increasing vascularity and secreting paracrine growth 
factors [185-188] and rodent models of neurological disorders to promote repair and 
regeneration of nervous tissue [189].  
 In reports in which MSCs were tracked in vivo, MSCs were shown to enhance 
tissue repair despite low or transient engraftment levels [182, 190]. Only a small 
proportion of MSCs were found to home and persist in the target sites, and typically 
MSCs were not detectable after 7 to 14 days after transplantation [191].  
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 Mesenchymal stem cells secrete soluble factors which can alter the tissue 
microenvironment including: interleukin 1 receptor antagonist (Il1rn) which inhibits 
inflammatory responses [192]; vascular endothelial growth factor (Vegf) which induces 
angiogenesis [193, 194]; basic fibroblast growth factor (bFgf), hepatocyte growth factor 
(Hgf), brain-derived neurotropic factor (Bdnf) and nerve growth factor (Ngf) which 
promote the survival and proliferation of endogenous cells [184, 195, 196]; and insulin-
like growth factor-1 (Igf1) and interleukin-6 (Il6) which decrease apoptosis [9, 197, 
198]. Notably, MSCs can also alter the host tissue microenvironment by transferring 
mitochondria. Spees et al., [199] used cells pre-treated with ethidium bromide so that 
mitochondrial DNA became mutated and depleted making the cells incapable of aerobic 
respiration and growth. Mutated cells were co-cultured with GFP-labeled human BM-
MSCs. The results from this study showed that after co-culture with MSCs, some of the 
mutated cells acquired functional mitochondria which were confirmed to be from the 
MSCs by genetic analysis of the rescued cells [199]. However, the results from this 
study did not establish the mechanism by which mitochondria were transferred from 
MSCs to mutated cells.  
 The results from these studies- showing a significant repair of diseased or injured 
tissue despite low levels of MSC engraftment, and identifying known tissue-repair 
factors secreted by MSCs- suggest that MSCs do not contribute physically to tissue 
regeneration by differentiating themselves. Instead, MSCs appear to promote tissue 
repair via paracrine effects of the secreted factors which stimulate proliferation of 
endogenous cells, and decrease inflammation and immune reactions. Thus, the ability of 
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MSCs to alter the host tissue microenvironment may contribute more significantly to the 
repair of tissue than does their ability to differentiate into other cells. 
 Since the groundbreaking identification of MSCs by Friedenstein et al., [200] in 
1970 and the first detailed description of the trilineage potential of MSCs by Pittinger et 
al., [201], many attempts have been made to better define what a MSC is. To address 
this issue, the Mesenchymal and Tissue Stem Cell Committee of the International 
Society for Cellular Therapy has proposed a set of standards to define human MSCs. The 
three criteria to define MSCs include adherence to plastic when maintained in standard 
culture conditions using tissue culture flasks, multipotent differentiation potential to 
osteoblasts, adipocytes, and chondrocytes under standard in vitro differentiating 
conditions, and specific surface antigen expression. Surface antigen expression allows 
for the rapid identification of a cell population and has been used extensively in 
immunology and hematology. The CD (cluster of differentiation) system is commonly 
used in immunophenotyping, because it allows cells to be defined based on the 
molecules that are present on their surface. Each CD indicates cell-surface protein or 
epitope (section of protein) that is recognized by an antibody. Human MSCs express (are 
positive for) CD105, CD73 and CD90 and lack expression of (are negative for) CD45, 
CD34, CD14 or CD11b, CD79α or CD19 and HLA-DR. These positive and negative 
markers are used to distinguish MSCs from other cells in the bone marrow compartment. 
The negative markers include surface antigens that are expressed by hematopoietic cells, 
while the positive markers are absent from most hematopoietic cells [202]. However, no 
such uniform immunophenotyping criteria are available for equine MSCs. This is further 
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hampered by the lack of equine-specific or cross-reacting monoclonal antibodies to CDs. 
De Schauwer et al., [203] screened 30 commercial monoclonal antibodies (raised in 
mouse and rat to human, mouse and dog) with flow cytometry to determine their ability 
to recognize equine epitopes and confirmed their specificity by confocal fluorescence 
microscopy. In this study, they found that equine MSCs were positive for CD44, CD29 
and CD90, negative for CD45 and CD79α, and had variable expression for CD73 and 
CD105 [203]. Equine MSCs have been found to have variable expression of MHC II, 
possibly due to a combination of factors including the animal of origin, bone marrow 
aspirate quality, immunologic background at a given time, and culture conditions [204]. 
This 8-marker panel is commonly used for the immunophenotyping of equine MSCs, 
although due to variability in immunophenotype, the physical attributes (shape and 
adherence to plastic) and the functional characteristics (ability to undergo trilineage 
differentiation) are currently the definitive measure of MSC identity. 
 
Cryopreservation 
 Cryopreservation of MSCs is critical for both research and clinical applications. 
The ability to preserve MSCs long-term permits the banking of cells to facilitate 
coordination of therapy with a patient care regimen, and allows the completion of quality 
and safety testing before use, as well as simplifying transportation of cells. In order to 
use cryopreserved cells successfully, MSCs need to be stored with minimal loss of cell 
viability and differentiation capacity and ideally their immunophenotype needs to remain 
unchanged. 
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 Although there is no consensus protocol for preserving MSCs, most 
cryopreservation procedures use a variation of a technique involving addition of a 
penetrating cryoprotectant such as dimethyl sulfoxide (DMSO) and a source of plasma 
protein, cooling at a defined rate, and storage at cryogenic temperatures (below -150 ºC) 
using mechanical refrigerators or liquid nitrogen refrigerators [205]. Preservation of the 
structural integrity of cells involves the use of very low temperatures. However, when 
cells are stored at low temperatures freezing damage can occur through the formation of 
intracellular ice, which can lead to cell death. Avoiding the formation of intracellular ice 
is therefore essential for the successful cryopreservation of cells. The cryoprotectant 
DMSO colligatively decreases the freezing point and interferes with ice crystal 
formation, thereby reducing the formation of intracellular ice [206]. Colligative effects 
depend upon the number of molecules, which is why most cryopreservation laboratories 
use high concentrations of DMSO (10% v/v) [205, 207]. However, the effectiveness of 
lower DMSO concentrations in human cell cryopreservation has been reported [208, 
209]. Cryopreservation with DMSO does not alter the differentiation capacity of MSCs 
[207] nor the expression of MSC markers [210].  
 Handling of MSCs during thawing can affect their viability. When frozen-thawed 
MSCs are centrifuged for removal of cryoprotectant and resuspension, viability 
decreases over time, with the rate of viability decrease varying depending on holding 
temperatures and holding media [211]. The rate of dilution during thawing also affects 
MSC viability [210, 212] due to osmotic injury from fast addition of dilution medium 
[210].  
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Quantum Dot Labeling 
 As reviewed above, regenerative therapies have seen rapid advances in the use of 
adult BM-MSCs for tissue repair because of their potential to promote angiogenesis and 
survival and proliferation of endogenous cells. However, the distribution and fate of 
MSCs once introduced in vivo are not well understood. This is in part due to the limited 
methods available to track and identify delivered MSCs in vivo. Current methods for 
labeling MSCs include ultra-small iron particles [213], radioactive labels [214], organic 
fluorescent dyes loaded exogenously into cells [215], and fluorescent proteins expressed 
by the cells [216]. Previous attempts at tracking delivered MSCs have been hampered by 
the autofluorescence of host tissue and limitations of existing labeling techniques 
including chemical and metabolic degradation, reduced photostability and signal quality 
[217]. Quantum dots (QDs), nanoparticles made of semiconducting material, have 
emerged as fluorescent alternatives to organic dyes because they are non-toxic, are more 
resistant to photochemical and metabolic degradation, and do not interfere with cellular 
function or proliferation [218]. Cells uptake QDs through endocytosis based on their 
surface coatings; QDs then distribute in the cytoplasm in perinuclear endosomes and 
lysosomes. The mechanism by which cells expel QDs is controversial and poorly 
defined in literature; however, QDs do not interfere with normal cell physiology and cell 
differentiation [219].  
 Quantum dots have been reported to persist for up to 8 weeks in human MSCs 
delivered into canine hearts [220]. Full-thickness defects were surgically induced and 
scaffolds seeded with QD-labeled MSCs were used to repair them. After 8 weeks, the 
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animals were euthanized and a region of myocardium circumscribing the scaffold was 
excised. Transmural sections within the scaffold region were imaged to identify QD-
labeled MSCs. Costa et al., [221] infused QD-labeled goat MSCs into goat mammary 
glands and mouse testicles. Mammary gland and testicle tissue biopsy samples were 
obtained 30 days after infusion and examined 30, 60 and 90 days after collection. 
Histological examination under fluorescence microscopy of the tissues revealed the 
presence of QD-labeled MSCs at all time points evaluated.  Whereas in vivo studies with 
QD-labeled human MSCs have reported long term persistence of QDs in target tissues, 
human MSCs maintained in standard in vitro culture conditions have shown a rapid loss 
of fluorescence signal.  Seleverstov et al., [222] reported a significant loss of 
fluorescence in QD-labeled human MSCs in culture 2 to 7 days after labeling and Wang 
et al., [223] recently reported a significant reduction in fluorescence in QD-labeled 
human MSCs after 24 h of culture. Flow cytometry indicated that cell proliferation was 
the main factor leading to decreased fluorescence [223]. Whole-body detection of QDs 
was achieved by Larson et al., [224] by injecting QDs intravenously into mice; using 
multiphoton imaging QD-containing vasculature was visible through the intact skin to 
the base of the dermal layer in live mice; however, whole-body detection of QD-labeled 
MSCs in higher organisms has not been reported, as larger quantities and volumes of 
cells may be required to enable this application [225].      
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MESENCHYMAL STEM CELLS AND FERTILITY RECOVERY 
 Each year millions of women are rendered sterile by chemotherapy-associated 
ovarian failure. The risk of developing premature depletion of functional ovarian 
follicles as a consequence of chemotherapy is dependent on several factors. Some 
chemotherapy agents are considered more gonadotoxic than others [226, 227]. Dosage of 
the treatment used is also important [227, 228] as is the age of the patient [229-231]. 
While damage to follicles occurs at all ages, the age-related difference is probably due to 
the fact that older women have a smaller primordial follicle reserve at the start of 
treatment compared with that of younger women [231].  
 Among the most ovo-toxic of the chemotherapy drug groups are the alkylating 
agents (cyclophosphamide (CTX), busulphan and dacarbazine), platinum complexes 
(cisplatin and carboplatin), and taxanes (paclitaxel) [232-236]. The fact that 
chemotherapy induces oocyte death is a conundrum, as chemotherapy agents target 
replicating DNA and dividing cells, and oocytes and the surrounding cells of the 
primordial follicle neither replicate DNA nor divide.  
 The most recent theory of chemotherapy-induced destruction of follicles suggests 
that in vivo, chemotherapy agents including CTX trigger an initiation of primordial 
follicle growth, which occurs simultaneously with growing follicle apoptosis induced by 
this chemical [237]. As described above, the activation of primordial follicles is 
mediated by an upregulation of the PI3K/PTEN/AKT signaling pathway [48-50]. The 
mechanism by which chemotherapy induces activation of the PI3K/PTEN/AKT pathway 
may be via direct influence on the primordial follicles, or indirectly via chemotherapy-
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induced destruction of larger follicles. In mice, treatment with CTX has been shown to 
cause severe primordial follicle loss and growing follicle apoptosis, resulting in 
depletion of the ovarian reserve [238]. Ovaries of CTX-treated mice also showed 
increased phospho-Akt and phospho-mTOR levels as well as increased phosphorylation 
of the downstream P70S6-rpS6-eIF4B proteins. Thus suggesting that CTX treatment 
over-activated the PI3K/Akt/mTOR signaling pathway in the ovary leading to excessive 
primordial follicle activation and recruitment into a vicious cycle of growth, 
development, and apoptosis, causing exhaustion of the ovarian reserve [238]. In vivo 
treatment of mice with AS101 (a non-toxic compound that acts on the PI3K/PTEN/AKT 
pathway [239]) reduced CTX-induced loss of primordial follicles and decreased CTX-
induced apoptosis of granulosa cells of growing follicles [237]; these results also suggest 
that destruction of primordial follicles by CTX is through activation of primordial 
follicles mediated by disruption of the PI3K/PTEN/AKT pathway.   
 Destruction of growing follicles results in a decrease in AMH and thus a loss of 
suppression of the primordial follicle pool. This loss of suppression results in activation 
of primordial follicles [240]. As mentioned above, AMH is produced by granulosa cells 
of small growing follicles and is a negative regulator of follicle activation; studies in 
knockout mice have shown that loss of AMH leads to excessive activation and depletion 
of the primordial follicle pool [58]. Analysis of AMH mRNA expression has shown that 
immediately following in vivo treatment of mice with CTX, the transcript levels of AMH 
were reduced by half [241]. When recombinant human AMH was added to ex vivo 
culture systems together with CTX, ovaries maintained higher numbers of primordial 
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follicles, with a loss of only 17% after one week in culture compared with the 53% loss 
of primordial follicles in ovaries exposed to CTX without AMH [241]. Chemotherapy 
drug-induced apoptosis in the ovary has been demonstrated in growing follicles, and has 
been shown to originate in the proliferating granulosa cells [242]. In cells, including 
mature oocytes, apoptosis is mediated by ceramide, BAX, and the caspases [243-245]. In 
mice, targeted disruption of Casp2, which activates Bax, results in retention of more 
primordial follicles and resistance to doxorubicin [26]. Tumor protein p63 is specifically 
expressed by oocytes of primordial follicles, and in particular the p63 isoform TAp63 is 
a key mediator of the DNA damage/apoptosis pathway regulating the response of 
primordial follicle oocytes to DNA injury [246-248]. The p63 pathway is upregulated 
when primordial oocytes are exposed to external triggers of DNA damage such as 
chemotherapy drugs [249]. Increased TAp63 activates apoptosis via BAX; thus loss of 
p63 in mouse oocytes results in resistance to the apoptotic effects of cisplatin [250]. The 
activation of apoptosis is also mediated by TAp73 [250], either directly or through the 
activation of p53-upregulated modulator of apoptosis (PUMA) and phorbol-12-
myristate-13-acetate-induced protein 1 (NOXA) [251]. Oocyte-specific deletion of 
PUMA or both PUMA and NOXA in mice prevents chemotherapy-induced apoptosis 
and can result in the production of healthy offspring in chemotherapy-treated mice, 
indicating that the protected oocytes are capable of DNA repair and subsequent normal 
function [251].  
 Another mechanism by which chemotherapy drugs induce follicle loss is via 
indirect damage to the ovarian stroma and the vascular system [252, 253]. In women, 
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ovarian blood flow was significantly reduced immediately after chemotherapy [254] and 
in mice, doxorubicin administration induced a significant acute reduction in ovarian 
blood volume and narrowing of the small vessels [255]. Examination of human ovarian 
tissue previously exposed to in vivo chemotherapy revealed evidence of thickening and 
hyalinization of cortical stromal blood vessels, proliferation of small and disorganized 
blood vessels in the ovarian cortex, and subcapsular focal cortical fibrosis [256]. 
Although larger follicles may be more sensitive to acute ischemic changes due to the 
requirements of proliferating granulosa cells, experimental models support the 
dependence of primordial follicles on adequate vascularization [257]. Ovarian stroma 
and ovarian extracellular matrix are important for normal ovarian function, follicle 
growth, and survival [258, 259], and in human ovarian tissue xenotransplants there is an 
inverse correlation between ovarian vascular density and primordial follicle apoptosis 
[257]. The fact that the blood supply to the ovary is an end-artery system makes it more 
likely that these stromal and vascular changes might impair ovarian function and 
contribute to the loss of primordial follicle reserve [252, 260].   
 Interestingly, there have been reports showing an unexpected return of ovarian 
function and fertility after chemotherapy in women who underwent bone marrow 
transplantation (BMT) as a component of their therapy. Salooja et al., [4] reported that 
of 10 women receiving a high-dose chemotherapy regimen followed by single BMT, 4 
developed ovarian failure and six resumed spontaneous cyclical menstruation. Five of 
the 6 menstruating women became pregnant between 4 and 40 months following BMT. 
Sanders et al., [261] described that of 187 women 43 women who had received BMT 
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following a high-dose chemotherapy regimen, 32 recovered normal ovarian function and 
9 of these women had 12 pregnancies. In a different report, Sanders et al., [6] also 
described that of 708 women who had received high-dose chemotherapy followed by 
BMT, 110 recovered normal ovarian function and 32 became pregnant. In a 
retrospective analysis, Hershlag et al., [7] reported that 4 patients with ovarian failure 
induced by high-dose chemotherapy established pregnancies following BMT. In 
humans, data on pregnancies in patients post-chemotherapy shows no increase in fetal 
malformations or pregnancy loss, indicating that prevention of infertility with 
reestablishment of normal hormonal function and viable pregnancies following BMT is a 
realistic possibility. It is not known whether these pregnancies resulted from oocytes that 
did not sustain any DNA damage or from oocytes that underwent DNA repair.  
 Several animal studies have been conducted to investigate the return of ovarian 
function following chemotherapy. In 2007, Lee et al., [8] demonstrated that BM-MSCs 
injected via the tail vein to chemotherapy-treated adult female mice rescued long-term 
fertility. Females administered non-lethal doses of busulfan and CTX without BMT 
became infertile whereas mice that underwent BMT achieved 4 to 6 pregnancies (per 
mouse) over the course of 7 months although the number of pups per litter was lower 
than that for non-treated control females. Two months after chemotherapy and MSC 
injection, fertility decreased. In the study of Lee et al., [8], bone marrow was harvested 
from transgenic females expressing green fluorescent protein (GFP). Two months after 
MSC injection, the ovaries of recipients possessed GFP-positive cells within apparent 
immature follicles, although the percentage of the total immature follicle pool containing 
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GFP-positive cells was low (1.4%). However, these cells only appeared in apparent 
immature follicles up to the pre-antral stage and were not observed in preovulatory 
follicles, and all offspring were derived from the recipient germline. This supports 
findings in other tissues, that the tissue microenvironment is repaired by the transplanted 
BM-MSCs or by factors released by the transplanted cells, and not by the differentiation 
of BM-MSCs into functional cells [8].  
 In other studies using similar protocols, transplanted MSCs were not found 
within follicle-like structures, but did persist in ovarian stromal tissue and even in the 
theca. Wang et al., [11] showed that in mice intravenous injection of human umbilical 
cord MSCs increased the number of follicles and decreased apoptosis of granulosa cells 
in females with CTX-induced premature ovarian failure. Ovaries were collected 1 week 
after MSC injection and the presence of normal follicles was determined. Ovaries of 
mice receiving MSCs after chemotherapy had more oocyte-containing follicles at 
different stages of development and had a significantly lower percentage of TUNEL-
positive (TUNEL staining identifies and quantifies the apoptotic cell fraction) granulosa 
cells than ovaries of mice that received chemotherapy only. Injected MSCs were labeled 
with the fluorescent tracker CM-Dil dye; 1 week after injection of MSCs, the labeled 
cells could be traced in the ovaries although these cells did not develop into follicles, 
granulosa cells or oocytes. Abd-Allah et al., [262] showed that intravenous injection of 
BM-MSCs increased the number of follicles in female rabbits with CTX-induced 
ovarian failure. Six weeks after CTX injection follicle count was performed on ovarian 
sections. CTX injection resulted in a significant decrease in the number of all types of 
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follicles. However, in the MSC-injected group, a significantly higher number of follicles 
was detected when compared to the CTX injection group. Donor MSCs were harvested 
from male rabbits and the SRY gene was detected by PCR in the ovarian tissue of 
recipient females. Fu et al., [9] reported that in female rats with CTX-induced ovarian 
damage, intra-ovarian injection of BM-MSCs improved ovarian function, as indicated by 
the restoration of the estrous cycle, increased serum estradiol levels and follicle numbers 
as counted on slides of ovarian sections, and reduced granulosa cell apoptosis which was 
analyzed by TUNEL staining. Donor MSCs were transfected with GFP; GFP-positive 
cells were found in the ovarian interstitium of recipient females 2 weeks after injection 
and persisted for 8 weeks. However, GFP-positive cells were not found in any follicles. 
Takehara et al., [10] used a rat model with CTX-damaged ovaries and showed that intra-
ovarian injection of adipose-derived MSCs induced angiogenesis, as shown by 
immunostaining of ovarian sections for CD34, expressed on vascular endothelial cells, 
and increased the number of follicles and corpora lutea in treated females. Eight weeks 
after MSC injection, females were euthanized and their ovaries were removed; 
histological sections were prepared and the number of follicles and corpora lutea was 
calculated and compared between the MSC-injected animals and the animals that 
received chemotherapy only. The injected MSCs were derived from male rats, and the Y 
chromosome was localized in the theca layer in the recipient ovaries 8 weeks after MSC 
injection using fluorescent in situ hybridization (FISH) to detect the distribution of cells 
exhibiting Y chromosomes in the ovarian tissues.  
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 In another model of ovarian dysfunction, Ghadami et al., [263] reported that the 
intravenous injection of BM-MSCs from wild-type mice restored estrogen hormone 
production and folliculogenesis in FORKO (follicle-stimulating hormone receptor 
knockout) mice. FORKO mice have a targeted disruption of the receptor for FSH 
(follicle-stimulating hormone) and show reduced fertility and early reproductive 
senescence due to disordered estrous cycles, decreased estrogen levels and absence of 
folliculogenesis. In this study, blood samples collected before and after MSC injection 
showed a 4- to 5.5-fold increase in estrogen in treated animals compared to FORKO 
mice that did not received MSC injections. After inducing ovulation with pregnant mare 
serum gonadotropin and human chorionic gonadotropin, oviductal flushings were 
performed. However, oocytes were not detected in oviductal flushings of the treated 
FORKO mice, suggesting that the MSC-induced resumption of folliculogenesis, based 
on serum estrogen concentrations, was not accompanied by ovulation. Lack of 
ovulations was also confirmed by the absence of corpora lutea on histological 
examination of the ovaries.  
 As described above, during the process of ovarian aging there is a decrease both 
in the quantity and quality of the ovarian follicle pool which leads to a decrease in 
fertility. This similarity to findings in chemotherapy-treated ovaries leads to the 
questions of whether MSC transplantation may help rescue ovarian function in aged 
females. Unfortunately, there is limited information on the effects of MSCs in females 
with decreased fertility due to aging. Selesniemi et al., [12] showed that once-monthly 
intravenous injections of young adult BM-MSCs increased the number of full-term 
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pregnancies and sustained the fertile potential of aged female mice long past the normal 
time of reproductive senescence (typically begins around 8 months of age). On average, 
75% of 11.5-14.5-month old, and 52% of 14.5-17.5-month old MSC-injected females 
remained fertile. In comparison, 56% of 11.5-14.5-month old, and 31% of 14.5-17.5-
month old control females achieved full-term pregnancies and delivered offspring. 
Injected MSCs harvested from young adult female mice (6 to 10 weeks of age) were 
transfected with GFP; there was little evidence of engraftment and all offspring were 
derived from the recipient germline. As reviewed previously, BM-MSCs secrete 
cytokines which improve cellular function and decrease the apoptosis of somatic cells 
after cytotoxic insult. It is possible that in the non-insult model of aging, the secreted 
factors from the injected MSCs could also act as anti-apoptotic signals in aging ovaries 
[12]. A case report by Mohammed Ali et al., [13] described the intra-ovarian injection of 
peripheral blood mononuclear cells in a 49-yr old woman with a 30-yr history of 
infertility. An increase in serum levels of anti-Müllerian hormone (AMH) followed by a 
pregnancy occurring 5 months after treatment, and a live birth, were reported. The 
authors of this report suggest that peripheral blood mononuclear cells stimulate 
mitotically-active oogonial stem cells and generate new oocytes in vivo. However, these 
are only assumptions as there is no evidence presented in the report to validate this 
hypothesis. Finally, in a recent pilot study, Buigues et al., [264] isolated autologous BM-
MSCs and injected them into one ovarian artery of 10 women of advanced maternal age 
with decreased fertility; the contralateral ovary of each woman was considered to be a 
control. Serum AMH and antral follicular count (AFC) were monitored for up to 5 
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months after the injection. An enhancement of AFC of ≥ 3 follicles was considered as a 
successful outcome. Injection of MSCs improved the AFC in 40% of the patients in the 
first two weeks after MSC injection; in 30% of the patients, in addition to an increase in 
AFC there were two consecutive increases in AMH.  
 In the studies reviewed above, increased follicular activity was detected in the 
ovaries of recipient females as early as 2 weeks after MSC injection; however, it takes a 
mouse primordial follicle about 1 month to grow and reach ovulatory maturity (this 
period is approximately 4 months in women) [22]. Thus, it is unlikely that the injected 
MSCs were triggering oogenesis or even growth of primordial follicles. Furthermore 
only one study reported the presence of injected MSCs in apparent follicles [8], but these 
cells did not develop or ovulate, suggesting that it is unlikely that they were functional 
oocytes and may have appeared in the follicles via migration. Therefore, based on the 
results of these studies, it appears that MSCs are unlikely to differentiate into follicle 
components or drive primordial follicle development, but rather may function through a 
paracrine pathway to protect endogenous cells within primary or larger follicles.  
 In summary, chemotherapy causes activation of primordial follicles and 
apoptosis of granulosa cells of growing follicles leading to oocyte and follicle loss. 
Several factors secreted by MSCs are known to promote the survival and decrease the 
apoptosis of endogenous cells. It is possible that these factors are acting on the granulosa 
cells of ovarian follicles and protecting them from the deleterious effects of 
chemotherapy. Similarly, ovarian aging causes cytological changes including oocyte 
atresia and degeneration of granulosa cells and mitochondria. It is possible that the 
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factors secreted by MSCs can act on the granulosa cells of aging follicles and protect 
them. Furthermore, it has been shown that MSCs can transfer mitochondria to other 
cells. Thus, there is a possibility that the injected MSCs could transfer healthy 
mitochondria to replace the damaged mitochondria of aging follicles.  
 
Mesenchymal Stem Cells and Ovarian Gene Expression 
 As described above, MSCs secrete a variety of growth factors, some of which 
have been found to affect follicular growth in ovaries; these factors include Vegf, which 
induces angiogenesis, promotes cell migration, and inhibits apoptosis of rat cumulus 
cells [265], Hgf, which induces angiogenesis and tissue regeneration [266], and Igf1, 
which suppresses apoptosis and causes proliferation of porcine cumulus cells [267].  
 After intra-ovarian injection of adipose-derived MSCs into rat ovaries damaged 
by CTX, Takehara et al., [10] extracted total RNA from ovaries and performed 
quantification of gene expression by RT-PCR according to the standard-curve method. 
Ovaries from females receiving CTX and MSCs had greater mRNA expression of Vegf, 
Hgf, and Igf1 than did ovaries from females that received CTX but not MSCs. MSC-
injected ovaries also had a higher expression of steroidogenic acute regulator (Star) 
which enhances the conversion of cholesterol to pregnenolone, the first step in 
production of sex steroids. Additionally, in MSC-injected ovaries, the production of all 
the HGF, VEGF and IGF-1 proteins reached levels seen in normal control ovaries. Wang 
et al., [11] also extracted total RNA from normal control ovaries and ovaries from 
females that received systemic injection of umbilical cord MSCs after CTX, and 
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performed qRT-PCR to determine levels of gene expression. The RNA expression 
pattern of ovaries from MSC-injected females was similar to that of ovaries of control 
mice, with only 33 genes differentially expressed including; Nuf2 which has a role in 
chromosome segregation during meiotic prophase, Ptgds which is important for 
reproductive tract development, Megf10 which plays a role in cell proliferation and 
apoptosis, and Saa1 which is highly expressed in response to inflammation and tissue 
injury. In contrast, 91 genes were differentially expressed between normal control 
ovaries and ovaries from CTX-treated females that did not receive MSCs. Additionally, 
Wang et al., [11] reported that umbilical cord MSCs rescued the expression of important 
proteins from the aldo-keto reductase family 1 which catalyze the conversion of 
progesterone to 20-alpha dihydroprogesterone, a reaction thought to be important for 
luteolysis and overall reproductive health. Amounts of this protein were very low in the 
CTX-treated group; however, after MSC therapy, they increased to normal levels. In 
both of these studies, the changes in gene expression were associated with increased 
ovarian activity, i.e., increased follicle numbers and corpora lutea in MSC-treated mice 
and rats [10, 11], and increased fecundity in MSC-treated mice (13.6 litters in MSC-
treated females compared to 9.4 litters in saline-injected control females) [10]. Finally, 
in a pilot study Buigues et al., [264] quantified the soluble factors released by BM-
MSCs used for ovarian artery injections in aged women; among the factors identified, 
fibroblast growth factor-2 (FGF-2) and thrombospondin (THSP-1) were positively 
correlated with the enhancement of AFC. 
 These studies indicate that intra-ovarian or systemic injection of MSCs into 
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ovaries induces mRNA and protein expression of genes that may improve the function of 
ovaries compromised by chemotherapy. However, little information is available on the 
effect of MSC injection on the aging ovary, an application which, if effective at 
increasing fertility, would have an impact on millions of women undergoing assisted 
reproduction because of age-related infertility.  
 
CONCLUSIONS AND AIMS 
 The findings from the papers reviewed indicate that MSCs secrete trophic factors 
and appear to restore the ovarian function of females who have decreased follicle 
numbers and oocyte quality due to chemotherapy. Age-related changes also result in 
decreased follicle numbers and oocyte quality reducing fertility in aging females, and it 
is possible that BM-MSCs could restore or improve ovarian function in aging females. 
The mare offers a useful model to explore this possibility as age-associated changes in 
fertility in the mare parallel those in women.  
 The studies presented in this dissertation aimed to evaluate for the first time, 
using the mare as a model, whether intra-ovarian injections of BM-MSCs may improve 
ovarian function in aging females, and if so, the mechanism by which these effects are 
accomplished, i.e., to: 1) determine whether intra-ovarian injections of BM-MSCs 
increase the number of antral follicles visible on ultrasonography; 2) determine whether 
QD-labeled BM-MSCs colonize the ovaries and if so, which areas; 3) determine whether 
in vitro co-culture of BM-MSCs with ovarian explants increases the expression of genes 
related to growth and repair; and 4) determine whether ovarian tissues recovered after in 
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vivo BM-MSC injection show different gene expression from non-injected mares. We 
hypothesized that injection of MSCs into the ovaries of mares would increase follicle 
numbers and increase the expression of genes related to follicle growth. The results from 
these studies could have potential implications in both human and equine reproduction. 
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CHAPTER III 
 PROOF OF CONCEPT: INTRA-OVARIAN INJECTION OF BONE  
MARROW-DERIVED MESENCHYMAL STEM CELLS IN MARES 
 
INTRODUCTION  
 Adult bone marrow-derived mesenchymal stem cells (BM-MSCs) have emerged 
as a key element in regenerative medicine therapies due to their ability to aid in repair of 
damaged tissue and their potential to treat degenerative disease [180-184, 189, 268, 
269]. In rat and mouse ovaries compromised by chemotherapy, injection of MSCs 
enhances ovarian function, as determined by follicle number, and induces mRNA and 
protein expression of genes that may improve ovarian function [10, 11]. However, little 
information is available on the effect of MSCs on the aging ovary, an understanding of 
which would have a potential impact on millions of women undergoing assisted 
reproduction because of age-related infertility. The mare offers a useful model to explore 
this possibility, as age-associated changes in fertility in the mare parallel those in 
women. In addition, the procedure also has potential clinical relevance in the mare, as 
considerable interest exists in the equine industry to establish pregnancies from older, 
valuable mares. To the best of our knowledge, intra-ovarian injections of MSCs in mares 
have not been performed previously. This preliminary study was performed to determine 
the feasibility of injection of autologous and allogeneic BM-MSCs into the stroma of the 
ovary in the live mare. 
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MATERIALS AND METHODS 
Animals 
 This study was performed from January to December 2014. Two mares, age 7 yr, 
were housed in pens at the College of Veterinary Medicine Research Park and had ad 
libitum access to hay and fresh water throughout the study, and supplemental grain. All 
procedures were approved by the Texas A&M University Institutional Animal Care and 
Use Committee and were performed using guidelines set forth by the United States 
Government Principles for the Utilization and Care of Vertebrate Animals Used in 
Testing, Research and Training.  
 
Experimental Design 
 The mares were randomly assigned to receive one of 2 MSC treatments: self (SF; 
autologous) or allogeneic (AL). Blood was collected from each mare and processed to 
recover serum, which was frozen. Bone marrow aspirates were harvested from the SF 
mare at two different time points during the study. MSCs were isolated from the 
aspirates and expanded in culture, labeled with fluorescent nanoparticles (Quantum dots; 
QDs) and cryopreserved in serum autologous to the mare to be injected. 
 Two intra-ovarian injections of MSCs, 5 months apart, were performed in each 
mare. The mares were monitored by physical examination and ultrasonography of the 
reproductive tract per rectum at 1, 3 and 7 days after each intra-ovarian injection of 
MSCs, then by ultrasonography per rectum every 14 days thereafter for 8 months. 
Starting 14 days post-injection, follicles greater than 8 mm in diameter were aspirated by 
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ultrasound-guided transvaginal aspiration (TVA) every 14 days to evaluate oocyte 
competence for nuclear maturation and development to the blastocyst stage in vitro after 
intracytoplasmic sperm injection (ICSI). 
 Seven months after the second injection, the ovaries of both mares were removed 
by ovariectomy via colpotomy. The ovaries were examined for gross pathology, 
histopathology, and presence of QDs, and ovarian tissue samples from the AL mare were 
submitted to the UC Davis Veterinary Genetics Laboratory for analysis of genomic and 
mitochondrial chimerism. 
 For analysis of follicle number, the number of follicles aspirated at each TVA in 
the two injected mares, and in the mares in the remainder of the research herd (control 
mares) which had not received intra-ovarian injections but which underwent similar 
follicular TVAs every 14 days, was recorded.  
 
Serum Samples 
 Blood, 120 ml from each mare, was obtained via venipuncture of the jugular vein 
using 60-ml syringes and an 18-G needle. After collection, blood samples were kept at 4 
ºC for 30 min and allowed to clot. The blood samples were then centrifuged for 10 min 
at 4000 x g and the serum was collected with a 20-ml syringe and an 18-G needle, 
filtered through a 0.2-µm filter, transferred into 15-ml conical tubes (Sigma-Aldrich, St. 
Louis, MO) and frozen at -20 ºC for later use. 
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Bone Marrow Harvest and Cell Culture  
 Bone marrow was harvested from sternal aspirates from the SF mare on two 
occasions, four months apart. To do this, the mare was sedated with intravenous (IV) 
administration of 0.4 mg/kg xylazine. The intersternebral spaces were identified by 
palpation on the ventral midline of the cranial thorax at the level of the elbows and the 
harvest sites were clipped of hair and aseptically prepared. Ten ml of 2% lidocaine were 
infiltrated through the subcutis and muscle layers and into the periosteum to provide 
local anesthesia. A Jamshidi Illinois sternal/iliac-aspiration needle (10-cm, 15-G) was 
introduced through the lidocaine-blocked area until it made contact with the surface of 
the sternebra. A slow, back-and-forth, rotational movement was used to advance the 
needle until it was firmly seated in the bone at a depth of 1 to 2 cm. The stylet was 
removed and a 60-ml syringe containing 10 ml of 1,000 IU/ml heparin in sterile saline 
was attached to the hub and aspiration was applied. This was repeated and a total of 100 
ml of bone marrow were collected per procedure.  
 Red blood cell lysis of the aspirates was achieved by adding 60 ml of ammonium 
chloride (7.7 mg/ml NH4Cl in phosphate buffered saline buffered with 206 mg/ml TRIS 
(hydroxymethane-aminomethane); pH 7.2) to the 120 ml of aspirate/heparin, suspending 
the cells by pipetting, and centrifuging at 300 x g for 5 min. The supernatant was 
aspirated and the remaining nucleated cellular portion of the marrow was resuspended to 
120 ml with standard MSC culture medium consisting of Dulbecco’s modified Eagle’s 
medium (DMEM 1 g/l glucose; Mediatech, Manassas, VA) supplemented with 10% fetal 
bovine serum (FBS; HyClone Inc, Logan, UT),  2.5% HEPES buffer (Corning, St. 
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Louis, MO), 1 ng/ml basic fibroblast growth factor (bFGF; Sigma-Aldrich) and 1% 
antibiotic-antimycotic (10,000 U penicillin, 10,000 µg/ml streptomycin, 25 µg/ml 
amphotericin B; GIBCO; Invitrogen, Carlsbad, CA). This suspension was plated at 30 
ml/175-cm2 flask and maintained at 37 °C in a humidified atmosphere of 5% CO2. The 
medium was refreshed and non-adherent cells discarded three times per week. When the 
monolayers reached 70% confluence, adherent MSCs were resuspended by treatment 
with 0.05% trypsin, counted with a hemocytometer, and reseeded as “Passage 1” (P1) at 
a density of 5 to 8 x 103 cells/cm2. P1 cells were allowed to multiply to 70% confluence 
before trypsinization and successive passage. 
 Cells from P4 were trypsinized, resuspended in Dulbecco’s phosphate-buffered 
saline (DPBS; BioWhittaker; Lonza, Walkersville, MD) and counted with a 
hemocytometer. To aid in identification of MSCs after injection, a commercially-
available fluorescent nanoparticle kit (Qtracker 605 Cell Labeling Kit, Q25001MP; 
Invitrogen) was used to label the cells with QDs following the directions provided by the 
manufacturer. Briefly, a QD labeling solution was prepared by mixing 1 µl each of 
Qtracker Reagent A and B in a 1.5 ml microcentrifuge tube (10 nM/l concentration of 
QDs) and incubated for 5 min at room temperature. Standard MSC culture medium (0.2 
ml) was added to the QD labeling solution and the solution was vortexed for 30 sec. A 1-
ml cell suspension containing 1 x 106 cells in MSC culture medium was added to the QD 
labeling solution. The cells in QD labeling solution were incubated at 37 °C for 60 min, 
after which they were washed twice with serum-free medium consisting of DMEM 
supplemented with antibiotics and 1% ITS premix (1 mg/ml insulin, 0.55 mg/ml 
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transferrin, and 0.5 µg/ml selenium; VWR, Radnor, PA). 
 After being washed, the cells were frozen in cryopreservation medium containing 
95% serum, autologous to the mare that would receive the injection, and 5% dimethyl 
sulfoxide (DMSO) at a concentration of 10 x 106 cells/ml. Cryovials containing this 
suspension were placed in a Cryo 1 °C Freezing Container (Thermo Scientific; VWR, 
Radnor, PA) for 24 h at -80 °C before transfer to liquid nitrogen where they were stored 
until used. 
 
Characterization of MSCs 
 The MSCs used in this study (from Mare SF) were characterized based on the 
criteria proposed by the International Society for Cellular Therapy [202] by their ability 
to adhere to plastic (as seen in cell culture, above), chondrogenic differentiation 
potential, and specific surface antigen expression based on the literature discussed in 
Chapter II, i.e., positive for CD44, CD29 and CD90, negative for CD45 [203], with 
variable expression of MHC II [204]. Cells from the first BM aspirate performed in this 
mare were characterized. 
 
In Vitro Colony-Forming Assay 
 To assess the proportion of MSCs in the first BM aspirate, the number of colony-
forming units (CFUs) per 1,000 BM cells, after red blood cell lysis, was determined. The 
proportion of viable cells was determined by staining a 100-µl sample with propidium 
iodide (PI; 1.35 mg/ml) and fluorescein diacetate (FDA; 67.57 mg/ml) in DPBS. 
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Immediately after staining, 10 µl of the cell suspension were placed in the chamber of a 
Neubauer hemocytometer and visualized by fluorescence microscopy (Olympus, Center 
Valley, PA). Non-viable cells were detected by nuclear staining with PI, as this 
fluorescent stain is excluded from cells with intact membranes. The FDA stain indicated 
viability, as enzymatic activity of live cells is required to activate FDA’s fluoresce and 
cell-membrane integrity is required for the intracellular retention of the fluorescent 
product. The live (green) and dead (red nucleus) cells were counted. A total of 10 
squares (corner and middle squares of each counting grid) were counted. The 
concentration of the cell suspension was determined and the amount of cell suspension 
calculated to contain 1,000 viable cells was seeded onto a 10-cm tissue culture dish 
containing 9 ml of standard MSC culture medium. The dish was maintained at 37 °C in a 
humidified atmosphere of 5% CO2 in air. Medium was changed every other day. After 
ten days, the cells were rinsed with phosphate-buffered saline (PBS) and stained with 
3% crystal violet solution for 8 min to visualize colonies. The number of colonies was 
determined by counting manually without magnification. 
 
In Vitro Chondrogenic Differentiation 
 QD-labeled MSCs were induced to differentiate into chondrogenic pellets by 
centrifuging 2.5 x 105 cells in chondrogenesis-induction media (DMEM with 4.5 g/l 
glucose, supplemented with 1% FBS, 2.5% HEPES buffer, 1% antibiotic-antimycotic 
(GIBCO), 10 ng/ml transforming growth factor beta (TGF-β3; Life Technologies), 0.6 
µg/ml dexamethasone (Sigma Aldrich), 50 µg/ml L-ascorbic acid, 40 µg/ml proline 
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(Sigma Aldrich), and 1% ITS premix (VWR). Pellets were maintained in static culture at 
37 °C in a humidified atmosphere of 5% CO2 for 21 days with medium changes every 
other day. On day 21 the pellets were fixed with 4% paraformaldehyde (PFA; Sigma 
Aldrich) at room temperature for 10 min, after which they were embedded in paraffin. 
Sections were stained with hematoxylin and eosin (H&E) and visualized under light 
microscopy to determine the presence of round chondrocytes embedded in extracellular 
matrix. This was performed in triplicate for the first aspirate. 
 
Phenotype Analysis by Flow Cytometry 
 Cells of P3 from the first aspirate were immunophenotyped by assessing 
immunoreaction using mouse anti-horse antibodies to MHC class II (Product No: 
MCS1085PE; Bio-Rad, Raleigh, NC), CD44 (Product No: MCA1082F; Bio-Rad), CD29 
(Product No: 6603177; Beckman Coulter, Brea, CA), CD90 (Product No: DG2011; 
VMRD Inc, Pullman, Washington), and CD45 (Product No: HR-DG2009; VMRD). The 
antibodies against MHC II, CD44 and CD29 were fluorescently-labeled with fluorescein 
isothiocyanate (FITC). The antibodies against CD90 and CD45 were not labeled with 
FITC and a secondary goat anti-mouse IgG antibody, labeled with phycoerythrin (PE), 
was used for visualization.  
 MSCs were aliquoted at 1 x 106 cells per Eppendorf tube in 50 µl staining buffer. 
To stain MSCs with directly-labeled antibodies (MHC II, CD44, and CD29), antibodies 
were diluted at 1:100 and incubated with the cells for 45 min at 4 ºC. Cells were 
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centrifuged at 400 x g for 5 min, then washed with 200 µl DPBS and centrifuged again 
before being resuspended in 500 µl DPBS for analysis. 
 To stain MSCs with non-labeled antibodies (CD90 and CD45), the dilutions used 
were 1:400 for CD90 and 1:10 for CD45. The cells were incubated on ice for 15 min 
before centrifugation (400 x g) for 3 min. Cells were then washed twice with 100 µl 
DPBS before being resuspended. One hundred microliters of secondary antibody at a 
dilution of 1:100 were added and the cells were incubated on ice in the dark for 15 min 
before centrifugation at 400 x g for 5 min. Cells were washed with 200 µl DPBS and 
centrifuged again before being resuspended in 500 µl DPBS for analysis.  
 All cell suspensions had 5 µl 7-aminoactinomycin (7-AAD; Biolegend, San 
Diego, CA) added immediately prior to analysis, for assessment of viability. 7-AAD has 
a strong affinity for DNA but does not readily penetrate intact cell membranes; 
therefore, it can be used to determine cell viability because only cells with compromised 
membranes will be stained with 7-AAD. A sample of unlabeled MSCs and MSCs 
labeled only with secondary antibody were also analyzed by flow cytometry as controls.  
 Acquisition of the cell surface marker data was performed using a Becton 
Dickenson FACS Caliber flow cytometer using Cell Quest Version 3.3 (BD San Jose, 
CA). FITC, PE and 7-AAD were detected using a 488 nm laser with a 515/30 bandpass 
filter, 585/42 bandpass filter, and 650 Long Pass filter, respectively. At least 10,000 live 
events were collected. Data analysis was performed using FlowJo 9.8 Mac version 
(TreeStar Corp., Ashland, OR).  
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Intra-ovarian Injections 
 For intra-ovarian injection, the mares were sedated by IV administration of 
0.005-0.01 mg/kg detomidine. Immediately prior to the MSC injection, 10 mg 
butorphanol tartrate and 120 mg n-butylscopolammonium bromide were administered 
IV. Previously-cryopreserved autologous or allogeneic MSCs, suspended in serum 
autologous to the mare receiving the injection, were thawed in a 37 °C water bath for 3 
min. One ml of cell suspension containing 1.0 x 107 cells was divided among 4 1-ml 
syringes (250 µl of cell suspension per syringe). The syringes were attached, one at a 
time, by tubing to an 18-G x 60-cm single-lumen transvaginal needle to perform the 
injections. The volume of the tubing and needle was measured prior to the injections in 
order to determine the volume of the apparatus itself, and thus the volume of medium 
needed to ensure that the entire 250 µl of the cell suspension were delivered into the 
ovary. This volume varied with the individual apparatus used, and was ~2 ml. When the 
injections were performed, the 250 µl of cell suspension was ejected into the line and 
this was followed by the predetermined amount of DPBS medium.  
 Intra-ovarian injection was performed using a transvaginal, ultrasound-guided 
technique as originally described for TVA by Brück et al., [270] and modified by 
Jacobson et al., [271]. Briefly, a curvilinear transducer housed in a vaginal probe handle 
was introduced through the vulva and vestibule and placed with the transducer in the 
anterior fornix of the vagina. The ovary to be injected was grasped per rectum and pulled 
toward the transducer. When the ovary was visualized on the ultrasound screen, the 
needle was advanced through the cranial vaginal wall and into the ovary. The needle was 
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passed into the ovarian stroma, avoiding visible follicles, and the cell suspension was 
gently expressed as the needle was withdrawn from the ovary. This procedure was 
performed in 4 different locations per ovary. After both ovaries were injected, the mares 
received 500 mg flunixin meglumine and 6.6 mg/kg gentamicin IV, and 22,000 U/kg 
penicillin G procaine intramuscularly (IM). 
 
Aspiration of Follicles for Oocyte Recovery 
 Ultrasound-guided TVA of all immature follicles ≥ 8 mm in diameter was 
performed on both mares every 14 days after MSC injection as described above for 
intra-ovarian injection, but with the modification that when the ovary was visualized on 
the ultrasound screen, a 12-G x 60-cm double-lumen oocyte aspiration needle (Cook 
Veterinary Products, New Buffalo, MI) was advanced through the cranial vaginal wall 
and into the ovary. Each visible follicle was aspirated and flushed 6 times with M199 
Hank’s salts with 25 mM HEPES (GIBCO) containing 0.4% FBS (GIBCO), 8 IU/ml 
heparin (Sigma Aldrich) and 25 µg/ml gentamicin (GIBCO). After TVA was completed, 
each mare was administered 500 mg flunixin meglumine IV.  
  Recovered flushed media and oocytes were filtered through an embryo filter 
(EmCon filter, Immuno Systems, Inc., Spring Valley, WI) and oocytes were located 
using a dissection microscope. 
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Assessment of Follicle Number 
 Every follicle ≥ 8 mm diameter visible on ultrasonography was aspirated by 
TVA. All the TVAs were performed by the same team; ovaries were manipulated by the 
same operator while a second operator manipulated the needle. The follicle numbers 
were determined from the count of aspirated follicles of both ovaries. 
 
In Vitro Maturation and Intracytoplasmic Sperm Injection of Recovered Oocytes 
 Recovered oocytes were held overnight in EH holding medium (40% M199 
Earle’s salts (GIBCO), 40% M199 with Hanks’ salts, and 20% FBS) at room 
temperature as previously described by Choi et al., [272]. After overnight holding, 
oocytes were transferred to maturation medium (M199 with Earle’s salts, 5 mU/ml FSH 
(Sioux Biochemicals, Sioux Center, IA), 10% FBS and 25 µg/ml gentamicin) for 24-30 
h before ICSI. Oocytes were cultured in droplets at a ratio of 10 µl medium per oocyte, 
under light mineral oil (Sage, Origio; Knardrupvej, Denmark.) at 38.2 °C in a humidified 
atmosphere of 5% CO2 in air.  After the maturation period, oocytes were denuded of 
cumulus by pipetting in a solution of 0.05% hyaluronidase (Sigma Aldrich), and oocytes 
with an intact membrane and a polar body underwent ICSI.  
 Intracytoplasmic sperm injection was performed as previously described by Choi 
et al., [273] under micromanipulation using a Piezo drill. After ICSI, oocytes were held 
in post-ICSI holding medium (CZB-H [274] or M199/Earle salts with 10% FBS) for 2 h 
at 38.2 °C in 5% CO2 in air. After the post-injection holding period, presumptive zygotes 
were cultured in a commercial human embryo culture medium (GB; Global medium, 
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LifeGlobal, Guilford, CT) supplemented with 10% FBS [273] in microdroplets under oil 
(1 µl  of medium/embryo). The culture environment was 6% CO2, 5% O2 and 89% N2 at 
38.2 °C. Medium change and cleavage examination were conducted at Day 5, and only 
cleaved embryos were cultured further. Medium was changed to GB with 20 mM added 
glucose at Day 5. Embryos were checked daily from Day 7 to Day 10 post-ICSI for 
blastocyst development as evidenced by the formation of a presumptive trophoblast layer 
immediately inside the zona pellucida and decreased density centrally. As a control for 
the in vitro maturation and ICSI procedures, an ICSI-control replicate was performed 
concurrently with a replicate of oocytes from MSC-injected mares, at least once every 
two weeks.  
 
Ovariectomy and Ovarian Tissue Processing 
 Seven months after the second injection, the ovaries of the mares were surgically 
removed. The mares were sedated by IV administration of 250 mg acepromazine, 0.005-
0.01 mg/kg detomidine, and 10 mg butorphanol. Immediately prior to surgery, each 
mare received 20 mg/kg ampicillin, 6.6 mg/kg gentamicin, and 500 mg flunixin 
meglumine IV, and 1 ml of tetanus toxoid vaccine IM.  
 Ovariectomies were performed via colpotomy as described by Slone [275]. 
Briefly, the tail of the mares was wrapped and secured, the rectum was evacuated of 
feces, and the perineal area was aseptically prepared. The vagina was distended with air 
and a blind stab incision was made in the right craniodorsal vaginal wall using the tip of 
a #10 scalpel blade. The incision was digitally enlarged and blunt scissors were used to 
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thrust through the peritoneum; the incision was enlarged enough for the entire hand to 
enter the peritoneal cavity. The ovarian pedicle was identified and anesthetized by 
holding gauze soaked with 2% lidocaine around the pedicle for 3 min. The gauze was 
secured with umbilical tape to prevent loss in the peritoneal cavity. The ovary was 
removed with an écraseur (Jorgensen Laboratories, Loveland, CO) and the opposite 
ovary was then anesthetized and removed in the same way through the same incision. 
Administration of penicillin G procaine (22,000 IU/kg, IM), gentamicin (6.6 mg/kg, IV), 
and flunixin meglumine (500 mg, IV) was continued for 5 days, and 10 mg of 
butorphanol was administered as needed if the mare showed signs of pain such as 
elevated heart or respiratory rates, agitation, or lack of appetite.  
 After removal, the ovaries were examined for gross pathology and each ovary 
underwent sagittal bisection. A scalpel blade was used to dissect 15 x 15 x 1 mm 
fragments from different sections of the ovary, which were placed in Bouin’s solution at 
room temperature, and after 24 h were placed in 70% ethanol until histological 
processing. The ovarian fragments were embedded in paraffin and cut into 7-µm 
thickness sections which were stained with periodic acid-Schiff (PAS) and hematoxylin 
(H&E) [276]. Four slides from each ovary of each mare were submitted to the Texas 
A&M Veterinary Medical Diagnostic Laboratory (TVMDL) for histopathological 
analysis. Four additional slides from each ovary of each mare were examined under a 
fluorescent microscope for the presence of QDs. 
 Additional 2 x 2 mm fragments were obtained from each ovary of the AL mare 
and were frozen at -20 °C. Ovarian tissue from the AL mare, as well as hair samples 
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from the AL and SF mares, were submitted to the Veterinary Genetics Laboratory at the 
University of California for genomic microsatellite profiling and mitochondrial genotype 
analysis to assess genomic microsatellite identification markers and sequence of the 
mitochondrial D-loop hypervariable region, to detect genomic or mitrochondrial 
chimerism indicating the presence of the transferred allogeneic cells (cells from mare 
SF). 
 
Statistical Analysis 
 Differences in number of follicles for MSC-injected and control mares among the 
treatment periods were determined using Bayesian modeling in WinBUGS 1.4.3. The 
follicle count for each mare was modeled as a Poisson distribution. The Poisson 
parameters were modeled as a function of the expected follicle count, a mare-specific 
random effect, and a treatment effect. The one-week period before the first injection and 
the 8-week period (4 TVAs) before the second injection were considered the “pre-
treatment” period; the 4-week period following MSC-injections was considered the 
“treatment” period; and, the 10-week (5 TVAs) and 6-week (3 TVAs) periods following 
the first and second injections, respectively, was considered the “post-treatment” period. 
The increase (or decrease) in follicles was compared in the MSC-injected mares between 
pre-treatment, treatment, and post-treatment periods, and in control mares during the 
concurrent times.  
 The oocyte recovery rate (oocytes recovered per follicle aspirated on TVA), 
proportions of oocytes reaching metaphase II in culture, and the proportion of oocytes 
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developing to blastocyst after ICSI were compared among the Pre-treatment, Treatment 
and Post-treatment periods within mare group (MSC-injected or control mares) using 
Chi-square analysis, with Fisher’s exact test used when a value < 5 was expected for any 
parameter. Significance was defined as P < 0.05. 
 
RESULTS 
Mare Health and Ovarian Status 
 Intra-ovarian injections of autologous or allogeneic MSCs were not associated 
with any observed signs of discomfort or systemic illness in the mares. Temperature, 
pulse and respiration rates were within normal limits for the 7-day period in which they 
were evaluated after injection. Both mares continued to appear bright, alert and 
responsive, and in good health for the 12 months after the first injection (7 months after 
the second injection) until ovariectomy.   
 Examination of the ovaries of the mares, removed after two MSC injections into 
each ovary, showed no gross pathology. Histopathologic examination revealed 
infiltration of the lining of some degenerating follicles by neutrophils and lymphocytes 
interpreted by the pathologist as mild to moderate folliculitis and considered to be of no 
clinical significance, in both ovaries of both mares. It was not possible to determine if 
the inflammatory changes were the results of normal follicle atresia or a result of ovarian 
puncture for TVA or MSC injection. 
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 There were no QDs detected in the ovarian sections examined (4 sections per 
ovary per mare). Genetic analysis of tissue from the AL mare revealed microsatellite ID 
and mitochondrial genotype for only this mare (no alleles present from the MSC donor). 
 
Colony-Forming Assay, Chondrogenic Differentiation and Phenotypic Analysis 
 The MSCs isolated and used for intra-ovarian injections formed 89 colonies per 
thousand original bone marrow aspirate cells. The MSCs showed evidence of 
differentiation to a chondrogenic cell lineage when pelleted and cultured in appropriate 
medium, as seen by the histological presence of round chondrocytes embedded in 
extracellular matrix (Figure 3.1). Immunophenotypic analysis of MSCs at P3 by flow 
cytometry revealed that MSCs had a high expression (99%) of CD29 and CD90 markers, 
low expression (3 to 4%) of CD44 and CD45 markers, and mixed expression of MHC II 
(Figure 3.2), consistent with results from De Schauwer [203] and Schnabel [204]. 
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Figure 3.1 Chondrogenic pellet after MSC differentiation. Overview of the entire 
pellet section shows the typical round morphology of chondrocytes (arrow heads) 
embedded in abundant extracellular matrix. Stained with H&E. Original magnification 
100 X. 
 
 
 
 
 73 
 
 
Figure 3.2 Flowcytometric histogram analyses of cell surface markers in P3 BM-
MSCs. The black lines represent negative control staining and the blue lines represent 
cell surface marker staining of MSCs. The percentage of positive cells is indicated in 
each histogram. 
 
 
 
Follicle Numbers 
 
 There was a marked increase in the number of ovarian follicles identified in 
MSC-injected mares in the 4 weeks after MSC injection for both injections (Figure 3.3). 
There was a significantly higher follicle number during the Treatment period than for 
these mares in either the Pre-treatment or Post-treatment periods (P < 0.0001 and P = 
0.0025, respectively; Figure 3.4). The number of follicles in the Post-treatment period 
was also significantly higher than in the Pre-treatment period (P = 0.003). Prior to 
injection the subject mares had a mean of 6 follicles (4.25, 8.5; lower 2.5% and upper 
97.5% limits, respectively) per two ovaries. This increased to 15.25 (11, 19.5) during the 
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Treatment period. The mean number of follicles during the Post-treatment period was 10 
(7.5, 12). In the Control mares, the mean number of follicles during the period 
concurrent with the Treatment period was 10.6 (8, 13) which was not significantly 
different from the number of follicles in the control mares during the periods concurrent 
with the Pre-treatment (11.24 (6.25, 15); P = 0.81) or Post-treatment periods (12.56 (8, 
13); P = 0.67).  
 
Oocyte Recovery, Maturation and Blastocyst Formation 
 Over the period of the study, 16 TVA sessions were performed in the treated 
mares. There was no difference in oocyte recovery rate between the MSC-injected and 
Control mares in any period (Table 3.1). The overall oocyte maturation rate was higher 
in control mares (61.2%, 85/139) than in MSC-injected mares (47.1%, 64/136; P = 0.02), 
and the overall blastocyst rate tended to be higher for Control (32.8%, 21/64) than for 
MSC-injected (18.8%, 12/64) mares. However, there were no significant differences in 
oocyte recovery, maturation or blastocyst rates in either MSC-injected or Control mares 
among periods (Table 3.1).  
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Figure 3.3 Total follicle numbers of autologous (SF) and allogeneic (AL) mares 
throughout the study.  Follicle numbers were those recorded on performing TVA. 
Arrows: dates on which MSC injections were performed. Pre-Treatment: filled square 
markers; Treatment: open square markers; Post-treatment: triangular markers. Gray 
squares denote follicle numbers determined prior to the onset of the study that were not 
included in the analysis.  
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Figure 3.4 Number of follicles in MSC-injected mares and control mares over the 
period of the study. Pre-treatment period: the 1 week preceding the date of the first 
injection and the 4 weeks preceding the date of the second MSC injection in treatment 
mares; Treatment: the 4 weeks following MSC injection to treatment mares; Post-
treatment: the 5 weeks after the first injection and the 3 weeks after the second injection. 
a, b, c: within MSC-injected mares, values with different superscripts differ significantly 
(P < 0.01). Within control mares, there was no significant effect of period (P > 0.05). 
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Table 3.1 Rates of oocyte recovery, in vitro maturation to metaphase II (MII), and 
of blastocyst formation after ICSI of MSC-injected and control mares.  
 
 
 
MSC-injected  Control 
 Oocyte recovery 
Maturation 
to MII Blastocyst 
 Oocyte 
recovery 
Maturation 
to MII Blastocyst 
Pre-
treatment 
47.4% 
(37/78)a 
48.6%  
(18/37)a 
16.7% 
(3/18)a 
 43.2% 
(41/95)b 
48.4%  
(15/31)b 
 
Treatment 46.7% (57/122)a 
45.6% 
(26/57)a 
23.1% 
(6/26)a 
 51.5% 
(69/134)b 
65.2% 
(45/69)b 
34.9% 
(15/39)b 
Post-
treatment 
35.3% 
(42/119)a 
47.6% 
(20/42)a 
15% 
(3/20)a 
 42.9% 
(102/238)b 
64.1% 
(25/39)b 
28.6%  
(6/21)b 
 
There was no ICSI performed in control mares during the pre-treatment period. There 
were no significant differences in oocyte recovery, maturation or blastocyst rates in 
either MSC-injected or control mares among periods (P > 0.05). In control mares, 
missing values represent oocytes used for separate projects. 
 
 
 
DISCUSSION 
 
 The results from this study suggest that intra-ovarian injections of allogeneic and 
autologous MSCs are safe to perform in mares, as no detrimental effects were seen in 
mare health or ovarian status in injected mares. The mild folliculitis found on 
histological examination could have been the result of the repeated TVAs (the injected 
mares underwent 16 TVAs in the yr before ovariectomy) or of the MSC injections. 
 Although the main purpose for this study was to evaluate the feasibility of intra-
ovarian injection of MSCs in mares, the apparent increase in follicle numbers in the two 
MSC-injected mares in the 4 weeks after injection led us to analyze whether this effect 
was significant. Because this analysis was not planned a priori, the numbers of 
evaluations in the different periods are not uniform.  
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 Injections of MSCs in other species have been associated with an improvement 
in ovarian function, as determined by an increase in follicle number and fecundity, in 
females with ovaries compromised by chemotherapy [8-11, 262, 263]. In the present 
study there was a significant increase in follicle numbers in treated mares when 
evaluated 14 and 28 days after MSC injection. Because this increase in follicle numbers 
was seen so soon after MSC injection, it is unlikely that the MSCs are differentiating 
into oocytes or follicle components. Instead, it is possible that MSCs stimulate the 
growth of large secondary follicles or antral (tertiary) follicles already present within the 
ovary, resulting in an increase in numbers of antral follicles identifiable on 
ultrasonography. Oocyte recovery, maturation and blastocyst rates remained unchanged 
in the treated mares following MSC injections. These data indicate that intra-ovarian 
injection of BM-MSCs does not affect the developmental competence of oocytes. 
 The MSCs used for the intra-ovarian injections in the present study were 
obtained from a 7 yr old mare, and characterized by their adherence to plastic, ability to 
differentiate into a chondrogenic lineage, and specific cell-surface markers. Although 
equine MSCs have been shown to express CD44 (a hyaluronate receptor involved in 
cell-cell interactions, cell adhesion and migration [277]), the MSCs used in the present 
study did not exhibit this marker. However, proper identification of equine MSCs 
remains a challenge due to the lack of suitable antibodies. Although a panel of markers 
has been proposed and is routinely used for the proper identification of equine MSCs, it 
has been suggested that expression of CD markers can be influenced by cell culture 
conditions and isolation methods [203, 204]. Thus, the cells’ ability to differentiate into 
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different mesenchymal tissue types, as shown by chondrogenic differentiation in this 
study, has been suggested to be the best method to characterize MSCs [278, 279].  
 The lack of chimerism detected in the ovaries of the AL mare 7 months after the 
second injection suggests that the injected MSCs did not persist or multiply within the 
ovary. However, it is possible that MSCs were present in the ovarian tissue but at levels 
that were below the threshold that could be detected by the analyses run. We evaluated 
both microsatellite ID markers and mitochondrial genotype in the AL mare, as it has 
been suggested that mitochondria from injected MSCs may be transferred to host cells 
[199]. The analyses were negative for both DNA species, thus there was no evidence of 
chimerism in the ovaries. However, the possibility exists that MSC-derived cells were 
present in the ovaries, just not in the ovarian sections evaluated.  
 We also attempted to determine if MSCs colonize the ovary by labeling the cells 
with fluorescent nanoparticles (QDs) and then identifying cells containing these particles 
after ovary removal. However, examination of ovarian sections post-ovariectomy did not 
reveal the presence of QDs. It is not possible to determine where the QD-labeled MSCs 
were injected, so the possibility exists that QDs were present and localized only to the 
area of injection, and were not in the examined ovarian sections. Although equine BM-
MSCs have been shown to migrate in vitro, these cells migrate at a slower rate than do 
adipose-derived MSCs [280]. In vivo it has been shown that equine BM-MSCs remain 
close to their site of injection in artificially-induced tendon lesions [281]. It is possible 
that QDs would have been found if the ovaries had been removed sooner after the MSC 
injection; however, to the best of our knowledge, there is no information on how long 
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QDs persist in equine MSCs in vitro or in vivo. To investigate this, we conducted a study 
(see Chapter V) to determine the duration for which the QDs were detectable in equine 
MSCs that were either proliferating or not proliferating in culture.   
 Currently, little information is available on the effect of MSCs in the aging ovary 
[12, 13]. If validated in a larger experiment, the information generated in this study 
could have potential implications in both human and equine reproduction. Based on the 
results of the present study, a more comprehensive study involving a larger sample size 
that included both young and old mares was performed and is described in Chapter VII 
of this dissertation.  
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CHAPTER IV 
 EFFECT OF DIFFERENT POST-THAW CONDITIONS ON EQUINE 
MESENCHYMAL STEM CELL VIABILITY 
 
INTRODUCTION 
 Adult mesenchymal stem cells (MSCs) are increasingly being used in 
regenerative therapies because of their capacity to repair tissue damaged due to injury 
and disease. In horses, bone marrow-derived mesenchymal stem cells (BM-MSCs) have 
been shown to enhance early chondrogenesis in articular defects [180], as well as to 
improve the biomechanical, morphological and compositional parameters in age-related 
[181] and experimentally-induced [182] tendon injuries. In other species, MSCs have 
been successfully used in models of lung injury [268], kidney disease [183], diabetes 
[184], myocardial infarction [269], and neurological disorders [189]. Mesenchymal stem 
cells can be grown in vitro to high numbers and cryopreserved for long term storage 
[207, 282, 283]. Cryopreservation allows elective storage of cells that may be 
transplanted to patients at a later point in a course of treatment.  
 There is no consensus protocol for preserving MSCs. At low temperatures, 
damage can occur because of the formation of intracellular ice which can lead to cell 
death. Avoiding formation of intracellular ice is therefore essential for successful 
cryopreservation. Most cryopreservation procedures use a penetrating cryoprotectant 
such as dimethyl sulfoxide (DMSO) and a source of plasma protein, cool at a defined 
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rate, and store at cryogenic temperatures (below -150 ºC) using mechanical or liquid-
nitrogen refrigerators [205].  
 For clinical applications, MSCs must also remain viable after thawing. However, 
after thawing, a decrease in MSC viability over time has been reported, with the rate of 
viability decrease varying between different post-thaw holding temperatures and holding 
media [211, 282, 284]. The rate of dilution during thawing also affects MSC viability 
[210, 212] as osmotic injury occurs after rapid addition of dilution medium [210].  
 For the intra-ovarian injections performed in the studies described in this 
dissertation, equine MSCs were cryopreserved in 95% autologous (to the horse being 
injected) serum and 5% DMSO prior to use. The cells were injected immediately after 
thawing, then placed on ice and viability was assessed when the remaining cells in the 
cryovial were taken back to the laboratory. Because of the time needed for mare 
handling and ovarian injection, assessment of cell viability was delayed for up to 60 min, 
and it is possible that delay to assessment and prolonged exposure to DMSO affected the 
observed viability, in comparison to the viability at the time of injection. This study was 
conducted to evaluate the effects of time and post-thaw conditions on MSC viability.  
 
MATERIALS AND METHODS 
 One cryovial of previously frozen MSCs (10 x 106 cells) was thawed in a 37 °C 
water bath for 3 min. The cells were then resuspended and the cryovial was placed in an 
ice bath at 4 °C. The cell suspension in the cryovial was divided into 4 treatment groups: 
DMSO) 400 µl of cell suspension remaining in the freezing medium (5% DMSO in 
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serum); Rinse) 400 µl of cell suspension rinsed to remove DMSO (see below); Dil1) 50 
µl of cell suspension mixed with 950 µl serum to rapidly dilute DMSO; Dil2) 50 µl of 
cell suspension mixed with 50 µl serum and after 5 min another 900 µl serum to dilute 
DMSO in a step-wise manner. Cell viability for each group was assessed immediately 
and at 15, 30, 45, 60, and 120 min. The cells and solutions used were maintained on ice 
(~ 4 °C) between time points and 6 replicates were performed.  
 To rinse the DMSO out in the Rinse group, the 400 µl of cell suspension was 
placed in a 50-ml conical tube and 400 µl of Dulbecco’s phosphate-buffered saline 
(DPBS; Life Technologies) was added; after 5 min, additional DPBS was added to the 
50-ml conical tube to q.s. to 20 ml. The cells were resuspended, then the suspension was 
centrifuged at 300 x g for 5 min. The supernatant was aspirated and the cells were 
resuspended in 300 µl DBPS. 
   
Assessment of Viability 
 Viability of MSCs was assessed by staining a 100-µl sample of cells from each 
treatment group at each time point using propidium iodide (PI; 1.35 mg/ml) and 
fluorescein diacetate (FDA; 67.57 mg/ml) in DPBS, as described in Chapter III. The live 
(green) and dead (red nucleus) cells were visualized by fluorescence microscopy and 
counted. A total of 10 squares (corner and middle squares of each counting grid) were 
counted per sample. 
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Statistical Analysis 
 Data were analyzed by a two-way (factorial) ANOVA model using JMP Pro ver. 
11 for Windows (SAS Institute Inc, Cary, NC). Data were log-transformed prior to 
statistical analyses to minimize interactions between means and variances. Treatment, 
time, and treatment x time interactions were included in the model. Multiple 
comparisons were performed using the post-hoc Tukey’s HSD method to determine 
differences in viability among all treatments and time points. Differences were 
considered significant when P < 0.05. 
 
RESULTS 
 There was no significant effect of dilution treatment on cell viability at any of the 
time points evaluated. All treatments behaved similarly over time, as there was no 
treatment x time interaction (P = 0.7735). A trend toward a decrease in viability over 
time was observed within all four treatment groups; however, this decrease was 
significant only for the DMSO group (Figure 4.1); Post-hoc Tukey’s HSD tests showed 
that the viability at 120 min in the DMSO group was significantly lower than the 
viability in the DMSO group at all other time points (Appendix Table A-1). 
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Figure 4.1 MSC viability measured for each treatment group at each time point 
throughout the trial. Values represent the mean ± s.d. for six independent replicates 
from different animals. a,b: within the DMSO treatment, values with different 
superscripts differ significantly (P < 0.05); all other values are not significantly different.    
 
 
 
DISCUSSION 
 
 To use MSCs effectively for cellular therapy in regenerative medicine, it is 
essential to transport, hold, and store MSCs in optimal conditions to maintain their 
viability, and to be able to assess the viability of the cells that are used. In this study, we 
analyzed the viability of frozen-thawed MSCs in four different conditions over time.  
Our results indicate that viability of MSCs held on ice decreases slowly over time up to 
60 min post-thaw in every medium tested; after which there is a rapid decrease in 
viability in cells that remain in 5% DMSO. This is in agreement with other studies that 
have shown a decrease in MSC viability over time after thawing [211, 282, 284]. Thus, 
if cells remain in 5% DMSO, it is best to evaluate viability prior to 60 min post-thawing 
to obtain an accurate measure. If the DMSO is removed from the cells or if the DMSO is 
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diluted, MSCs can be held on ice without a significant decrease in viability for up to 120 
min post-thawing. Although it has been reported that osmotic injury from rapid addition 
of dilution medium can affect MSC viability [210], we found no significant differences 
in MSC viability between samples in which DMSO was diluted rapidly and those diluted 
in a step-wise manner, using equine serum.  
 In conclusion, following freeze-thaw, MSCs held on ice demonstrate a slow 
decrease in viability, which is more apparent if cells remain in DMSO. Rinsing cells to 
remove DMSO or adding serum, either rapidly or in a step-wise manner, to dilute 
DMSO can be used to hold MSCs with no significant effect on viability, for up to 120 
min. Thus, if cells are injected and it is anticipated that more than 60 min will elapse 
before the remaining cells can be assessed for viability, it would be advisable to add 
previously frozen/thawed serum to the remaining cells and to maintain the cells on ice 
(at ~ 4 ºC) until viability can be determined. It is possible that viability, as shown in the 
present study, does not correlate directly with functional measures of stem cell potency. 
Therefore, inclusion of other analyses such as cell-surface markers and differentiation 
assays may have yielded significant differences among the different conditions evaluated 
in the present study.  
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CHAPTER V 
 PERSISTENCE OF QUANTUM DOTS IN DIVIDING AND NON-DIVIDING 
EQUINE MESENCHYMAL STEM CELLS 
 
INTRODUCTION 
 Quantum dots (QDs) are fluorescent nanoparticles that can be used as markers 
for long-term in vitro and in vivo cell imaging applications [218, 285]. The quantum dot 
product, Qtracker® (ThermoFisher Scientific; Invitrogen; Carlsbad, CA) is frequently 
used for stem cell labeling [218] because it is resistant to metabolic degradation [285], 
has minimal cytotoxic effects, and does not interfere with cell proliferation [217]. 
Visualization of QDs in labeled rat mesenchymal stem cells (MSCs) is possible in 
cardiomyocyte co-cultures for up to seven days [217], and QDs have been demonstrated 
to be present in canine hearts 8 weeks following delivery of QD-labeled human MSCs 
[220].  
 Stem cell therapy is commonly used clinically in horses but little research has 
been done on the persistence or function of MSCs after injection in this species. In our 
study on intra-ovarian injection of bone marrow-derived MSCs (BM-MSCs; experiment 
detailed in Chapter III), to help determine if injected MSCs colonize the equine ovary, 
and, if so, in which areas, the MSCs used were labeled with QDs. However, to the best 
of our knowledge, there is no information available on the behavior of QDs in dividing 
or in differentiated equine BM-MSCs.  
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 To determine this, we conducted an in vitro study on QD persistence, i.e., the 
ability to identify QDs in MSCs over time. Live MSCs were labeled with QDs and the 
persistence of QDs in both dividing cells (in cell culture conditions) and non-dividing 
cells (in chondrogenic pellets) was evaluated. We hypothesized that dilution of QDs as a 
result of cell division would lead to decreased detection of QD-labeled MSCs as cells 
proliferated in culture, whereas they would persist in non-dividing cells. Additionally, 
we evaluated the effect of QDs on the trilineage differentiation potential and the 
immunophenotypic markers of MSCs by inducing QD-labeled MSCs to differentiate 
into adipocytes, chondrocytes and osteocytes and performing flow-cytometric 
immunophenotypic analysis on QD-labeled MSCs. 
 
MATERIALS AND METHODS 
 Previously-frozen BM-MSCs were thawed and re-plated in standard MSC culture 
medium consisting of Dulbecco’s modified Eagle’s medium with 1 g/l glucose (DMEM; 
Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS; 
Sigma-Aldrich), 1 ng/ml basic fibroblast growth factor (bFGF; Sigma-Aldrich) and 1% 
antibiotic-antimycotic (10,000 U penicillin, 10 mg streptomycin, 25 µg amphotericin 
B/ml; GIBCO; Invitrogen). The cells were plated at a density of 5-8 x 103 cells/cm2 and 
cultured at 37 °C in a humidified atmosphere of 5% CO2. Once the cells reached 70% 
confluence, they were trypsinized and divided into two groups, control and QD-labeled.  
 Cells in the QD treatment were labeled with QDs using the Qtracker® 625 Cell 
Labeling Kit (ThermoFisher Scientific) following the directions provided by the 
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manufacturer. Briefly, 2 µl of a 10-nM QD-labeling solution were added to 0.2 µl of 
medium containing 1 x 106 cells in suspension. The cells were incubated at 37 °C for 60 
min, after which they were washed twice with serum-free medium consisting of DMEM 
supplemented with antibiotics and a culture supplement providing 1 mg/ml insulin, 0.55 
mg/ml transferrin, and 0.5 µg/ml selenium (ITS; BD Biosciences, Sparks, MD). The 
cells in both Control and QD groups were then placed in either standard monolayer 
culture conditions (dividing cells) or were induced to differentiate into chondrogenic 
pellets (non-dividing). Three replicates were performed.  
 In a parallel study, control and QD-labeled cells were induced to differentiate 
into adipocytes, chondrocytes and osteocytes, then stained and evaluated for evidence of 
differentiation. Furthermore, QD-labeled cells after 4 passages in proliferative culture 
were immunophenotyped by flow cytometry. 
 
Monolayer Culture 
 Cells in the QD treatment were imaged using a fluorescent inverted microscope 
(excitation 405-585 nm) 1 h after labeling to ensure uptake of QDs, as evidenced by the 
presence of red fluorescent dots in the cytoplasm of the cells. QD-labeled and control 
MSCs were plated in cell culture flasks in standard MSC culture medium and cultured at 
37 °C in a humidified atmosphere of 5% CO2 in air. The cells within culture flasks were 
evaluated every other day until QDs were no longer detected. Multiple flasks were 
prepared and each flask was imaged only once, to eliminate the effect of photobleaching. 
The medium was replaced every other day and the flasks were passaged at 70-80% 
 90 
 
confluence throughout the study. At every passage, the cell concentration was 
determined using a hemocytometer (as described in Chapter IV) and a sample of MSCs 
was cryopreserved in 95% autologous serum and 5% DMSO at a concentration of 10 x 
106 cells/ml. Cryopreserved cells were later thawed and evaluated by flow cytometry to 
determine changes in mean fluorescence intensity (MFI; measures the mean 
fluorescence intensity of a population of cells) as well as the proportion of viable, 
labeled cells over time; viability was assessed by adding 5 µl of 7-aminoactinomycin (7-
AAD; Biolegend, San Diego, CA) to the cell suspensions. This compound has a strong 
affinity for DNA but does not readily penetrate intact cell membranes; therefore, it can 
be used to determine cell viability because only cells with compromised membranes will 
stain with 7-AAD. 
 The proportion of cells showing QD-associated fluorescence was detected using 
a Beckman Coulter MoFlo Astrios high-speed cell sorter (Beckman Coulter, Brea, CA). 
The 405-nm laser and the 620/29 bandpass filter were used and the PMT voltage was set 
to 390 volts. Dead cells labeled with 7-AAD were detected using the 488-nm laser and 
the 664/22 bandpass filter; the PMT voltage was set to 575 volts. At least 20,000 live 
cell events were collected per sample.  
 
Chondrogenic Differentiation  
 Induction of chondrogenic differentiation was performed as described in Chapter 
III. Multiple pellets were prepared and three pellets were removed from culture every 
two weeks for evaluation. Following removal of the pellets and cutting of chondrogenic 
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sections, the sections were stained with the nuclear dye 4’,6-diamidino-2-phenylindole 
(DAPI) and imaged with a fluorescent microscope (Ex/Em 405-585/625 nm) to 
determine the presence of QDs. Additional sections were stained with Toluidine Blue to 
assess chondrogenic differentiation by identification of cartilaginous extracellular 
matrix, which stains purple (metachromasia), and fibrous tissue, which stains blue. To 
stain with Toluidine Blue, the chondrogenic sections were first deparaffinized by 
dipping them into xylene for 15 min, 100% ethanol for 10 min, 95% ethanol for 10 min, 
80% ethanol for 5 min and then into deionized water. Toluidine Blue staining was 
accomplished by dipping the sections into Toluidine Blue solution for 5 min followed by 
rinsing with deionized water, 95% ethanol for 2 min, 100% ethanol for 2 min, and 
xylene for 4 min. Excess xylene was blotted off and a coverslip was applied while the 
specimen was still moist. Pictures of the sections were taken with a phase-contrast 
microscope immediately after the cover slip was applied. 
 
Adipogenic Differentiation 
 To induce adipogenic differentiation, MSCs were seeded onto 10-cm plates at a 
density of 1000 cells/cm2 in standard MSC culture medium. Once the cells reached 70% 
confluence, the medium was exchanged for adipogenic induction medium consisting of 
DMEM/F12 (VWR) supplemented with 3% FBS, 1% antibiotic-antimycotic, 5% rabbit 
serum (Life Technologies), 33 µM biotin (Sigma-Aldrich), 17 µM/l pantothenate 
(Sigma-Aldrich) , 1 µM/l insulin (Sigma-Aldrich), 1 µM/l dexamethasone, 225 µl 
isobutylmethylxanthine (Sigma-Aldrich) and 89 µl rosiglitazone and cultured for 72 h. 
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After 72 h the medium was exchanged for adipogenic maintenance media (adipogenic 
induction medium without isobutylmethylxanthine and rosiglitazone) for an additional 
72 h. Induced cells were stained with Oil Red O (Sigma-Aldrich) to detect lipid droplets 
within the cells, which stain red. To stain with Oil Red O, the medium in induced plates 
was aspirated and the cells were rinsed with phosphate buffered saline. The cells were 
then fixed in the plates with 5 ml of 4% paraformaldehyde for 20 min at room 
temperature. After 20 min the plates were rinsed with distilled water and soaked with 5 
ml of 60% isopropanol for 5 minutes at room temperature. After 5 min, the isopropanol 
was aspirated and each plate was stained with 5 ml of Oil Red O solution for 5 min at 
room temperature. The Oil Red O-stained plates were rinsed with distilled water and set 
out to dry. Pictures of each plate were taken under a phase contrast microscope within 2 
h of staining.  
 
Osteogenic Differentiation 
 To induce osteogenic differentiation, MSCs were seeded onto 10-cm plates at a 
density of 1000 cells/cm2 in standard MSC culture medium. Once the cells reached 70% 
confluence, the medium was exchanged for osteogenic induction medium consisting of 
DMEM/F12 supplemented with 10% FBS, 1% antibiotic-antimycotic, 10 µM/l ß-
glycerophosphate (Sigma-Aldrich), 20 nM/l dexamethasone, and 50 µg/ml L-ascorbic 
acid. The plates were maintained in culture for 21 days. After 21 days, the plates were 
stained with 2% Alizarin Red (Sigma-Aldrich) to identify the presence of calcified 
extracellular matrix and bone nodules, which stain red. To stain with Alizarin Red, the 
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induced cells were rinsed with phosphate buffered saline and fixed with 5 ml of 70% 
ethanol for 20 min at 4 °C. After 20 min the ethanol was aspirated from the plates and 
the plates were allowed to dry completely for 1 to 2 h. After drying, each plate was 
stained with 5 ml of 2% Alazarin Red solution for 10 min at room temperature. After 10 
min the plates were rinsed with distilled water and set out to dry. Pictures of cells in each 
plate were taken under a phase-contrast microscope within 2 h of staining.  
 
Immunophenotype Analysis by Flow Cytometry 
 Immunophenotype analysis was performed as described in Chapter III.  
 
Statistical Analysis 
 Data were analyzed using JMP Pro ver. 11 for Windows (SAS Institute Inc, 
Cary, NC). Data were log-transformed prior to analyses to minimize interactions 
between means and variances. Paired t-tests were performed to determine differences in 
MFI between P1 and P2 and between P2 and P3. Differences were considered significant 
when P < 0.05. 
 
RESULTS 
Dividing MSCs 
 In dividing MSC cultures, flow-cytometric analysis showed a rapid decrease in 
the percentage of QD-labeled cells, as well as in the MFI, as passage number increased 
(Table 5.1). The initial MFI at P1 varied among trials, between 154 and 1796; however 
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the percentage of cells labeled with QDs at P1 was consistently high (between 98.1 and 
99.9%). Both the proportion of labeled cells and the MFI dropped precipitously between 
P1 and P2, and again between P2 and P3. The proportion of labeled cells and the MFI 
then stayed at fairly consistent low levels for 2 to 5 more passages. For P2 and P3, the 
MFI measured by flow cytometry was less than the MFI expected due to dilution 
associated with cell division, calculated based on the MFI of the previous passage, the 
number of cells seeded and the number of cells present at confluence (Table 5.2).  The 
time between passages and the number of cells present at each passage was similar for 
QD-labeled and control cells (Table 5.3), indicating that QD labeling did not cause 
increased cell death or reduced cell division.  
 Visual assessment of cell cultures under fluorescent microscopy supported the 
flow-cytometric results; the proportion of cells labeled with QDs as well as the number 
of QDs per cell decreased from P1, when an estimated 100% of the cells were labeled 
with QDs to P2 (estimated 50% of cells labeled with QDs) and continued to decrease 
rapidly thereafter (Figure 5.1).   
 
Non-dividing MSCs 
 
 In contrast to the rapid decrease in fluorescence seen in dividing MSC cultures, 
non-dividing MSCs (chondrogenic pellets) remained labeled with QDs, without an 
apparent decrease in intensity on visual examination under fluorescence microscopy, for 
the duration of the study (up to 8 wk; Figure 5.2). Notably, while the majority of the 
 95 
 
pellet retained QDs, the cells on the periphery of the pellet lost QD labeling within 2 
weeks. 
 
Table 5.1 Percentage of QD-labeled cells and measured MFI for cells in monolayer 
culture conditions. 
 
Cells from a different horse were used for each replicate. Within the Mean column, 
values with different superscripts differ significantly (P < 0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Cell line A  Cell line B  Cell line C   
P 
 Labeled 
cells (%) MFI  
Labeled 
cells (%) MFI  
Labeled 
cells (%) MFI 
 MFI 
Mean ± s.d. 
1 
 
99.9 651.0  99.6 1796.0  98.1 156.0 
 867.7
a
 ± 
847.2 
2  51.5 31.6  78.4 83.9  82.0 38.0 
 
51.2
b
 ± 28.5 
3  11.0 4.4  20.1 5.4  24.4 2.9 
 4.2
c
 ± 1.3 
4  2.1 4.4  5.8 4.9  8.5 2.2 
 3.8 ± 1.5 
5  0.3 3.0  5.5 5.4  1.9 2.1 
 3.5 ± 1.7 
6  0.1 4.7  13.0 6.9    
 5.8 ± 1.5 
7  0.1 3.9           
 3.9 
C 
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Table 5.2 Expected MFI for cells in monolayer culture conditions. 
 
Cells from a different horse were used for each replicate. Expected (Exp) MFI was 
calculated based on the measured MFI of the previous passage (Table 5.1), the number 
of cells seeded (initial # of cells) and the number of cells present when the cells were 
passaged (final # of cells). Exp MFI was higher than the MFI measured by flow 
cytometry for passages 2 and 3 (Table 5.1).  
 
 
 
 
Table 5.3 Number of cells and time between passages for control and QD-labeled 
cells. 
 
  Cell line A  Cell line B  Cell line C 
P 
 
Control QD-labeled CT  Control 
QD-
labeled CT  Control 
QD-
labeled CT 
1  1.01x107 1.02x107   1.00x107 1.02x107   5.20x106 5.40x106  
2  1.98x107 2.04x107 4  5.74x107 5.76x107 6  1.25x107 1.23x107 4 
3  2.98x107 3.03x107 4  4.10x107 4.08x107 4  5.40x106 5.60x106 2 
4  4.20x107 4.28x107 4  2.05x107 2.07x107 4  2.00x107 2.01x107 4 
5  7.40x106 7.40x106 5  2.25x107 2.28x107 4  8.40x106 8.60x106 4 
6  5.30x106 5.50x106 4  3.00x105 3.20x105 3  1.96x107 1.95x107 4 
7  6.50x106 6.60x106 6         
 
The time between passages (CT- culture time in days) and the number of cells present at 
each passage was similar for QD-labeled and control cells. Cells from a different horse 
were used for each replicate.  
 
 
  Cell line A  Cell line B  Cell line C 
P 
 Initial 
# of 
cells 
Final 
# of 
cells 
Exp 
MFI  
Initial 
# of 
cells 
Final 
# of 
cells 
Exp 
MFI  
Initial 
# of 
cells 
Final 
# of 
cells 
Exp 
MFI 
1  1.02x10
7
  651.0  1.02x10
7
  1796.0  5.40x10
6
  156.0 
2  1.02x10
7
 2.04x10
7
 325.5  1.02x10
7
 5.76x10
7
 318.0  5.40x10
6
 1.23x10
7
 68.5 
3  1.10x10
7
 3.03x10
7
 11.5  1.15x10
7
 4.08x10
7
 23.6  4.30x10
6
 5.60x10
6
 29.2 
4  1.98x10
7
 4.28x10
7
 2.1  8.75x10
6
 2.07x10
7
 2.3  4.60x10
6
 2.01x10
7
 0.7 
5  4.38x10
6
 7.40x10
6
 2.6  8.75x10
6
 2.28x10
7
 1.9  5.00x10
6
 8.60x10
6
 1.3 
6  1.55x10
6
 5.50x10
6
 0.8  4.38x10
6
 3.20x10
5
 74.2     
7  4.75x10
6
 6.60x10
6
 3.4       
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Figure 5.1 Dividing QD-labeled MSC cultures. Overlays of phase contrast and 
fluorescent images showing a rapid decrease in QD-labeled cells (Cell line A); QDs 
appear as red dots. A) 24 hr post-QD label; B) 3 d (P2) post-QD label; C) 8 d (P5) post-
QD label. Original magnification 200 X, scale bar = 100 µm. 
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Figure 5.2 Non-dividing QD-labeled MSCs (chondrogenic pellets).  Overlays of 
DAPI and fluorescent images showing persistence of QDs (red dots) in chondrogenic 
pellets. A) 2 wk post QD-label; B) 4 wk post-QD label; C) 6 wk post-QD label; D) 8 wk 
post-QD label. Original magnification 100 X, scale bar = 200 µm. 
 
Adipogenic, Osteogenic and Chondrogenic Differentiation 
 Labeling MSCs with QDs did not affect the cells’ ability to undergo trilineage 
differentiation into chondrogenic, adipogenic and osteogenic lineages, as assessed by 
visualizing positive staining for Toluidine Blue, Oil Red O, and Alizarin Red, 
respectively (Figure 5.3). QD-labeled cells harvested at the standard time allotted for 
differentiation into chondrocytes, adipocytes and osteocytes (21, 3, and 21 days, 
respectively), showed characteristic attributes of each type of cell, including round pellet 
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shape and extensive extracellular matrix in chondrogenic pellets, intracellular lipid 
droplets in adipocytes, and extracellular calcium deposition in osteocytes. 
 
 
 
Figure 5.3 Trilineage differentiation of QD-labeled (A, B, C) and control (D, E, F) 
MSCs. A, D) chondrogenic- purple staining of cartilaginous extracellular matrix with 
Toluidine Blue (original magnification 200 X, scale bar = 100 µm) B, E) adipogenic- red 
staining of lipid droplets with Oil Red O (original magnification 100 X, scale bar = 200 
µm) C, F) osteogenic- red staining of calcified extracellular matrix with 2% Alizarin Red 
(original magnification 100 X, scale bar = 200 µm). 
 
 
Immunophenotyping  
 On immunophenotyping, the expression of CD29, CD44, and CD90 varied 
among control (unlabeled) cell lines, whereas CD45 was low in all three cell lines (Table 
5.4). In QD-labeled cells, the percentage of cells expressing CD29 was high in all three 
cell lines, CD44 and CD90 varied among all cell lines, and CD45 was low in all three 
cell lines. Immunophenotyping of QD-labeled cells showed differences in CD 
expression from that of the control cells of that line; however, these differences were not 
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repeatable among cell lines (e.g. for Cell line A, CD44 was expressed in 86% of control 
cells vs 23% of cells with QDs; whereas for Cell line B, CD44 was expressed in 2% of 
control cells vs. 30% of cells with QDs). All cell lines in both control and QD treatments 
showed low expression of MHC II.  
 
Table 5.4 Cell surface markers of control and QD-labeled MSCs determined by 
flow cytometry. 
 Control (unlabeled)  QD-labeled 
  CD29 CD44 CD90 CD45 MHC II  CD29 CD44 CD90 CD45 MHC II 
Cell line A 99.2 85.5 5.25 5.23 3.61  99.8 22.8 82.8 1.89 2.57 
Cell line B 99.8 1.81 54.5 1.15 1.06  99.7 29.5 35.6 5.41 1.11 
Cell line C 1.7 16.8 41.4 1.99 6.23  78.7 0 0.16 0 0 
 
P4 cells were used; each cell line was from a different horse. Data are presented as % of 
cells positive for a given marker. 
 
DISCUSSION 
 This study examined for the first time the use of QDs to label equine BM-MSCs 
and the factors affecting interpretation of results with this system. To be useful for MSC 
tracking, QDs must not interfere with cellular function or proliferation. We found that in 
monolayer culture conditions, QD-labeled MSCs continued to divide normally. 
However, they did not retain sufficient QD label to provide an effective method for cell 
tracking after the first 2 passages (4-6 days of in vitro culture). Similar results have been 
found with rat and human MSCs. Muller-Borer et al., [217] reported that QD labeling 
was visible in live rat MSC cultures for up to 7 days. Seleverstov et al., [222] reported a 
significant loss of fluorescence in QD-labeled human MSCs in culture 2-7 days after 
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labeling and Wang et al., [223] recently reported a significant reduction in fluorescence 
in QD-labeled human MSCs after 24 h of culture. In contrast, Rosen et al., [220] 
reported that proliferating human MSCs retained sufficient QDs to be easily imaged for 
more than 6 weeks in vitro. In the study of Rosen et al., QDs were loaded into the cells 
by incubation of MSCs with QD labeling solution for 12-24 hr at 37 °C, rather than the 
one-h incubation used in the present study and that of Muller-Borer et al., [217]. It is 
possible that the method used to label MSCs with QDs could have an effect on the 
persistence of the QDs; further studies are needed to determine the optimal method for 
labeling equine MSCs with QDs.  
 The proliferation of MSCs in culture likely leads to the dilution of QDs, as the 
cytoplasmic content of the parent cell is split between daughter cells at each division, 
reducing the concentration of QDs in progeny over time. Thus the MFI and the 
proportion of QD-labeled MSCs detected with flow cytometry decreases. In the present 
study, the expected MFI calculated based on the MFI of the previous passage and the 
initial and final numbers of cells, was notably higher at P2 and P3 than was the MFI 
measured by flow cytometry. These results suggest that QD-labeled cells died in culture 
and were rinsed out during medium changes, or that the cells ejected the QDs during 
culture. Because there was no difference in the time to reach confluence or in the 
number of cells at confluence in QD-labeled cells compared to control cells, the latter 
possibility may be more likely.  
 In contrast, non-dividing MSCs, i.e., MSCs that were induced to differentiate 
into chondrogenic pellets, retained QDs without an apparent decrease in label for up to 8 
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weeks (the length of the experiment). However, we noted that cells on the periphery of 
the pellet lost QD labeling; again, as the outermost cells are more likely to divide, these 
cells could have diluted the label via division, died and have been lost into the medium, 
or ejected the QDs into the medium. The retention of label in the chondrogenic pellets 
reflects the findings of Ohyabu at al. [286] who reported that chondrocytes, adipocytes 
and osteocytes (which also do not proliferate rapidly in culture), differentiated from 
human, rabbit, rat and monkey MSCs, retain strong QD label for 28 days in vitro and 
that chondrocytes differentiated from rat and rabbit MSCs retain QD label for 8 weeks 
after in vivo transplantation into experimentally-induced osteogenic defects. This 
indicates that QDs would be an effective method to track MSCs injected into areas in 
which, if they were retained, they would differentiate into non-dividing tissue types such 
as cartilage, adipose tissue or bone, or cells with limited capacity for division, such as 
cardiac muscle. 
 The results from the present study suggest that QD-labeled MSCs should be used 
immediately after QD labeling to maximize the QD load per injected cell, and that the 
majority of rapid loss of QD label is not directly related to cell proliferation, but could 
also be due to death of QD-labeled cells or to ejection of QDs by the cells. As the 
majority of the cells retained the QD-label in proliferating culture in vitro for only 4 to 6 
days, a loss of QD label may occur after in vivo delivery of QD-labeled MSCs in this 
time, if cells proliferate after injection. Since the fate of MSCs after injection is unclear 
[182, 190, 191], histological examination of the target and other tissues (e.g. lymph 
nodes) within a week of delivery of QD-labeled cells should allow both tracking of the 
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MSCs and evaluation of their relative fluorescence intensity, which might be suggestive 
of the degree of proliferation the cells underwent after delivery. This finding might be 
useful to determine the fate of MSCs after injection. 
 Another requirement for use of QDs to label and track MSCs is that they must 
not affect the cells’ trilineage potential and immunophenotypic characteristics. The 
results from the current study showed that the ability of equine BM-MSCs to 
differentiate into chondrocytes, adipocytes, and osteocytes was not affected by labeling 
with QDs. These results are similar to those from Ohyabu et al., [286], Ranjbarvaziri et 
al., [287] and Tautzenberger et al., [288] for human, rabbit, rat, and monkey MSCs.  
 The immunophenotypic results in the present study were unexpected. According 
to the panel of immunophenotypic markers proposed by De Schauwer et al., [203] and 
Schnabel et al., [204] for equine MSCs, these cells tend to be positive for CD29, CD44 
and CD90, negative for CD45, and heterogeneous (positive or negative) for MHC II. In 
the present study, all the cells used had low expression of CD45 and, interestingly, of 
MHC II; however, the cell lines varied in expression of CD29, CD44 and CD90. 
Notably, the lines cultured with QDs showed different immunophenotypes from the 
original cell line, although the effect of QDs was not consistent among cell lines. 
Whether this was due to an effect of QDs or to drift of the cell line immunophenotype 
over the passages in separate cultures is not clear, and further studies are needed in this 
area. While molecular markers continue to be used to characterize stem cell populations, 
recent studies with human MSCs indicate that cells isolated from different donors [289], 
or from different sites from the same donor [278, 290], and cells treated with different 
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enzymatic digestion methods for detachment [291] can have different surface antigen 
expression, and even MSCs with identical cell surface phenotype from different tissues 
and donors have distinct transcriptomic signatures and differentiation capacities, likely 
due to the broad overlap of cells with MSC markers with other cell populations [278, 
279]. Thus, the immunophenotypic characterization of MSCs remains unclear and MSCs 
are currently best defined functionally. 
 In summary, while QD-labeled MSCs retain their ability to proliferate and 
differentiate, QDs as applied in this study do not appear to be a good option for long-
term tracking of equine BM-MSCs in vivo for most indications, because the percentage 
of labeled cells and the MFI of the cells decreased rapidly in proliferating cells. This 
makes the absence of QD-labeled cells, such as was found in the study detailed in 
Chapter III (ovaries injected with QD-labeled MSCs showed no evidence of QDs seven 
months after injection) difficult to interpret- it cannot be determined if the cells were 
eliminated, migrated elsewhere, or proliferated in situ and lost their label. Further 
research is needed to determine if QDs can be used for short-term tracking of MSCs in 
vivo and to determine if the method used to label MSCs with QDs could have an effect 
on the long-term persistence on QDs in equine MSCs.   
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CHAPTER VI 
 CO-CULTURE OF EQUINE OVARIAN EXPLANTS  
WITH MESENCHYMAL STEM CELLS  
 
INTRODUCTION 
 As discussed above, mesenchymal stem cells (MSCs) secrete a number of growth 
factors, some of which affect ovarian follicular growth [10, 11, 265-267]. Additionally, 
intra-ovarian injections of MSCs in rats [10] and systemic injections of MSCs in mice 
[11] induce mRNA and protein expression of genes that improve the function of ovaries 
compromised by chemotherapy. However, little is known about the effect of MSC 
injection on the aging ovary. This procedure has clinical relevance in the mare, as 
considerable interest exists in the equine industry to establish pregnancies from older, 
valuable mares. However, to the best of our knowledge, no information is available on 
the direct effect of in vitro co-culture of ovarian tissue with MSCs on ovarian gene 
expression, which is an essential step in determining the mechanism of action of MSCs 
in vivo.  
 Co-culture systems have been studied to simulate the in vivo microenvironment, 
and the transwell co-culture system has served as an effective method to determine the 
paracrine effects of MSCs on tissue. Lovati et al., [292] co-cultured equine tendon tissue 
fragments in a transwell system with equine bone marrow-derived MSCs (BM-MSCs) 
for 7 and 15 days in serum-free medium. In that study, cells from tendon fragments in 
the transwell system showed the same viability as cells from tendon fragments grown in 
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monolayer as a control; gene expression, via real time PCR (RT-PCR), revealed that 
mRNA expression of collagen type 1 (Col1), tenomodulin (Tnmd) and tenascin-C (Tnc) 
genes was upregulated in the tendon fragments co-cultured with MSCs. Similarly, co-
culture of equine articular chondrocytes with equine BM-MSCs revealed changes in 
chondrocyte gene expression as determined via RT-PCR; expression of collagen type 2 
(Col2), aggrecan (Acan), and SRY-box 9 (Sox9) genes was upregulated in co-cultured 
tissue [293]. 
 This study was conducted to determine if the transwell co-culture system would 
enable evaluation of the effect of soluble factors secreted by MSCs on gene expression 
of equine ovarian explants. Ovarian tissue was co-cultured in a transwell system with 
BM-MSCs, fibroblasts or media alone and differences in gene expression were evaluated 
by RNA-sequencing.  
 
MATERIALS AND METHODS 
 BM-MSCs were obtained from sternebral aspirates, cultured, and frozen as 
described in Chapter III. Skin fibroblasts were obtained from a subcutaneous connective 
tissue biopsy sample. The biopsied tissue was cultured in DMEM/F12 (Invitrogen) 
supplemented with 10% FBS (Sigma-Aldrich) and 1% antibiotic-antimycotic 
(Invitrogen) which was changed every three to four days until growth of fibroblasts from 
the tissue was obtained. Cells from P3 were frozen in 90% DMEM/F12 with 10% 
DMSO. 
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 Ovaries were obtained after euthanasia of mares aged 3 to 4 yr old, with normal 
reproductive tracts on palpation and ultrasonography per rectum. The ovaries were 
minced within 1 h of collection. Tissue explants (approximately 5 mm3, 60-80 mg total 
wet weight/well) were maintained in the top well of 6-well 24-mm Transwell® 
permeable plates (Corning, Corning, NY). These plates have a permeable membrane 
which prevents cell-to-cell contact while allowing the diffusion of soluble factors 
between the two compartments. The tissue was cultured in a final volume of 2 ml 
DMEM/F12 (Invitrogen) supplemented with 10% FBS (Sigma-Aldrich) and 1% 
antibiotic-antimycotic (Invitrogen). The contents of the bottom well were 1) previously 
cryopreserved/thawed BM-MSCs (5.0 x 104 cells/well), 2) previously 
cryopreserved/thawed skin fibroblasts (5.0 x 104 cells/well), or 3) medium alone. The 
ovarian tissue was co-cultured at 37 °C in a humidified atmosphere of 5% CO2 in air. 
After 4 days the tissue was flash-frozen in liquid nitrogen and stored at -80 ºC until RNA 
isolation was performed. Three replicates were performed. 
  
RNA Isolation  
 RNA isolation from the co-cultured ovarian tissues was performed at the Texas 
A&M Institute for Genome Sciences and Society (TIGSS). Two different protocols were 
used. In Protocol 1, RNA was extracted using a Maxwell LEV SimplyRNA Tissue Kit 
(Promega, Madison, WI). Tissue was lysed using a TissueLyser II (Qiagen, Valencia, 
CA) and RNA was purified on the automated Maxwell 16 Instrument (Promega). 
Quantitative and qualitative parameters of the RNA preparations were assessed using a 
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Qubit 2.0 fluorometer (ThermoFisher; Invitrogen, Carlsbad, CA) and an Agilent RNA 
ScreenTape 2200 assay (Agilent Technologies, Santa Clara, CA). During the 
ScreenTape assay, RNA samples are loaded on top of a gel matrix contained in the 
ScreenTape lane and the samples are driven by a voltage gradient and separated by size 
according to the length of the RNA chain; smaller molecules migrate through the gel 
more quickly and therefore travel further than larger fragments. Dye molecules 
intercalate into the RNA strands and these complexes are detected by laser-induced 
fluorescence. Data is then translated into gel-like images (bands) and electropherograms 
(peaks). The qualitative parameter evaluated was RNA integrity as measured by the 
RNA integrity number (RIN) and the 28S/18S ribosomal RNA (rRNA) ratio. The RIN 
ranges from 1 to 10 with a score of 10 indicating no degradation, and a high 28S/18S 
ratio (> 2 is considered the benchmark) indicates that the purified RNA is intact and has 
not degraded (see Discussion for an explanation of these measures). 
 In Protocol 2, the ovarian tissues were pulverized with a biopulverizer (Cole-
Parmer, Vernon Hills, IL) and RNA was extracted using a guanidinium thiocyanate-
phenol-chloroform protocol (TRIzol Reagent; Life Technologies; Invitrogen). Samples 
were processed with a final silica-gel spin-column clean up and quantitative and 
qualitative parameters were assessed as in Protocol 1.  
 To determine if the poor-quality RNA obtained from co-cultured ovarian tissues 
(see Results) was due to an intrinsic nature of equine ovaries or to effects of processing 
of the tissue to obtain RNA vs an effect of tissue degradation over the time of co-culture, 
fresh ovarian tissue was recovered from one 9-yr old mare at euthanasia and snap-frozen 
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within 1 h of ovary removal. This tissue was processed by Protocol 2; quantitative and 
qualitative analysis of RNA was performed as described above. 
 
RESULTS 
 When Protocol 1 was used, the concentration of RNA detected by the Qubit 2.0 
was not adequate for analysis; therefore, gel-like images and electropherograms were not 
generated. When the ovarian tissues were pulverized via Protocol 2, adequate 
concentrations of RNA were obtained; however, the quality was poor due to RNA 
degradation (Figure 6.1). Highly intact RNA appears as sharp, compact bands as seen in 
the A0 (L) lane, whereas with progressive RNA degradation, the 28S and 18S bands 
become thinner, and highly degraded RNA appears as a diffuse smear extending into the 
lower molecular weight range of the lane (lanes A1 and B1), which correspond to two 
different co-cultured ovarian samples processed by Protocol 2. Similar results were 
obtained when a combination of methods from the two protocols was attempted. The 
electropherograms of samples A1 and B1 (Figure 6.2) showed that most of the RNA 
present was smaller than 200 nucleotides (nt), further indicating degradation of the 
samples. 
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Figure 6.1 Quantitative and qualitative assessment of two RNA samples from 
ovarian tissue from two different mares. Although the RNA concentrations in the 
ovarian tissues (A1 and B1) were high, the quality of the RNA, as determined by the 
RIN and the 28S/18S rRNA ratio, was low. A1 and B1 represent two RNA samples from 
ovarian tissue from two different mares; both samples were pulverized and processed by 
Protocol 2. A0 (L) is the RNA ladder which sets the markers or standards against which 
the samples are compared.    
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Figure 6.2. Electropherograms of two ovarian RNA samples (A1 and B1) from gel 
images shown in Figure 6.1. The y-axis represents fluorescence units (FU) and the x-
axis represents the nucleotide length (nt) of the RNA fragments. As RNA degrades the 
18S and 28S peaks become less sharp and smaller. The peaks generated prior to the 18S 
represent the small RNA fragments produced during RNA degradation; small fragments 
migrate faster through the gel and thus appear in the fast region of the electropherogram 
(see Figure 6.5). In both of these samples most of the RNA present was smaller than 200 
nt and the 18S and 28S peaks were very small, both of these characteristics are 
indicative of degradation. These electropherograms can be compared to that shown in 
Figure 6.5 which corresponds to a sample of intact RNA with a RIN of 10.  
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 In contrast to the co-cultured samples, when Protocol 2 was used to isolate RNA 
from equine ovaries that were not co-cultured (sample D1), RNA of adequate 
concentration and quality was obtained (Figures 6.3 and 6.4). The results of RNA-
sequencing of this tissue are presented in Chapter VIII.  
 
 
 
Figure 6.3. Quantitative and qualitative analysis of RNA obtained from equine 
ovaries that were not co-cultured. There are two sharp, compact bands corresponding 
to the 28S and 18S rRNAs. There is still some degradation present as seen by the slight 
smearing that extends into the lower molecular range of the lane; however, the RIN of 
8.1 and the 28S/18S ratio of 2.2 are both indicative of high quality RNA that is adequate 
for RNA-sequencing analysis. 
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Figure 6.4 Electropherogram of equine ovarian sample from gel image shown in 
Figure 6.3. Unlike the electropherogram from the two degraded samples shown in 
Figure 6.2, this electropherogram has sharp 18S and 28S peaks. There is still a small 
amount of degradation present as seen by the small peaks generated prior to the 18S 
peak; however, the RIN, 28S/18S ratio and RNA concentrations were all indicative of 
high quality RNA. 
 
 
DISCUSSION 
 
 This study was performed to evaluate whether co-culture of ovarian explants 
with BM-MSCs could be used to determine the effect of MSCs on gene expression of 
equine ovarian tissue in culture. To the best of my knowledge, this is the first attempt at 
this procedure using equine ovarian tissue. Information gathered in such a system, if 
effective, would serve as a first step in determining the mechanism of action of MSCs on 
ovarian tissue. While the transwell co-culture approach has been successful with other 
tissue, including equine tendon explants and equine cartilage tissue [292, 293], the 
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ovarian explants that we evaluated had degraded RNA, indicating that the explants had 
degenerated in culture. Equine ovaries, like tendons, are fibrous in nature [294]; the co-
culture time of four days was selected based on previous co-culture studies in which 
equine tendon tissue fragments were co-cultured with MSCs for 7 and 15 days [292].  
 While the co-culture system was not effective due to tissue degradation, this 
study had value in determining methods for isolation of RNA from ovarian tissue. RNA 
isolation was problematic; when Protocol 1 was used, the RNA concentrations obtained 
were too low to be detected by the fluorometer. This was attributed to the fibrous nature 
of the equine ovary interfering with lysis by enzymatic digestion. This issue was 
resolved when the ovarian tissues were physically pulverized in Protocol 2. In this 
protocol, RNA isolation from the pulverized ovarian tissues was performed with 
guanidinium thiocyanate-phenol-chloroform. Even though there was significant RNA 
degradation, adequate RNA concentrations were obtained with this protocol even from 
the degenerating tissue, and it would appear to be the protocol of choice for future 
examination of equine ovarian tissue. To determine if the degradation seen was due to an 
intrinsic nature of RNA in equine ovaries or to sample processing, vs an effect of tissue 
degeneration during culture, ovarian tissues that were not co-cultured were pulverized 
and processed by Protocol 2. The RNA obtained from these ovaries was of high quality 
and adequate for RNA-sequencing (see RNA-sequencing results in Chapter VIII); 
therefore, it appears that the RNA degradation observed in co-cultured tissue was due to 
the ovarian tissue degrading during culture. 
 Integrity of RNA is summarized by two main statistics; 1) rRNA ratio (28S/18S), 
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and 2) RNA integrity number (RIN). Ribosomal RNA (rRNA) makes up > 80% of the 
total RNA in tissues. The majority of rRNA is comprised by the 28S and 18S rRNA 
species. The 28S and 18S rRNAs are produced in equal numbers by the cleavage of a 
single RNA transcript. Because mammalian 28S and 18S RNAs are approximately 5 kb 
and 2 kb in size, respectively, the theoretical 28S/18S mass ratio is approximately 2.7:1, 
but a 2:1 ratio has long been considered the benchmark for intact RNA that has not 
degraded [295]. The 28S RNA degrades more quickly than does the 18S RNA, so a 
decrease in mass ratio below 2:1 is considered a sign of RNA degradation; the lower the 
mass ratio, the greater the amount of degradation. In the RNA analyzed in the present 
study, the 28S/18S ratio was 0.3 and “unable to be detected,” respectively, in the two 
ovarian samples that were co-cultured with MSCs; whereas it was 2.2 in the ovarian 
sample that was not co-cultured (desired is ≥ 2). This indicates that the RNA in co-
cultured samples had undergone significant degradation over time in culture while RNA 
in the non-co-cultured sample was intact. 
 The RIN is a software algorithm that assigns integrity values to electrophoretic 
RNA measurements including; 1) total RNA ratio, which is calculated by taking the 
fraction of the area under the 18S and 28S rRNA peaks compared to the total area under 
the graph. A large number indicates that much of the rRNA is still at its initial (known) 
size and thus little to no degradation has occurred, 2) relative height of the 28S to 18S 
peaks which allows determination of the stage of degradation, as during degradation the 
28S rRNA is degraded faster than the 18S rRNA; a large number is desired, 3) fast area 
ratio, which is the area under the curve between the 18S and 5S rRNA (which is the 
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smallest type of cytoplasmic rRNA) peaks. Initially as this value increases it indicates 
degradation of the 18S and 28S rRNA to an intermediate size (> 5S), however the ratio 
decreases as RNA degrades further to smaller sizes, and 4) marker height, which 
indicates the amount of RNA that has been degraded to small pieces, a small number, ie., 
short marker, is desired (Figure 6.5). From all these measurements, the RIN software 
will assign a final value between 1 and 10, with 1 being the most degraded and 10 being 
the most intact [296]. In the present study, the RIN numbers of co-cultured samples A1 
and B1 were 5.3 and 6.8, respectively, and the non-co-cultured sample D1 had a RIN 
number of 8.1 (desired is > 8).  
 The methods used for co-culture may have an effect on the viability of the co-
cultured tissue. In a recent study by Morgan et al., [297] viability of intact neonatal 
mouse ovaries was maintained for up to six days in a specialized culture system. The 
ovaries were co-cultured with individual, intact ovarian follicles to study the interactions 
between primordial and growing follicles. The method used was floating polycarbonate 
membranes, which allow greater oxygenation of the tissue, and basic medium consisting 
of only αMEM and BSA, avoiding the use of serum. In a study by Riley et al., [298] 
equine ovarian tissue explants were maintained in culture for 24 h on a hydrophilic mat 
in serum-free medium. Similarly, a study by Ricci et al., [299] maintained rat ovarian 
explants in culture for 4 h in serum-free medium. In the present study, FBS was added to 
the co-culture media in order to support the MSCs and the Transwell® permeable plates 
were used based on positive results from previous equine tendon co-culture experiments. 
FBS-enriched media promotes the active proliferation of cells in culture [300, 301]; 
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however, FBS also induces excessive tissue swelling [302], and suppresses the function 
and size of cultured granulosa [301, 303]  and theca cells [300]. Furthermore, 
degradation of tissue matrix can occur during long-term maintenance with media 
supplemented with serum; matrix degradation is seen especially when cartilage from 
juvenile bovines and rats is cultured in FBS-supplemented media for up to 6 wk because 
juvenile tissue is more responsive to chemical stimuli than mature tissue [304]. In 
addition, it is harder to establish the involvement or contribution of certain growth 
factors when serum-enriched media is used because serum itself contains growth factors. 
Use of serum-free media should be investigated in future ovarian co-culture 
experiments.   
 Additional research is needed to determine if different co-culture systems and 
serum-free media would support the co-culture of equine ovarian explants and prevent 
the RNA degradation seen in the present study.  
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Figure 6.5. Electropherogram showing the regions used to compute the RIN, an 
indicative of RNA quality; figure from [296]. This electropherogram corresponds to 
an RNA sample with a RIN of 10. Common features of intact RNA include distinct 18S 
and 28S rRNA peaks, the absence of smaller peaks between the two ribosomal peaks, 
and a flat baseline prior to the 18S peak. 
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CHAPTER VII 
 EFFECT OF INTRA-OVARIAN INJECTION OF  
BONE MARROW-DERIVED MESENCHYMAL STEM CELLS  
ON OVARIAN FUNCTION IN OLD AND YOUNG MARES  
 
INTRODUCTION 
 Age-related changes result in decreased follicle numbers and oocyte quality, 
reducing fertility in aging women [1]. The same changes have been reported to occur in 
mares [159]. As discussed in Chapter II, systemic and intra-ovarian injections of adult 
mesenchymal stem cells (MSCs) in mice [11] and rats [10] induce mRNA and protein 
expression of genes that improve the function of ovaries and rescue fertility following 
chemotherapy. However, little information is available on the effect of MSC injection on 
the aging ovary, an application which, if effective at increasing fertility, would have an 
impact on millions of women undergoing assisted reproduction because of age-related 
infertility. This application would also have clinical relevance in the mare, as 
considerable interest exists in the equine industry to establish pregnancies from older, 
valuable mares. Based on the results from the study presented in Chapter III showing 
that it is feasible to perform intra-ovarian injections of bone marrow-derived MSCs 
(BM-MSCs) in mares and that there is an apparent increase in follicle numbers in the 4 
weeks after injection, a more comprehensive study that included both old and young 
mares was performed to determine if MSCs affect ovarian function in mares 
experiencing ovarian failure associated with aging.  
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MATERIALS AND METHODS 
Animals 
 This study was performed from February 2015 to February 2016. Eight old 
mares, aged 20-29 yr, and six young mares, aged 7-12 yr, were housed in pens at the 
College of Veterinary Medicine Research Park and had ad libitum access to hay and 
fresh water throughout the study, and supplemental grain. Two yearling fillies were used 
as BM-MSC donors. All procedures were approved by the Texas A&M University 
Institutional Agricultural Animal Care and Use Committee, and were performed using 
guidelines set forth by the United States Government Principles for the Utilization and 
Care of Vertebrate Animals Used in Testing, Research and Training.  
 
Experimental Design 
 The old mares were stratified by age and divided randomly into three treatment 
groups and assigned to intra-ovarian injection with: 1) BM-MSCs from filly A (n = 3), 
2) BM-MSCs from filly B (n = 3), or 3) control (Vehicle injection, n = 2). The young 
mares were also stratified by age and divided similarly into these groups; n = 2, 2 and 2, 
respectively.  
 Bone marrow from the yearling donors was collected from sternebral aspirates 
and MSCs were isolated, expanded in culture, and cryopreserved in serum (autologous 
to the mare receiving the injection) as described in Chapter III. Aliquots of donor MSCs 
were induced to differentiate into chondrocytes, adipocytes and osteocytes and 
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characterized, and immunophenotyped by flow cytometry, as described in Chapters III 
and V. 
 Starting in February (~ 6 weeks before the beginning of the equine breeding 
season) the reproductive tracts of the old mares were evaluated by ultrasonography per 
rectum 3 times per week to determine the total number of follicles > 5 mm diameter in 
each ovary. Each ultrasound examination was recorded with a videotape recorder. The 
entire ovary was examined for ~15 sec (depending on the size of the ovary) of 
continuous taping. The videotapes were then viewed, on the same day that the recording 
was made, and the number of follicles > 5 mm in diameter in each ovary was counted. 
 Starting in March, blood was collected from the jugular vein of each old mare 
three times per week and the serum frozen for later evaluation of concentrations of anti-
Müllerian hormone (AMH), FSH and total estrogens. Blood continued to be collected on 
this schedule until two weeks after the mares were ovariectomized at the end of the 
study. Mares were evaluated once every 14 days starting in mid-February, and if five or 
more follicles > 8 mm in diameter were present, transvaginal follicle aspiration (TVA) 
was performed to recover oocytes. All follicles > 8 mm diameter were aspirated; the 
aspirate was filtered and the granulosa cells from each ovary of MSC-injected mares 
were separately centrifuged and flash-frozen for later DNA analysis to determine the 
presence of DNA from the transferred BM-MSCs. Oocytes were recovered from the 
aspirates and matured in vitro, subjected to intracytoplasmic sperm injection (ICSI) and 
cultured to determine the blastocyst rate, as described in Chapter III.  
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 Intra-ovarian injections were performed in the old mares starting in mid-April. 
Each mare had one ovary randomly assigned to be injected. Three mares underwent 
ovarian injection on Week 1, three mares on Week 3, and three mares on Week 5. The 
person performing the injections was blind as to treatment. 
 Twelve to sixteen weeks after the first injection, three MSC-injected mares 
received a second injection with MSCs from the alternate donor to that used in the first 
injection. The MSCs used in the second injection had been labeled with fluorescent 
nanoparticles (QDs) as described in Chapter III, before being frozen and subsequently 
thawed for injection. 
 The ovaries of all 8 old mares were removed by ovariectomy via colpotomy, as 
described in Chapter III, 14 to 19 weeks after the first injection. This was scheduled so 
that ovariectomies were performed two weeks after the second injection for the three 
mares in that treatment. 
 The young mares received one intra-ovarian injection. These mares similarly had 
their reproductive tracts evaluated by ultrasonography per rectum three times per week, 
and follicle counts obtained from video recordings, starting in June, 7 to 8 weeks before 
ovarian injection, and continuing until six months after ovarian injection. Blood was 
collected from young mares 3 times per week starting 5 to 7 weeks before ovarian 
injection and continuing for 8 weeks after injection. TVAs were performed in young 
mares having more than five follicles > 8 mm in diameter once every 14 days from June 
to August; however, the oocytes recovered were used for separate projects, thus 
maturation and blastocyst rates after ICSI were not available. 
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Ovarian Tissue Processing 
 Ovarian tissue processing was performed as detailed in Chapter III. Fragments 
(15 x 15 x 1 mm, 4 per ovary) of all the recovered ovaries were placed in Bouin’s 
solution at room temperature, and after 24 h were placed in 70% ethanol and held until 
histological processing. Four slides from each ovary of each mare were submitted to the 
Texas A&M Veterinary Medical Diagnostic Laboratory (TVMDL) for histopathological 
analysis. For ovaries of the three old mares that received a second intra-ovarian 
injection, with QD-labeled MSCs, four additional slides from each ovary were examined 
under a fluorescent microscope for the presence of QDs.  
 Ovarian fragments (2 x 2 mm fragments, 5 per ovary per MSC-injected mare) 
were flash-frozen for later genetic analysis. The remainder of the ovarian tissue was 
minced into 5 x 5 mm fragments which were pulverized to extract RNA (see Chapter 
VIII). 
 
Genetic Analysis 
 Hair samples from the BM-MSC donors underwent analysis of genomic and 
mitochondrial genotype at the Veterinary Genetics Laboratory at the University of 
California, Davis.  
 Genomic DNA was genotyped using loci for one sex-associated gene (AME), 
one X-linked marker (LEX3) and 16 microsatellite identification markers (AHT4, 
AHT5, ASB17, ASB2, ASB23, HMS2, HMS3, HMS6, HMS7, HTG10, HTG4, LEX33, 
TKY333, TKY374, TKY394 AND VHL20), for a total of 18 loci for each sample. 
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 Mitochondrial (mt) genotype analysis was determined by sequencing a 744 bp 
fragment of mtDNA spanning bases 15382 through 16125 of the hypervariable region of 
the D-loop between tRNAPro and the large conserved sequence block (HVeqmitA 50-
AACGTTTCCTCCCAAGGACT-30, HVeqmit B 50-GTAGTTGGGAGGGTTGCTGA-
30).  
 The granulosa cells obtained on each TVA of the MSC-injected mares (pooled 
separately from each ovary) and the 5 samples from each ovary recovered via 
ovariectomy of the MSC-injected mares were then analyzed at the Veterinary Genetics 
Laboratory to identify any MSC-donor genomic or mitochondrial DNA in the samples. 
 
Serum Hormone Analysis 
 Collected serum was sent to the Clinical Endocrinology Laboratory at the 
University of California for analysis of AMH and FSH, and to BET Labs (Lexington, 
KY) for analysis of total estrogens.  
 
Statistical Analysis 
 A Bayesian model was implemented to evaluate a potential difference in follicle 
numbers in the injected ovary relative to the mare’s untreated ovary. Ovary-specific 
follicle counts were modeled separately as Poisson distributions. The Poisson parameters 
were modeled as a function of the expected follicle count, with a within-mare, ovary-
specific random effect, and a treatment effect. The 8-week period before injection (the 
first injection, for those mares injected twice) was considered the “Pre-treatment” 
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period; the 4-week period following injections were considered the “Treatment” period; 
and the 8-week period following the Treatment period was considered the “Post-
treatment” period. The numbers of follicles in the MSC-injected ovary relative to the 
mare’s non-injected ovary were compared at each period. For mares injected twice, the 
4-week period before the second injection was considered the “Pre-treatment” period, 
and the 2-week period after injection until ovariectomy was considered the “Treatment” 
period. The number of follicles on the injected ovary was then compared within mare 
group (MSC vs Vehicle) among treatment periods. 
 For old mares, the oocyte recovery rate (oocytes recovered per follicle aspirated 
on TVA), proportion of oocytes reaching metaphase II in culture, and the proportion of 
oocytes developing to blastocyst after ICSI were compared among treatment periods 
within mare group (MSC or Vehicle) using Chi-square analysis, with Fisher’s exact test 
used when a value < 5 was expected for any parameter. 
 Bayesian models were also implemented to evaluate AMH, FSH and total 
estrogen concentrations in relation to treatment. For hormone concentrations, in old 
mares the Pre-treatment period was the 4 wks before injection, the Treatment period was 
the 4 wks after injection, and the Post-treatment period was the 8 wks after the 
Treatment period. Significance level was defined as P < 0.05. 
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RESULTS 
Mare Health and Ovarian Status 
 Intra-ovarian injections of allogeneic BM-MSCs (n = 10) or Vehicle (n = 4) in 
old or young mares were not associated with any observable signs of discomfort or 
systemic illness. Temperature, pulse and respiration rates were within normal limits for 
the 7-day period in which they were evaluated after injection. All the mares continued to 
appear bright, alert, responsive, and in good health for the duration of the study. 
 Of the 8 old mares, four mares (ages 20, 24, 20 and 20 yr) consistently had 
follicular activity as defined by the presence of antral follicles visible on 
ultrasonographic examinations; the other four mares (ages 22, 23, 29 and 29 yr) had no 
visible follicles throughout the study.  
 Gross examination of the ovaries of the old mares after ovariectomy revealed an 
abscess in the ovary of one of the mares. This mare had received two intra-ovarian MSC 
injections into the ovary in question, and had undergone a total of six TVA procedures. 
The rest of the ovaries showed no gross pathology. Histopathologic examination of the 
old mare ovaries revealed small areas of granulation tissue in ovaries in all categories 
(MSC-injected, vehicle-injected and non-injected), this was considered by the 
pathologist to be of no clinical significance.  
 On fluorescent microscopic evaluation of four sections from each ovary of the 
three mares injected with QD-labeled MSCs two weeks previous to ovariectomy, no 
QDs were detected in either the injected ovary or the contralateral ovary. 
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 TVA was performed on 8 occasions after MSC injection of old mares: at 12 and 
16 wks after injection in one mare; 2, 5, 8, and 10 wks after injection in a second mare; 
and at 4 and 11 weeks after injection in a third mare. At all other 14-day evaluations in 
these mares and all 14-day evaluation in the other three mares, there were insufficient 
follicles present (fewer than five follicles with a diameter > 8 mm) and TVA was not 
performed.  
 
Characterization and Phenotypic Analysis of Donor MSCs 
 The MSCs isolated and used for intra-ovarian injections showed evidence of 
differentiation to chondrogenic, adipogenic and osteogenic cell lineages when cultured 
in appropriate conditions, as seen by the presence of cartilaginous extracellular matrix, 
intracytoplasmic lipid droplets, and calcified extracellular matrix, respectively (Figures 
7.1 and 7.2).  
 Immunophenotypic analysis of MSCs at P3 by flow cytometry revealed that 
MSCs from both donors had a high expression of CD29 and CD90 markers, and low 
expression of CD44, CD45, and MHC II markers (Figures 7.3 and 7.4), consistent with 
results from equine MSCs as reported by De Schauwer [203] and Schnabel [204]. 
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Figure 7.1 Trilineage differentiation of Donor A BM-MSCs. A) chondrogenic pellet 
stained with Toluidine Blue showing cartilaginous extracellular matrix (purple) and 
fibrous tissue (blue), original magnification 200 X, scale bar = 100 µm; B) adipogenic 
differentiation showing fat cells (red) stained with Oil Red O, original magnification 100 
X, scale bar = 200 µm; and C) osteogenic differentiation showing calcified extracellular 
matrix and bone nodules (red) stained with 2% Alizarin Red, original magnification 40 
X, scale bar = 500 µm.  
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Figure 7.2 Trilineage differentiation of Donor B BM-MSCs. A) chondrogenic pellet 
stained with Toluidine Blue showing cartilaginous extracellular matrix (purple) and 
fibrous tissue (blue), original magnification 200 X, scale bar = 100 µm; B) adipogenic 
differentiation showing fat cells (red) stained with Oil Red O, original magnification 100 
X, scale bar = 200 µm; and C) osteogenic differentiation showing calcified extracellular 
matrix and bone nodules (red) stained with 2% Alizarin Red, original magnification 40 
X, scale bar = 500 µm.  
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Figure 7.3 Flowcytometric histogram analyses of cell surface markers of Donor A 
BM-MSCs. For CD29, CD44 and MHC II the gray lines represent negative control 
staining and the red lines represent cell surface marker staining of MSCs. For CD90 and 
CD45the red lines represent secondary antibody staining and the blue lines represent cell 
surface marker staining of MSCs. The percentage of positive cells is indicated in each 
histogram. 
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Figure 7.4 Flowcytometric histogram analyses of cell surface markers of Donor B 
BM-MSCs. For CD29, CD44 and MHC II the gray lines represent negative control 
staining and the red lines represent cell surface marker staining of MSCs. For CD90 and 
CD45 the red lines represent secondary antibody staining and the blue lines represent 
cell surface marker staining of MSCs. The percentage of positive cells is indicated in 
each histogram. 
 
Follicle Numbers 
 Before injection, the number of ovarian follicles identified on the ovary 
designated for injection was not significantly different from the number of follicles 
identified on the contralateral ovary, for both old and young mares. This continued to be 
the case after injection within each MSC-injected mare, regardless of MSC donor 
(Figure 7.5). Because there were no significant differences in any parameter associated 
with the different MSC donors, mares injected with MSCs from either donor were 
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grouped as “MSC-injected mares.” Within group (MSC or Vehicle) there were no 
significant differences in the number of ovarian follicles in the injected ovary among the 
Pre-treatment, Treatment, and Post-treatment periods for either old or young mares 
(Figure 7.5). Similarly, after the second MSC injection in old mares there was no 
difference in follicle numbers between the Pre-treatment and Treatment periods (Figure 
7.5).   
 Considering only the ovary that received the injection, regarding the first 
injection, old mares had a mean of 2.8 follicles (1, 4; lower 2.5% and upper 97.5% 
limits, respectively) in the Pre-treatment period, 1.7 follicles (1, 3) in the Treatment 
period, and 2.3 follicles (1, 4) in the Post-treatment period. Old mares that received 
Vehicle injection had a mean of 1.9 follicles (1, 2) in the Pre-treatment period, 1.8 
follicles (1, 3) in the Treatment period, and 2 follicles in the Post-treatment period.  
 Old mares that received a second MSC injection had a mean of 1.4 follicles (0, 
3.5) in the Pre-treatment prior to the second injection and 1.1 follicles (0, 3) in the 2-
week Treatment period after this injection. There is no Post-treatment period for these 
mares since they were ovariectomized two weeks after the second injection.  
 Young mares that received one MSC injection had a mean of 4.1 follicles (2, 7) 
in the Pre-treatment period, 4.8 follicles (2, 7) in the Treatment period, and 4.1 follicles 
(2, 6) in the Post-treatment period. Young mares that received one Vehicle injection had 
a mean of 2.8 follicles (1, 4.25) in the Pre-treatment period, 1.8 follicles in the Treatment 
period, and 2.4 follicles (1, 4) in the Post-treatment period.  
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 Follicle numbers in the young mares continued to be assessed three times weekly 
for 5 months after the Post-treatment period (7 months after injection). The number of 
follicles did not change significantly during this time. The number of follicles in each 
ovary for each mare throughout the study is represented in Figures 7.6 – 7.10. 
 
Oocyte Recovery, Maturation and Blastocyst Formation 
 In old mares, there was no difference in oocyte recovery rate between the MSC-
injected and Vehicle-injected mares in any period (Table 7.1). The overall oocyte 
maturation rate was 55% (99/179) in old MSC mares and 53.7% (29/54) in old Vehicle 
mares. Similarly, there were no significant differences among periods in oocyte 
recovery, maturation or blastocyst rates within either old MSC- or vehicle-injected 
mares (Table 7.1).  
 
Genetic Analysis 
 The MSC donor fillies had distinguishable mtDNA sequences. Genetic analysis 
of granulosa cells recovered from MSC-injected mares on TVA, pooled separately from 
the injected ovary and from the non-injected ovary, revealed no genomic chimerism and 
no mitochondrial chimerism, in the 16 samples analyzed.  
 Separate genetic analysis of the 5 fragments from each of the 6 ovaries injected 
with BM-MSCs and of the 6 contralateral (non-injected) ovaries of these same mares 
revealed no genomic or mitochondrial chimerism in any fragment. Ovaries from the 
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mares that received a second MSC injection 2 weeks before ovariectomy had no 
evidence of chimerism for either MSC donor.  
 
 
 
Figure 7.5 Mean follicle number in ovaries of MSC-injected and Vehicle-injected 
old and young mares over the period of the study. Pre-treatment period: the 8 weeks 
preceding the date of injection; Treatment: the 4 weeks following MSC-injection; Post-
treatment: the 8 weeks after the Treatment period. Within mare group, there was no 
significant effect of period and there was no significant difference in follicle number 
between injected and non-injected ovaries (P > 0.05). Follicle graphs for individual 
mares are presented in Figures 7.6 to 7.10. 
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Figure 7.6 Follicle numbers of the injected and non-injected ovaries of old mares 
that received one MSC injection. Follicle numbers were those recorded during 
videotaping of ultrasound examinations. Arrows: dates on which MSC injections were 
performed. Arrow heads: dates on which TVAs were performed.  
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Figure 7.7 Follicle numbers of the injected and non-injected ovaries of old mares 
that received two MSC injections. Follicle numbers were those recorded during 
videotaping of ultrasound examinations. Arrows: dates on which MSC injections were 
performed. Arrow heads: dates on which TVAs were performed.    
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Figure 7.8 Follicle numbers of the injected and non-injected ovaries of old mares 
that received one vehicle injection. Follicle numbers were those recorded during 
videotaping of ultrasound examinations. Arrows: dates on which vehicle injections were 
performed. Arrow heads: dates on which TVAs were performed.    
 
 
 
 
 
 
 
 138 
 
 
 
Figure 7.9 Follicle numbers of the injected and non-injected ovaries of young mares 
that received one MSC injection. Follicle numbers were those recorded during 
videotaping of ultrasound examinations. Arrows: dates on which MSC injections were 
performed. The ovarian activity of the mares continued to be assessed for 5 months after 
the Post-treatment period.  
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Figure 7.10 Follicle numbers of the injected and non-injected ovaries of young 
mares that received one vehicle injection. Follicle numbers were those recorded 
during videotaping of ultrasound examinations. Arrows: dates on which vehicle 
injections were performed. The ovarian activity of the mares continued to be assessed 
for 5 months after the Post-treatment period. 
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Table 7.1 Rates of oocyte recovery, in vitro maturation to metaphase II (MII), and 
blastocyst formation after ICSI of old MSC-injected and Vehicle-injected mares.  
 
 MSC-injected  Vehicle-injected 
 Oocyte recovery 
Maturation 
to MII Blastocyst 
 Oocyte 
recovery 
Maturation 
to MII Blastocyst 
Pre-
treatment 
56.1% 
(64/114)a 
57.8%  
(37/64)a 
29.7% 
(11/37)a 
 62.9% 
(17/27)b 
58.8%  
(10/17)b 
 
0/10b 
Treatment 43.5% (10/23)a 
50%  
(5/10)a 
40%  
(2/5)a 
 45.5% 
(5/11)b 
60%  
(3/5)b 
  
0/3b 
Post-
treatment 
59.5% 
(25/42)a 
60% 
(15/25)a 
13.3% 
(2/15)a 
 43.7% 
(7/16)b 
85.7% 
(6/7)b 
 
0/6b 
 
There were no significant differences in oocyte recovery, maturation or blastocyst rates 
in either MSC-injected or Vehicle-injected mares among periods (P > 0.05).  
 
Serum Hormone Levels 
 There was no significant difference in AMH, FSH or total estrogens among 
periods in old or young mares. Hormone concentrations for old and young mares 
throughout the study are presented in Figures 7.11 – 7.16. AMH values were reflective 
of follicle activity in the mares, in that the mares with no ovarian activity had basal 
AMH concentrations throughout the study, and AMH values for mares with follicle 
activity fell precipitously after ovariectomy (Figure 7.11).  FSH values rose with the 
onset of the breeding season and were higher for mares with no follicular activity than 
for mares with follicular activity (Figure 7.12). Total estrogen levels tended to be higher 
in mares with follicular activity (Figure 7.13).  
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Figure 7.11 AMH concentrations for old mares injected once (top graph) or twice 
(middle graph) with MSCs or Vehicle (bottom graph).  Solid lines: mares with 
follicular activity; Dashed lines: mares with no follicular activity; Arrows: dates on 
which injections were performed. Vertical line: date when ovariectomies were 
performed. Within mare group, there were no significant differences in AMH 
concentrations among the Pre-treatment, Treatment or Post-treatment periods. 
 142 
 
 
Figure 7.12 FSH concentrations for old mares injected once (top graph) or twice 
(middle graph) with MSCs or Vehicle (bottom graph).  Solid lines: mares with 
follicular activity; Dashed lines: mares with no follicular activity; Arrows: dates on 
which injections were performed. Vertical line: date when ovariectomies were 
performed. Within mare group, there were no significant differences in FSH 
concentrations among the Pre-treatment, Treatment or Post-treatment periods. 
 143 
 
 
Figure 7.13 Total estrogens concentrations for old mares injected once (top graph) 
or twice (middle graph) with MSCs or Vehicle (bottom graph).  Solid lines: mares 
with follicular activity; Dashed lines: mares with no follicular activity; Arrows: dates on 
which injections were performed. Vertical line: date when ovariectomies were 
performed. Within mare group, there were no significant differences in total estrogens 
concentrations among the Pre-treatment, Treatment or Post-treatment periods. 
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Figure 7.14 AMH for young mares injected with MSCs (top graph) or Vehicle 
(bottom graph). Arrows: dates on which injections were performed. Within mare group, 
there were no significant differences in AMH concentrations among the Pre-treatment, 
Treatment or Post-treatment periods. 
 
 
 
 
 
 
 145 
 
 
Figure 7.15 FSH concentrations for young mares injected with MSCs (top graph) 
or Vehicle (bottom graph). Arrows: dates on which injections were performed. Within 
mare group, there were no significant differences in FSH concentrations among the Pre-
treatment, Treatment or Post-treatment periods. 
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Figure 7.16 Total estrogens concentrations for young mares injected with MSCs 
(top graph) or Vehicle (bottom graph). Arrows: dates on which injections were 
performed. Within mare group, there were no significant differences in total estrogens 
concentrations among the Pre-treatment, Treatment or Post-treatment periods. 
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DISCUSSION 
 Supporting the preliminary study described in Chapter III, the results from this 
study indicate that intra-ovarian injections of allogeneic BM-MSCs are safe to perform 
in mares, as no detrimental effects were seen in mare health or ovarian status in injected 
mares. The exception to this is the abscess found in one ovary; this may have been 
related to either the MSC injections or the repeated TVAs. Abscess formation has been 
reported previously following TVA, but at a low incidence (~1 in 400 procedures) [305]. 
The small areas of granulation (scar tissue) found on histological examination of the 
ovarian tissue of the 8 old mares were considered to be of no significance by the 
pathologist. It is possible that these changes were intrinsic in these aged ovaries, or were 
the result of MSC injections, as this condition was observed in the ovaries of mares in 
which TVAs were not performed due to lack of follicles. 
 Injections of MSCs in other species have been associated with an improvement 
in ovarian function, as determined by an increase in ovarian follicles and fecundity, in 
females with ovaries compromised by chemotherapy [8-11, 262, 263]. In the preliminary 
study presented in Chapter III, there appeared to be a significant increase in follicle 
number 4 weeks after MSC injection in two randomly selected young mares. However, 
in the present study, there was no significant increase in follicle number after MSC 
injection in young or old mares. The ovarian activity of the young mares in the present 
study continued to be evaluated for 7 months after the injection, to detect any evidence 
of MSC stimulation of development of earlier-stage follicles, estimating 4 to 6 months 
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for growth from primordial to ovulatory follicle [22], but no increase in follicle numbers 
was seen during that time (Figure 7.9). 
 The lack of follicular response to MSC treatment is supported by the hormone 
concentrations, which were also not affected by MSC treatment. If MSCs had increased 
the number of growing follicles, we would have expected to see a concurrent increase in 
AMH, as concentrations of AMH are closely related to the total number of antral 
follicles present on the ovaries in mares, as in women [306]. Elevated FSH 
concentrations are a diagnostic finding in women with low follicle counts, as feedback 
from follicular inhibin is lost [307-309], and this is also true in other species such as 
cattle [310, 311]. The old mares that had no visible follicular activity on ultrasonography 
in the present study had correspondingly low AMH concentrations and high FSH 
concentrations.  
 Total estrogens were measured as this was the only commercial assay available 
to detect equine estrogen concentrations that we could identify; however, these values 
are less correlated with ovarian activity than are the AMH and FSH values. This assay is 
not specific for estradiol (the form of estrogen produced by antral follicles) and has a 
strong cross reactivity with adrenal estrogens; therefore, it is likely that much of the 
estrogen detected, including the high estrogen concentrations seen in the mare with no 
follicular activity, were not being produced by ovarian follicles but by another source, 
probably the adrenal glands. This is clearly shown by the persistence of moderate 
estrogen levels after ovariectomy. 
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  The main question from evaluating the preliminary and main studies is: why did 
the two mares in the preliminary study have significantly higher follicle activity in the 4 
weeks after MSC injection, whereas neither the old nor young mares in the main study 
showed an effect? One possible explanation for the lack of follicular number increase in 
the present study is that the mares in the preliminary study received two MSC injections 
(one in each ovary), i.e., in total they received twice the number of cells as the mares in 
the main study. Further research is needed to determine if there is an optimal number of 
cells needed to induce changes in follicle number. Another possible explanation is that 
the source of the MSCs used in the preliminary study and in the main study differed. The 
MSCs used in the preliminary study were obtained from a sexually-mature (7 yr) mare, 
whereas the MSCs used in the main study were obtained from two yearling fillies. We 
used these fillies as we felt that in young mares, MSC numbers in the BM aspirates 
would be higher, the cells would proliferate more readily, which was important as we 
had to produce sufficient cells for 13 injections, and the cells may have more stem-like 
properties. We used two different donor fillies in case there was a donor specific-effect. 
Unfortunately, by the time we obtained the results of the main study showing a lack of 
effect, the donor used in the preliminary study was no longer in the herd, and there were 
no remaining MSCs from that mare. Further research is needed to determine if MSCs 
from some categories of horses, or some individual donors, elicit changes in follicle 
numbers while MSCs from other donors do not.  
 The lack of donor MSC genomic DNA and mitochondrial chimerism detected in 
the ovaries of the old mares suggests that the injected MSCs did not persist or multiply 
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within the ovary; lack of chimerism in ovaries of mares injected two weeks before 
ovariectomy suggest that the MSCs do not persist for even this period. However, it is 
possible that MSCs were present in the ovarian tissue but at levels that were below the 
threshold detectable by the PCR performed.  
 We evaluated mitochondrial chimerism as it has been suggested that 
mitochondria from MSCs may be transferred to host cells [199]. Human alveolar 
epithelial cells with defective mitochondria or mutated mtDNA, which had rendered 
them incapable of aerobic respiration and growth, acquired functional mitochondria and 
regained their ability to propagate exponentially following 14 days of co-culture with 
human BM-MSCs [199]. Genetic analysis of the cells demonstrated the presence of 
mtDNA from the MSCs. As discussed in Chapter II, mitochondrial dysfunction and 
mtDNA mutations are thought to be a contributing factor or a hallmark of mammalian 
oocyte aging [95-100]. Therefore, transfer of mitochondria or mtDNA from the injected 
MSCs could have served to rescue or improve their function. 
 We also attempted to determine if MSCs colonize the ovary by labeling the cells 
with fluorescent nanoparticles (QDs) and then identifying cells containing these particles 
after ovary removal two weeks after injection. However, examination of ovarian sections 
in these mares post-ovariectomy did not reveal the presence of QDs. It is not possible to 
determine where the QD-labeled MSCs were injected, so the possibility exists that QDs 
were present and localized only to the area of injection, and were not in the examined 
ovarian sections. Although equine BM-MSCs have been shown to migrate in vitro, these 
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cells have been found to remain close to their site of injection following in vivo injection 
into artificially-induced tendon lesions [281].  
 In rat, mouse and rabbit ovaries damaged by chemotherapy, injection of MSCs 
increases ovarian function as indicated by an increase in follicle numbers [10, 11, 262]. 
However, in the present study there was no increase in follicle numbers following MSC 
injection. It is possible that MSCs have a different effect on chemotherapy-treated 
ovaries than in aged ovaries, or that rodent and rabbit ovaries react differently to MSCs 
than do equine ovaries.  
 It has also been reported that in rat and mouse ovaries damaged by 
chemotherapy, injection of MSCs induces changes in mRNA expression [10, 11]. 
Therefore we performed the study presented in Chapter VIII to determine if injection of 
BM-MSCs induces changes in gene expression in equine ovaries.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 152 
 
CHAPTER VIII 
EFFECT OF INTRA-OVARIAN INJECTION  
OF BONE MARROW-DERIVED MESENCHYMAL STEM CELLS  
ON EQUINE OVARIAN GENE EXPRESSION  
 
INTRODUCTION 
 Mesenchymal stem cells (MSCs) secrete factors that have the potential to affect 
follicular growth in ovaries; these include Hgf (hepatocyte growth factor), which induces 
angiogenesis and tissue regeneration [266], Vegf (vascular endothelial growth factor), 
which induces proliferation and migration of vascular endothelial cells and which has 
been found to inhibit apoptosis of rat cumulus cells [265], and Igf1 (insulin-like growth 
factor 1), which is involved in mediating growth and development and has been shown 
to stimulate the proliferation of porcine cumulus cells [267]. Thus the possibility exists 
that injection of MSCs into ovaries could improve ovarian function.  This has in fact 
been demonstrated repeatedly in ovaries damaged by chemotherapy.  Protein and mRNA 
expression of Hgf, Vegf, and Igf1 were higher in chemotherapy-damaged rat ovaries that 
had been injected with adipose-derived MSCs; additionally, expression of Star 
(steroidogenic acute regulator), which enhances the conversion of cholesterol to 
pregnenolone, was also increased [10].  Injection of ovaries with umbilical cord MSCs 
returned the RNA expression pattern of chemotherapy-damaged mouse ovaries back to 
that of control ovaries, and rescued the expression of important proteins from the aldo-
keto reductase family 1, which catalyze the conversion of progesterone to 20-alpha 
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dihydroprogesterone [11]. These changes were associated with increased ovarian activity 
and fecundity in the MSC-treated mice and rats [10, 11].  
 The above-referenced studies indicate that intra-ovarian or systemic injection of 
MSCs in females with ovaries compromised by chemotherapy induces expression of 
mRNA and proteins that may improve ovarian function. However, little information is 
available on the effect of MSCs on gene expression of ovaries from old females.  In the 
main study of this dissertation (detailed in Chapter VII), 8 old mares received intra-
ovarian injections, in 1 ovary only, of MSCs or vehicle.  The ovaries of these mares were 
removed via colpotomy and RNA sequencing was performed on the ovarian tissue to 
determine differences in gene expression between MSC-injected and vehicle-injected 
ovaries, and between these ovaries and the contralateral, non-injected, ovaries.  
 
MATERIALS AND METHODS 
 In the study described in Chapter VII, intra-ovarian injections were performed in 
8 old mares; of these, 6 mares had 1 ovary injected with MSCs and 2 mares had 1 ovary 
injected with vehicle. Of the 6 mares that had 1 ovary injected with MSCs, 3 mares 
received a second MSC injection into the same ovary 12 to 17 weeks after the first 
injection (MSC2 mares). Two weeks after the second injection to MSCs mares, both 
ovaries of all 8 old mares were removed by ovariectomy via colpotomy and ovarian 
tissue was processed as detailed in Chapter VII.  
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Samples 
 Samples were obtained by combining 5 tissue sections from each ovary, 
providing one combined sample for each ovary. This resulted in 3 samples from old 
mare ovaries injected once with MSCs (MSC1) and 3 samples from the contralateral 
ovaries of these mares (MSC1opp); 3 samples from old mares injected twice with MSCs 
(MSC2) and 3 samples from the contralateral ovaries of these mares (MSC2opp); 2 
samples from old mares injected once with vehicle (V) and 2 samples from the 
contralateral ovaries of these mares (Vopp). 
 
RNA Isolation and RNA-Sequencing 
 Isolation of RNA from pulverized ovarian tissues was performed by the Texas 
A&M Institute for Genomic Sciences and Society (TIGSS) as described in Chapter VI. 
The RNA samples were submitted to the Texas A&M AgriLife Genomics and 
Bioinformatics core for generation of RNA-Sequencing (RNA-Seq) libraries and for 
RNA-Seq reactions. RNA-Seq libraries were generated using the TruSeq RNA 
preparation kit (Illumina) with a polyA selection step; polyA mRNA was fragmented 
and reverse-transcribed to cDNA for sequencing. The samples were sequenced (50-base-
pair, single-end sequencing) on 8 sequencing lanes of a HiSeq 2500 (Illumina). 
 
Gene Expression Analysis 
 The raw data from the RNA-Seq reactions was processed by the TIGSS. Briefly, 
A total of 1.36 billion reads were checked to trim any adapter sequences and low quality 
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bases using Trimmomatic [312], resulting in approximately 1.31 billion filtered reads 
(96%) out of which a total of 1.18 billion filtered reads (approximately 87%) mapped to 
the equCab2 genome assembly. All samples had Phred scores > 20. The quality of the 
bases is determined by a Phred score, which represents the probability that a given base 
call is incorrect. Quality scores range from 4 to 60, with higher values corresponding to 
higher quality; the scores are linked to error probabilities. A Phred score of 20 represents 
a 1 in 100 probability that the base is called wrong, i.e., a 99% accuracy of the base call. 
High quality bases are those with a Phred score ≥ 20 [313]. Read mapping was 
performed using HISAT version 2.0.5 [314]. HTSeq [315] was used to generate raw read 
counts per gene using intersection-nonempty parameters to account for ambiguous read 
mappings. Differential gene expression tests were then performed using DESeq2 [316]; 
differentially expressed genes were defined as those having a false discovery rate (FDR) 
≤ 0.5 and log2FC +/- 1. Plots were generated using R programming language. 
 Biological pathway analysis was performed by the PI at the Equine Embryo 
Laboratory, using the Ingenuity Pathway Analysis tool-kit (QIAGEN, Venlo, 
Netherlands; www.ingenuity.com Application Build 261899, Content Version 
18030641). 
 
RESULTS 
Analysis of Gene Expression 
 To determine the effects of MSCs on equine ovarian gene expression, we first 
compared the gene expression of MSC1 (injected once with MSCs) ovaries to V 
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(injected once with vehicle) ovaries. There were 93 significantly different genes with 57 
upregulated and 36 downregulated in MSC1 ovaries compared to V ovaries, and these 
two groups shared 1270 genes in common (Figure 8.1). Pathway analysis revealed 
biological processes involving cell-to-cell signaling and interaction (17 genes), small 
molecule biochemistry (14 genes), cellular assembly and organization (12 genes), 
cellular function and maintenance (12 genes), and lipid metabolism (9 genes; Table 8.1). 
The twenty most highly differentially-regulated genes between MSC1 and V ovaries are 
presented individually in Table 8.2.  
 To determine if the injected MSCs may have a systemic effect, we compared the 
gene expression between MSC1opp (contralateral ovary of MSC1 mares) and Vopp 
(contralateral ovary of V mares) ovaries. There were 286 significantly different genes 
with 75 upregulated and 211 downregulated in MSC1opp ovaries compared to Vopp 
ovaries, and these two groups shared 2135 genes in common (Figure 8.3). Pathway 
analysis revealed biological processes involving cellular development (64 genes), cell 
morphology (61 genes), cellular growth and proliferation (56 genes), cellular assembly 
and organization (44 genes), and cell cycle (37 genes; Table 8.3). The twenty most 
highly regulated genes between MSC1opp and Vopp ovaries are presented individually 
in Table 8.4. 
 To determine whether there were differences in the acute and long-term effects 
of MSC injection, we compared gene expression between MSC2 (injected twice with 
MSCs) and MSC1 ovaries. There were 261 significantly different genes with 200 
upregulated and 61 downregulated in MSC2 ovaries as compared to MSC1, and these 
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two groups shared 1618 genes in common (Figure 8.5). Pathway analysis revealed 
biological processes involving cellular function and maintenance (85 genes), cell-to-cell 
signaling and interaction (84 genes), cellular movement (76 genes), cellular development 
(75 genes), and cellular growth and proliferation (72 genes; Table 8.5). The twenty most 
highly regulated genes in MSC2 ovaries are presented individually in Table 8.6. 
 All the differentially-expressed genes identified for each of the comparisons 
mentioned above are presented, in alphabetical order, in Appendix Tables A-2 to A-4. 
The complete list of identified genes in each group is given in Supplementary Table S-1. 
 Other comparisons were reviewed to detect any pronounced differences in gene 
expression; the most prominent was Tac1 (tachykinin precursor). This gene, which was 
the most highly upregulated gene in MSC2 ovaries vs MSC1 ovaries (Table 8.6), was 
also the most highly upregulated gene in MSC2 ovaries vs V ovaries (3.99, 1.81E-15; 
log2FC, P-value, respectively; Figure 8.4), and in MSC2opp (contralateral ovary of 
MSC2 mares) vs Vopp ovaries (3.70, 1.72E-13; Figure 8.5).  
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Figure 8.1 Volcano plot of upregulated and downregulated genes in ovaries injected 
once with MSCs (MSC1) compared to ovaries injected once with Vehicle (V). There 
were 57 upregulated genes and 36 downregulated genes. The 10 most differentially-
regulated genes are given in the figure: KRT (keratin 5, 14, and 17); PRLR (prolactin 
receptor); TSGA10 (testis specific 10); HIST2H2BE (histone cluster 2 H2B family 
member e). Unknown gene products are designated by “UK.” 
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Table 8.1 Biological processes representative of the top five functional annotation 
clusters among genes differentially expressed in ovaries injected once with MSCs 
(MSC1) versus ovaries injected once with Vehicle (V).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Genes 
Biological 
Process 
Gene 
count P-value  Upregulated Downregulated 
Cell-to-cell 
signaling and 
interaction 
17 3.65E-05 
CNTN5, CTNND2, ERBB4, 
GRM5, IL33, LRRTM2,  MSLN, 
NR1H4, SEMA3E, TLR1 
ADCY1, ASGR1,  
CAMSAP3,  CCR3, 
 KRT17, PIGR, PRLR 
     
Cellular 
assembly and 
organization 
12 2.97E-04 
CNTN5, CTNND2, ERBB4, 
GRM5,  IL33,  KCNK2, 
LRRTM2, SEMA3E, NR1H4 
CAMPSAP3, PRLR, 
HIST2H2BE 
     
Cellular 
function and 
maintenance 
12 2.97E-04 
CTNND2,  ERBB4, GRM5, 
LRRTM2,  IL33, SEMA3E, 
SLC1A2, SLC4A9,  
ASGR1, CAMSAP3, 
PIGR, SCNN1G 
     
Lipid 
metabolism 9 4.68E-04 
AKR1D1, ERBB4, GRM5, IL33, 
NR1H4, TLR1 
CCR3, DPEP2, PRLR 
     
Small 
molecule 
biochemistry 
14 4.68E-04 
AKR1D1, CNTNAP5, ERBB4, 
GRM5, NR1H4, IL33, SLC1A2, 
TLR1 
ADCY1,  CCR3, DPEP2 
 KRT14,  NMNAT2, 
PRLR, 
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Table 8.2 The twenty most differentially-expressed genes identified by DESeq2 in 
MSC1 ovaries compared to Vehicle-injected ovaries. 
 
Gene symbol Log2FC P-value Gene description 
KRT5 -1.55 5.70E-05 keratin 5 
KRT14 -1.76 5.80E-05 keratin 14 
KRT17 -1.68 2.47E-04 keratin 17 
PRLR -1.57 1.72E-03 prolactin receptor 
TSGA10 1.10 2.24E-03 testis specific 10 
HIST2H2BE -1.21 2.53E-03 histone cluster 2 H2B family member e 
CNTN5 1.40 2.55E-03 contactin 5 
CISH -1.43 3.03E-03 cytokine inducible SH2 containing protein 
ASB15 -1.48 3.42E-03 Ankyrin repeat and SOCS box containing 15 
DCST2 1.42 4.59E-03 DC-STAMP domain containing 2 
RASSF9 1.07 4.98E-03 Ras association domain family member 9 
RNF17 -1.41 5.39E-03 ring finger protein 17 
EPS8L3 1.26 6.71E-03 EPS8 like 3 
MSLN 1.37 6.76E-03 mesothelin 
ERBB4 1.34 7.10E-03 erb-b2 receptor tyrosine kinase 4 
SLC4A9 1.32 7.66E-03 solute carrier family 4 member 9 
ADCY1 -1.17 9.33E-03 adenyl cyclase 1 
TLR1 1.09 1.14E-02 toll like receptor 1 
IL33 1.25 1.16E-02 interleukin 33 
ACVR1C 1.26 1.20E-02 activing A receptor type 1C 
 
FC fold-change.  
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Figure 8.2 Volcano plot of upregulated and downregulated genes in MSC1opp 
ovaries compared to Vopp ovaries. There were 75 upregulated genes and 211 
downregulated genes. The 10 most differentially-regulated genes are given in the figure: 
CITED (Cnp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal 
doimain 1); MMP7 (matrix metallopeptidase 7); UPK1B (uroplakin 1B); DNAH6 
(dynein axonemal heavy chain 6); INSL3 (insulin like 3); MUC16 (mucin 16); PTPN5 
(protein tyrosine phosphatase, non-receptor type 5). Unknown gene products are 
designated by “UK.” 
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Table 8.3 Biological processes representative of the top five functional annotation 
clusters among genes differentially expressed in MSC1opp versus Vopp ovaries. 
 
   Genes 
Biological 
Process 
Gene 
count P-value Upregulated Downregulated 
Cellular 
development 64 1.11E-08 
ADAD1, 
FABP7, 
FGL1, 
FOXC2, , 
HSF4, 
IL22RA1, 
IL2RG, 
ITIH4, LTB, 
NOV 
ADAMTS9, AQP5, BMP7, BNC1, BUB1, CCNB2, 
CDCA5, CDH1, CDHR2, CDKN3, CITED1, 
CLDN2, COL1A1, CXADR, DPP4, DSC1, DSP, 
E2F1, EHF, EPHA1, ESRP1, ESRP2, FGF5, 
FOXJ1, FOXM1, FST, GABRP, GGT1, GRHL2, 
HMMR, HPN, INHA, INHBB, INSL3, KIF20A, 
LPAR3, LRP8, MMP7, MUC16, MUC4, OPRK1, 
PAX8, PCLAF, PKP3, PPP1R1B, PRLR, PTPRQ, 
RAB25, SP6, ST14, TNC, UPK1B, WFDC2, WWC1 
     
Cell cycle 37 5.94E-07 IL2RG, UBD 
ANLN, BMP7, BUB1, BUB1B, CEP55, CCNB2, 
CCNB3, CDC20, CDCA5, CDH1, CDKN3, 
CENPF, CKAP2, COL1A1, DPP4, DUOXA1,E2F1, 
EHF, EXO1, FOXM1, HJURP, HMMR, INHA, 
KIF11, KIF20A, MIS18A, PAX8, PCLAF, 
PKMYT1, PRC1, PRR11, TNC, TOP2A, WWC1 
     
Cell 
morphology 60 1.03E-06 
CD36, 
CD8B, 
FGL1, 
FOXC2, 
HSF4, 
IL2RG, 
IL33, LTB, 
MPO, 
MYOC, 
NOV, 
PRKG2, 
AP1M2, AQP5, BMP7, BNC1, BUB1, CADPS, 
CDH1, CLDN2, CNTN2, COL1A1, COL3A1, 
CX3CR1, CXADR, CYP17A1, DKK2, DPP4, E2F1, 
ELOVL3, EXO1, FCMR, FOXJ1, FOXM1, FST, 
GRHL2, GRIN3A, HPN, INHA, INHBB, KIF11, 
KIF20A, LPAR3, LRP8, MUC4, NEFH, NRCAM, 
PAX8, PCLAF, PIGR, PRLR, PTPRQ, SERINC2, 
SLC2A2, SLC4A4, SP6, SPTA1,  
SPTBN2, ST14, TNC 
     
Cellular 
growth and 
proliferation 
55 2.55E-06 
ADAD1, 
FABP7, 
FGL1, 
FOXC2, 
HSF4, 
IL22RA2, 
IL2RG, 
ITIH4, 
LTB, , NOV  
AQP5, BMP7, BNC1, BUB1, CCNB2, CDCA5, 
CDH1, CDKN3, CITED1, CLDN2, COL1A1, 
CXADR, DPP4, E2F1, EHF, EPHA1, ESRP1, 
ESRP2, FGF5, FOXM1, FST, GABRP, GGT1, 
GRHL2, HMMR, HPN, INHA, INHBB, INSL3, 
KIF20A, LPAR3, LRP8, MMP7, MUC16, MUC4, 
PAX8, PCLAF, PKP3, PPP1R1B, PRLR, PTPRQ, 
SP6, TNC, WFDC2, WWC1 
     
Cellular 
assembly and 
organization 
44 1.09E-05 FOXC2, IL33, MYOC 
ADCY1, AQP5, BMP7, BUB1, BUB1B, CAMSAP3, 
CCDC113, CCNB2, CDC20, CDH1, CENPF, 
CKAP2, CNTN2, CNTN4, COL1A1, COL3A1, 
CXADR, DSP, EPHA8, ESRP2, EXO1, FOXJ1, 
FOXM1, FTCD, GRIN3A, HJURP, HMMR, KIF11, 
KIF20A, LRP8, MIS18A, MMP7, NEFH, NRCAM, 
PRC1, PTPRQ, SPTA1, SPTBN2, ST14, TNC, 
TOP2A 
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Table 8.4 The twenty most differentially-expressed genes identified by DESeq2 in 
MSC1opp ovaries compared to Vopp ovaries. 
 
Gene symbol Log2FC P-value Gene description 
CITED2  -2.09 1.38E-05 Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 1 
MMP7 -1.90 4.47E-05 matrix metallopeptidase 7 
UPK1B -1.73 5.85E-05 uroplakin 1B 
DNAH6 -1.80 6.54E-05 dynein axonemal heavy chain 6 
INSL3 -1.65 1.72E-04 insulin like 3 
MUC16 -1.55 2.37E04 mucin 16, cell surface associated 
PTPN5 -1.75 2.91E-04 protein tyrosine phosphatase, non-receptor type 5 
LRRN4 -1.74 4.25E-04 leucine rich repeat neuronal 4 
CILP -1.73 4.62E-04 cartilage intermediate layer protein 
UNC45B -1.72 6.69E-04 unc-45 myosin chaperone B 
OPRK1 -1.33 6.76E-04 opioid receptor kappa 1 
PIGR -1.65 7.58E-04 polymeric immunoglobulin receptor 
MUC4 -1.53 8.22E-04 mucin 4, cell surface associated 
SERINC2 -1.68 9.80E-04 serine incorporator 2 
C6ORF118 -1.50 1.03E-03 chromosome 6 open reading frame 118 
THAP12 -1.30 1.04E-03 THAP domain containing 12 
DAW1 -1.56 1.07E-03 dynein assembly factor with WD repeats 1 
FBXO47 -1.65 1.11E-03 F-box protein 47 
ESRP2 -1.03 1.15E-03 epithelial splicing regulatory protein 2 
BNC1 -1.15 1.31E-03 basonuclin 1 
 
FC fold-change.  
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Figure 8.3 Volcano plot of upregulated and downregulated genes in ovaries injected 
twice with MSCs (MSC2) compared to ovaries injected once with MSCs (MSC1). 
There were 200 upregulated genes and 61 downregulated genes. The 10 most 
differentially-regulated genes are given in the figure: TAC1 (tachykinin precursor); 
MS4A7 (membrane spanning 4-domains A7); SLAMF9 (SLAM family member 9); 
PDE6A (phosphodiesterase 6A); IRF8 (interferon regulatory factor 8). Unknown gene 
products are designated by “UK.” 
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Table 8.5 Biological processes representative of the top five functional annotation 
clusters among genes differentially expressed in ovaries injected twice with MSCs 
(MSC2) versus ovaries injected once with MSCs (MSC1).  
 
   Genes 
Biological 
Process 
Gene 
count P-value  Upregulated Downregulated 
Cellular 
movement 76  6.23E-31 
ACP5, ALOX5, BATF, BTLA, C3AR1, CCL2, 
C5AR1, CASP1, CD86, CD300LB, CSF1R, 
CCR3, CX3CR1, CD48, CEBPE, CHI3L1, 
CLEC7A, CTSS, CXCL9, CXCL11, CYBB, 
EEF1A2, FCER1G, FLT3, GHSR, HCK, HCLS1, 
HMGA1, HPSE, IL10RA, IL1A, IL1RN, IRF5, 
IRF8, ITGAX, ITGB2, LCP1, LTF, MUC2, NCF4, 
NCKAP1L, P2RY12, POU2AF1, RAC2, 
RASGRP4, RGS1, SERPINB1, SLAMF8, ST14, 
TAC1, THBS1, TLR2, TLR7, TNFSF8, TNFSF9, 
TNFSF15, TREM2, TRPM2,TYROBP, UCP2, 
VAV1, VDR, XCR1  
CAV3,  
CCL20, 
CHRM3 
 FOXC2, 
GFRA3, 
IL2, IL33, 
KCNMA1, 
KISS1, 
MEOX2, 
MPZ, 
SELL, 
SEMA3E 
     
Cell-to-cell 
signaling and 
interaction 
84  9.26E-29 
ALOX5, ASGR1, BCL2A1, BTLA, C1QA, C3AR1, 
C5AR1, CACNA1B, CASP1, CCL2, CCL20, 
CCR3, CD163, CD180, CD300LB, CD48, CD68, 
CD84, CD86, CEBPE, CHI3L1, CLEC6A, 
CLEC7A, CP, CSF1R, CTSS, CX3CR1, CXCL11, 
CXCL9, CYBB, EEF1A2, FCER1G, FLT3, GHSR, 
HCK, HCLS1, HNF4A, HPSE, IL10RA, IL1A, 
IL1RN, IL27, IRF5, IRF8, ITGAX, ITGB2, LAT2, 
LCP1, LTF, NCF4, P2RY12, PLA2G2D, PLD4, 
POU2AF1, RAC2, RASGRP4, RGS1, SELL, 
SIGLEC1, SLAMF6, TAC1, THBS1, TIGIT, 
TLR2, TLR7, TLR8, TNFSF15, TNFSF8, 
TNFSF9, TREM2, TRPM2, TYROBP, UCP2, 
VAV1, VDR 
FOXC2, 
IL2, IL33, 
KCNMA1, 
KISS1, 
LGALS4, 
MEOX2, 
MPZ 
MSLN 
     
Cell function 
and maintenance 85 2.37E-28 
AIM2, ASGR1, BATF, BCL2A1, BTLA, C1QA, 
C3AR1, C5AR1, CASP1, CCL2, CCL20, CCR3, 
CD163, CD48, CD84, CD86, CEBPE, CHI3L1, 
CLEC6A, CLEC7A, CP, CSF1R, CTSS, CX3CR1, 
CXCL9, CYBB, FCER1G, FLT3, GHSR, GPR65, 
HCK, HMGA1, HNF4A, IFI30, IL10RA, IL1A, 
IL1RN, IL27, IRF5, IRF8, ITGAX, ITGB2, LAT2, 
LCP1, LY9, NCKAP1L, P2RX2, P2RY12, 
PLA2G2D, PLD4, POU2AF1, RAC2, RASGRP4, 
RGS1, SELL, SIGLEC1, SLAMF6, SLAMF8, 
SLC46A2, TAC1, THBS1, TIGIT, TLR2, TLR7, 
TLR8, TNFSF15, TNFSF8, TREM2, TRPM2, 
TYROBP, UCP2, VAV1, VDR, XCR1 
CAV3, 
CHRM3, 
FOXC2, 
IL2, IL33, 
JPH2, 
KCNMA1, 
KISS1, 
MPZ, 
PPP1R3C, 
SEMA3E 
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Table 8.5 continued 
 
   Genes 
Biological 
Process 
Gene 
count P-value  Upregulated Downregulated 
Cellular 
development 75 4.02E-25 
ALOX5, BATF, BCL2A1, BTLA, C1QC, C3AR1, 
C5AR1, CASP1, CCL2, CCL20, CD163, CD180, 
CD48, CD84, CD86, CEBPE, CLEC6A, 
CLEC7A, CSF1R, CXCL11, EEF1A2, FCER1G, 
FLT3, HCK, HCLS1, HMGA1, HNF4A, IL10RA, 
IL1A, IL1RN, IL27, IRF5, IRF8, ISG20, ITGAX, 
ITGB2, LAT2, LCP1, LTF, LY86, LY9, MNDA, 
MUC2, MUSK, NCKAP1L, NFAM1, PIK3AP1, 
PLA2G2D, POU2AF1, RAC2, RASGRP4, SELL, 
SEZ6L2, SIGLEC1, SLAMF6, SLAMF7, 
SLC46A2, TAC1, THBS1, TIGIT, TLR2, TLR7, 
TLR8, TNFSF15, TNFSF8, TNFSF9, TREM2, 
TRPM2, TYROBP, VAV1, VDR 
IL2, IL33, 
KCNMA1, 
LGALS4 
 
 
Cellular growth 
and proliferation 72 4.02E-25 
ALOX5, BATF, BCL2A1, BTLA, C1QC, C3AR1, 
C5AR1, CASP1, CCL2, CCL20, CD163, CD180, 
CD48, CD84, CD86, CEBPE, CHI3L1, CLEC6A, 
CSF1R, CXCL11, EEF1A2, FCER1G, FLT3, 
HCK, HCLS1, HMGA1, IL10RA, IL1A, IL1RN, 
IL27, IRF5, IRF8, ISG20, ITGAX, ITGB2, LAT2, 
LCP1, LTF, LY86, LY9, MNDA, MUSK, 
NCKAP1L, NFAM1, PIK3AP1, PLA2G2D, 
POU2AF1, RAC2, RASGRP4, SELL, SIGLEC1, 
SLAMF6, SLAMF7, SLC46A2, TAC1, THBS1, 
TIGIT, TLR2, TLR7, TNFSF15, TNFSF8, 
TNFSF9, TREM2, TRPM2, TYROBP, VAV1, VDR 
IL2, IL33, 
KISS1, 
LGALS4, 
MSLN 
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Table 8.6 The twenty most differentially-expressed genes identified by DESeq2 in 
MSC2 ovaries compared to MSC1 ovaries. 
 
Gene symbol Log2FC P value Gene description 
TAC1 4.36 7.79E-18 tachykinin precursor 
MS4A7 1.80 4.52E-05 membrane spanning 4-domains A7 
SLAMF9 2.01 6.82E-05 SLAM family member 9 
PDE6A 1.84 7.89E-05 phosphodiesterase 6A 
IRF8 1.49 3.00E-04 interferon regulatory factor 8 
LGALS4 -1.80 4.12E-04 galectin 4 
SIGLEC1 1.38 6.34E-04 sialic acid binding IG like lectin 1 
PLD4 1.48 6.53E-04 phospholipase D family member 4 
LAT2 1.20 7.23E-04 linker for activation of T-cells family member 2 
GPR31 1.45 8.08E-04 G protein-coupled receptor 31 
VAV1 1.44 8.60E-04 vav guanine nucleotide exchange factor 1 
CD300LB 1.69 8.95E-04 CD300 molecule like family member b 
CD163 1.52 9.80E-04 CD163 molecule 
RHBG 1.63 1.08E-03 Rh family B glycoprotein (gene/pseudogene) 
GPR151 1.22 1.19E-03 G protein-coupled receptor 151 
CD86 1.47 1.23E-03 CD86 molecule 
CRADD -1.05 1.30E-03 CASP2 and RIPK1 domain containing adaptor with death domain 
SLAMF7 1.58 1.32E-03 SLAM family member 7 
RASSF9 -1.13 1.40E-03 Ras association domain family member 9 
CYBB 1.50 1.51E-03 cytochrome b-245 beta chain 
 
FC fold-change.  
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Figure 8.4 Volcano plot of upregulated and downregulated genes in ovaries injected 
twice with MSCs (MSC2) compared to ovaries injected once with Vehicle (V). There 
were 237 upregulated genes and 25 downregulated genes. The 10 most differentially-
regulated genes are given in the figure: TAC1 (tachykinin precursor); GPR141 (G 
protein-coupled receptor 141); ETV7 (ETS variant 7); and RHGB (Rh family B 
glycoprotein (gene/pseudogene)). Unknown gene products designated by “UK.” 
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Figure 8.5 Volcano plot of upregulated and downregulated genes in MSC2opp 
ovaries compared to Vopp ovaries. There were 75 upregulated genes and 489 
downregulated genes. The 10 most differentially-regulated genes are given in the figure: 
TAC1 (tachykinin precursor); LAMC2 (laminin subunit gamma 2); CITED1 (Cbp/p300 
interacting transactivator with Glu/Asp rich carboxy-terminal domain 1); PIGR 
(polymeric immunoglobulin receptor); FBLN7 (fibulin 7); P4HA3 (prolyl 4-hydroxylase 
subunit alpha 3); DNAH6 (dynein axonemal heavy chain 6); OLFML2B (olfactomedin 
like 2B); C2orf54 (chromosome 2 open reading frame 54); and SPTA1 (spectrin alpha, 
erythocytic 1).  
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DISCUSSION 
 This study presents some of the first data on global gene expression in equine 
ovaries. Three of the most highly differentially-expressed genes in MSC1 ovaries were 
keratin 5, 14 and 17, all of which were downregulated when compared to Vehicle-
injected ovaries. These genes encode keratin proteins, which are intermediate filament 
proteins involved in cellular assembly and organization [317]. While we could find no 
data on these specific keratin proteins as they relate to ovarian or MSC function, the 
expression of Krt8 (keratin 8) in cumulus cells has been associated with embryos that 
arrested at the 2- to 8-cell stage during in vitro culture, and thus has been proposed as a 
marker of poor oocyte quality [317, 318]. DMSO itself has been shown to downregulate 
Krt15 (keratin 15) in embryonic stem cells [319], however, both MSC1 and V mares 
received the vehicle (DMSO) at relatively the same time before tissue collection, so the 
downregulation observed is related to the MSCs rather than the DMSO.  
 Prolactin receptor (PRLR) was also among the differentially-expressed genes 
being downregulated in MSC1 ovaries compared to V ovaries. Prolactin (PRL) is a 
polypeptide hormone that, in addition to stimulating mammary gland development and 
lactation, is involved in folliculogenesis in mice [320]. The effects of prolactin are 
mediated through its interaction with the PRLR. In mice, the interaction of PRL with 
PRLR is a key component in folliculogenesis and the regulation of corpora luteal (CL) 
function [320]. Although it is not clear whether PL/PRLR play a role in folliculogenesis 
in mares, follicular diameter has been found to be highly correlated with plasma 
prolactin concentrations, and PRL seems to play a role in the transition out of anestrus 
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[321]. Therefore, the downregulation of PRLR in the present study would not seem to 
argue for a stimulatory role of MSCs on folliculogenesis. Again, DMSO (1-5%) has 
been shown to cause a dose-dependent decrease in prolactin receptor levels in other 
tissue (normal mammary cells [322]) but both MSC1 and V ovaries received DMSO at 
the same time before ovariectomy.    
 Among the 20 most differentially-expressed genes, testis specific 10 (TSGA10) 
was upregulated in MSC1 ovaries vs V ovaries. TSGA10 is a gene that was once 
considered testis restricted, i.e., expressed exclusively in adult testes. However, it has 
since been shown to be expressed in normal tissues, including undifferentiated 
embryonic stem cells [323], and in a wide range of neoplasms, including ovarian cancer 
[324]. In the testis, TSGA10 is related to spermatogenesis and has been used as a marker 
of active spermatogenesis in vivo and in vitro [325]. In embryonic stem cells, the 
expression of TSGA10 increases during transition from the proliferation phase to the 
differentiation phase [323]. In cancer cells, TSGA10 may be involved in angiogenesis, 
cell growth and division, motility and migration, all of which are factors important for 
tumor metastasis and invasion [326]. The increased expression of TSGA10 appears to be 
an effect of MSCs; the upregulation of TSGA10 was localized only to the MSC-injected 
ovaries and was not seen in the non-injected contralateral ovaries. To the best of our 
knowledge, this is the first report of TSGA10 expression in the ovary. 
 Another interesting finding was that RASSF9 (Ras-association domain family 
member 9) was upregulated in MSC1 ovaries compared to both V and MSC2 ovaries. 
RASSF genes encode proteins that control cellular processes including membrane 
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trafficking, apoptosis, and proliferation [327]. Although the expression and functional 
significance of RASSF9 is not well known, Rassf9-deficient mice exhibit signs of 
senescence, including alopecia, growth retardation, and decreased lifespan [328]. In the 
present study, upregulation of RASSF9 in MSC1 ovaries appears to be an effect of MSCs 
and may indicate an anti-senescence effect of these cells.  
 Activin A receptor type 1C (ACVR1C, formerly known as ALK7) was also 
upregulated in the ovaries of old mares injected with MSCs, in comparison to those 
injected with vehicle. Activins belong to the TGF-β (transforming growth factor-beta) 
family of cytokines, and expression patterns during post-natal follicular development in 
rodents and humans indicate that activin A stimulates the differentiation of primordial 
follicles into antral follicles [329-331]. The ACVR1C is involved in Nodal signaling in 
early embryo development [332], and it has been found in mare luteal tissue, in which it 
may play a role in luteolysis [333]. ACVR1C is expressed in human pre-antral follicles 
[334] and mouse granulosa cells [335]. It serves as a receptor for not only TGF-beta 
ligands, but also bone morphogenic proteins, which play an important role in ovarian 
function and germ line differentiation [336].  
 From the above gene expression findings, we can conclude that while increased 
antral follicle growth was not observed after MSC injection in the present study (see 
results from Chapter VII), some proliferative and folliculogenic effects of MSCs on gene 
expression were evident.  
 Studies performed in mice [11] and rabbits [262] have shown that in females 
with chemotherapy-damaged ovaries, both systemic (tail- or ear-vein) injection and 
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intra-ovarian injection of MSCs have resulted in restored ovarian function (increased 
number of follicles) and fecundity. In the present study, we decided to perform intra-
ovarian injection rather than systemic injection for several reasons: A) intra-ovarian 
injection allowed us to deliver a meaningful number of cells to the ovary, whereas 
systemic injections using a peripheral vein would have required a markedly higher 
number of cells than was available in order to deliver the same number to the ovary; B) 
methods to deliver the cells to an artery immediately serving the ovary, as done in 
humans via ultrasound-guided catheterization from the common femoral artery [337] 
have not been developed in the horse; and C) the technique of transvaginal ultrasound-
guided ovarian injection is well-established in our laboratory. The possibility exists that 
MSCs injected in the ovary could be distributed in the bloodstream and thus have a 
systemic effect. Therefore, to determine any systemic effects of MSCs, we compared the 
contralateral non-injected ovary of MSC1 mares (MSC1opp) to the contralateral non-
injected ovary of Vehicle mares (Vopp). If MSCs had had a systemic effect, we would 
have expected the same genes that were differentially-regulated in MSC-injected ovaries 
(MSC1) to be differentially-regulated in the contralateral ovary (MSC1opp) when 
compared to Vopp. Analysis of differentially-regulated genes between the two 
comparisons (Tables 8.2 and 8.4) show that there was no overlap in these sets; none of 
the 20 most differentially-expressed genes in the MSC1-injected ovary, vs V, were 
among the most differentially-expressed genes in MSC1opp vs Vopp. This suggests that 
there were limited systemic effects of MSCs 14 to 19 weeks after MSC injection.  
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 To determine whether there were differences in the acute and long-term effects 
of MSCs, we compared the gene expression between ovaries of mares that received one 
MSC injection (MSC1) and ovaries of mares that received two MSC injections (MSC2). 
Tissue collection and processing for RNA analysis was performed 14 to 19 weeks after 
the first injection and 2 weeks after the second injection. There were 200 upregulated 
genes and 61 downregulated genes in MSC2 ovaries compared to MSC1 ovaries.   
 One of the most striking findings on evaluation of gene expression in MSC2 and 
MSC2opp ovaries was the expression of tachykinin precursor (TAC1). Expression of this 
gene was highly significantly upregulated in MSC2 compared to both MSC1 (P = 7.79E-
18) and V (P = 1.81E-15); and in MSC2opp compared to Vopp (P = 1.72E-13). TAC1 
encodes four neurally-active gene products, including substance P. Substance P is a 
neuropeptide, and is also a well-known mediator of response to inflammation and injury 
[338]. However, substance P has also been shown to stimulate cell growth, including 
proliferation of bone marrow cells, lymphocytes and endothelial cells, and to promote 
angiogenesis [339]. The MSC2 mares received the second injection two weeks before 
being ovariectomized, raising the possibility that TAC1 was upregulated in MSC2 in 
response to the trauma of injection; however, the MSC2opp ovary had not been injected 
and TAC1 was equally upregulated in the MSC2opp vs the Vopp ovaries. Additionally, 
one of the V mares, to which the MSC2 ovaries were compared, had undergone a TVA 
in which both ovaries were subjected to ovarian puncture 4 weeks before the 
ovariectomy with similar ovarian trauma as for the mares receiving MSCs. Treatment 
with DMSO has been shown to decrease levels of substance P [340]. Thus, it appears 
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that this notable increase in TAC1 is acutely associated with the injection of MSCs, and 
that is a systemic effect, as it was seen in both the injected and non-injected ovary.  
 Another remarkable finding in MSC2 mares was that one of the 20 most 
differentially-expressed genes, CRADD, which was significantly downregulated in 
MSC2 compared to MSC1, encodes a protein containing a death domain motif which 
recruits caspase 2/ICH1 to the cell death signal transduction complex to promote 
apoptosis. This suggests an acute anti-apoptotic effect of MSC injection. Some of the 
genes that were upregulated, including SIGLEC1, PLD4, LAT2, CD300LB, and CD86 
encode products involved in immunomodulation. In general, there was a pronounced 
difference in the acute and long-term effects of MSC injection, as ovaries that had been 
injected 2 weeks prior to ovariectomy had upregulation of genes involved in immune 
responses, and downregulation of genes involved in apoptosis, in comparison to ovaries 
that had been injected 14 to 19 weeks before ovariectomy.  
 As mentioned above, RASSF9 was upregulated in MSC1 ovaries compared to 
both V and MSC2, suggesting that upregulation of this gene in MSC1 is an effect of 
MSCs. However, it is not clear why RASSF9 was upregulated only in MSC1 and not 
acutely, in MSC2 ovaries. 
  In rat and mouse ovaries damaged by chemotherapy, injection of MSCs 
increases the expression of factors known to affect ovarian function, including Vegf, Hgf, 
Igf1 and Star, and these changes are associated with an increase in ovarian activity and 
fecundity [10, 11]. However, in the present study, changes in the expression of these 
genes was not seen after MSC injection, and MSC injection was not associated with 
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increases in follicle numbers in old or young mares (results presented in Chapter VII). It 
is possible that rodent ovaries react differently to MSCs than do equine ovaries, or that 
MSCs have a different effect on chemotherapy-treated ovaries than in aged ovaries. This 
latter may be related to the finding that it is necessary to induce prior injury to tissues to 
clear the target tissue’s cell niches in order to enable engraftment of donor stem cells 
[341]. It is possible that chemotherapy causes injury to the ovarian tissue that allows 
MSC engraftment in functional niches, whereas injection of MSCs in an intact aged 
ovary does not support MSC engraftment. Thus, it is tempting to speculate that MSCs 
would improve ovarian function in chemotherapy-damaged ovaries but not in aging 
ovaries.  Additional studies are needed to investigate this. 
 In the present study, the vehicle used to inject the cells (DMSO) has been shown 
to have direct effects on gene regulation [319, 340]. A vehicle control was included for 
the MSC1 group, but not for the MSC2 group. The possible contribution of the DMSO 
confounds the interpretation of the data. In future studies, use of non-frozen MSCs, or 
MSCs rinsed to remove DMSO prior to injection, would minimize any potential effect of 
DMSO. In the present study, with the exception of TAC1 in the MSC2 and MSC2opp 
ovaries, there did not appear to be a systemic effect of MSC injection, as the gene 
expression in the contralateral non-injected ovaries was different than the gene 
expression in the injected ovaries. There seemed to be a difference in the acute and long-
term effects of MSCs, as ovaries that had been injected 2 weeks prior to ovariectomy 
had upregulation of genes involved in immune responses, and downregulation of genes 
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involved in apoptosis, in comparison to ovaries that had been injected 14 to 19 weeks 
prior to ovariectomy. 
 In conclusion, in contrast to the effects seen in rats, mice, and rabbits with 
chemotherapy-damaged ovaries, intra-ovarian injection of MSCs in old mares did not 
regulate the same subset of genes known to be involved in the improvement of ovarian 
function. Further research is needed to explore the potential of MSC injection on 
improving ovarian function in aged mares.   
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CHAPTER IX 
CONCLUSIONS 
 
 The research presented in this dissertation examined the effects of MSCs on 
equine ovarian function and gene expression. In a preliminary study there was an 
apparent increase in follicle numbers four weeks after MSC injection in 2 young mares. 
However, in a more comprehensive study that included both old and young mares there 
were no increases in follicle numbers. One possible explanation for the different results 
obtained between these 2 studies is that the mares in the preliminary study received 2 
MSC injections (one in each ovary), i.e., in total they received twice the number of cells 
as the old or young mares in the subsequent study. Another possible explanation is that 
the source of the MSCs used in the preliminary study and in the main study differed; it is 
possible that some categories of horses, or some individual donors, elicit changes in 
follicle numbers while MSCs from other donors do not.  
 Intra-ovarian injection of MSCs in old mares did not increase the expression of 
factors known to improve ovarian function, in contrast to what has been reported in 
rodent studies, which indicate that the systemic of intra-ovarian injection of MSCs in 
females with chemotherapy-damaged ovaries induces expression of mRNA and proteins 
that may improve ovarian function. It is possible that rodent ovaries react differently to 
MSC injection than do equine ovaries, or that MSC injection improves ovarian function 
after chemotherapy-induced damage, perhaps due to clearance of a cellular niche which 
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the injected MSCs can occupy, but not  in females experiencing ovarian failure 
associated with aging.  
 We evaluated the use of fluorescent QDs to label equine MSCs. Although QDs 
did not interfere with the proliferation and differentiation capacity of MSCs, QDs did not 
appear to be an effective method to track and label MSCs long-term. We also determined 
that when recording MSC viability, it is best to do so within 60 min post-thaw; 
alternatively, the cells can be rinsed to remove DMSO and held on ice for up to 120 min 
without an effect on viability. Although the co-culture system we utilized has been used 
successfully with other tissues, this system was not effective when equine ovarian tissue 
was co-cultured with MSCs. Nonetheless, this study had value in determining methods 
for isolation of RNA from ovarian tissue which was problematic due to the fibrous 
nature of the equine ovary interfering with lysis by enzymatic digestion.  
 Further research is needed to study alternative methods to label and track MSCs, 
to determine if different co-culture systems would support co-culture of equine ovarian 
explants, and to better understand the mechanism of action of MSCs on follicular 
populations and ovarian gene expression in mares.  
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APPENDIX  
Table A-1 Percent MSC viability for each treatment group. 
 
  Immediately 15 min   30 min 45 min 60 min 120 min 
DMSO 83.0 ± 3.99 81.2 ± 4.19 77.7 ± 5.18 75.3 ± 4.46 71.8 ± 4.34 46.9 ± 7.48 
Rinse 79.4 ± 3.39 79.0 ± 2.94 76.5 ± 2.90 76.4 ± 3.55 73.1 ± 2.94 69.5 ± 5.52 
Dil1 83.0 ± 5.04 79.9 ± 3.17 81.1 ± 4.57 79.2 ± 4.53 75.9 ± 3.31 71.7 ± 4.20 
Dil2 81.8 ± 4.18 81.5 ± 3.20 76.9 ± 2.48 80.0 ± 3.06 75.5 ± 2.95 65.4 ± 7.95 
 
Values represent the mean ± SE for six independent replicates with cells from a different 
horse used for each replicate. 
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Table A-2 Differentially expressed genes identified by DESeq2 in ovaries injected 
once with MSCs (MSC1) compared to ovaries injected once with Vehicle (V).  
 
ID log2FC P-value Gene Description 
Acvr1c 1.26 1.20E-02 activin A receptor type 1C 
Adcy1 -1.17 9.33E-03 adenylate cyclase 1 
Akr1d1 1.02 3.66E-02 aldo-keto reductase family 1 member D1 
Angptl7 1.00 4.41E-02 angiopoietin like 7 
Asb15 -1.48 3.42E-03 ankyrin repeat and SOCS box containing 15 
Asgr1 -1.10 2.96E-02 asialoglycoprotein receptor 1 
C21orf62 1.03 3.18E-02 chromosome 21 open reading frame 62 
C6orf163 -1.04 3.56E-02 chromosome 6 open reading frame 163 
Camsap3 -1.06 3.56E-02 calmodulin regulated spectrin associated protein family member 3 
Ccdc102b 1.23 1.28E-02 coiled-coil domain containing 102B 
Ccr3 -1.04 3.95E-02 C-C motif chemokine receptor 3 
Cish -1.43 3.03E-03 cytokine inducible SH2 containing protein 
Cntn5 1.40 2.55E-03 contactin 5 
Cntnap5 1.05 3.82E-02 contactin associated protein like 5 
Ct83 -1.00 4.74E-02 cancer/testis antigen 83 
Ctnnd2 1.09 2.88E-02 catenin delta 2 
Dcst2 1.42 4.59E-03 DC-STAMP domain containing 2 
Depdc4 1.04 3.76E-02 DEP domain containing 4 
Dll3 -1.06 3.52E-02 delta like canonical Notch ligand 3 
Dpep2 -1.22 1.34E-02 dipeptidase 2 
Ensecag00000000093 1.05 3.56E-02  
Ensecag00000000422 1.07 1.74E-02  
Ensecag00000000778 -1.04 3.80E-02  
Ensecag00000001271 -1.30 1.02E-02  
Ensecag00000001947 1.07 3.07E-02  
Ensecag00000002196 -1.06 3.35E-02  
Ensecag00000003457 -1.25 1.06E-02  
Ensecag00000003763 1.25 1.09E-02  
Ensecag00000004041 1.34 7.63E-03  
Ensecag00000004103 1.16 1.09E-02  
Ensecag00000004574 1.16 2.14E-02  
Ensecag00000005577 1.14 2.38E-02  
Ensecag00000006200 1.14 2.09E-02  
Ensecag00000006631 -1.26 1.01E-03  
Ensecag00000007937 -1.59 3.81E-04  
Ensecag00000008828 1.26 8.62E-03  
Ensecag00000011121 1.17 1.99E-02  
Ensecag00000011772 1.42 3.92E-03  
Ensecag00000012375 1.21 1.69E-02  
Ensecag00000012909 -1.39 6.19E-03  
Ensecag00000014202 1.50 2.45E-03  
Ensecag00000014719 1.03 3.60E-02  
Ensecag00000015570 1.01 4.02E-02  
Ensecag00000016810 -1.47 3.75E-03  
Ensecag00000018574 -1.38 6.01E-03  
Ensecag00000018854 -1.24 5.62E-03  
Ensecag00000019820 1.00 4.63E-02  
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Table A-2 continued 
 
ID log2FC P-value Gene Description 
Ensecag00000022656 1.15 2.28E-02  
Ensecag00000022921 -1.03 2.84E-02  
Ensecag00000023091 1.49 2.68E-03  
Ensecag00000024042 1.06 3.42E-02  
Ensecag00000024765 1.34 2.37E-03  
Ensecag00000026593 1.01 4.52E-02  
Ensecag00000027051 1.06 2.96E-02  
Ensecag00000027178 1.02 4.00E-02  
Eps8l3 1.26 6.71E-03 EPS8 like 3 
Erbb4 1.34 7.10E-03 erb-b2 receptor tyrosine kinase 4 
Grm5 1.04 3.67E-02 glutamate metabotropic receptor 5 
Hand2 1.05 3.35E-02 heart and neural crest derivatives expressed 2 
Hist1h2bn 1.10 1.91E-02 histone cluster 1 H2B family member n 
Hist2h2be -1.21 2.53E-03 histone cluster 2 H2B family member e 
Il33 1.25 1.16E-02 interleukin 33 
Ilt11b 1.00 3.55E-02  
Kcnk2 1.05 3.85E-02 potassium two pore domain channel subfamily K member 2 
Kctd19 -1.09 3.23E-02 potassium channel tetramerization domain containing 19 
Krt14 -1.76 5.80E-05 keratin 14 
Krt17 -1.68 2.47E-04 keratin 17 
Krt5 -1.55 5.70E-05 keratin 5 
Lrrtm2 1.19 1.29E-02 leucine rich repeat transmembrane neuronal 2 
Lyg1 1.10 2.88E-02 lysozyme g1 
Msln 1.37 6.76E-03 mesothelin 
Myhc-Alpha -1.33 8.11E-03  
Nalcn 1.01 2.45E-02 sodium leak channel, non-selective 
Nmnat2 -1.02 4.16E-02 nicotinamide nucleotide adenylyltransferase 2 
Notum -1.00 4.58E-02 NOTUM, palmitoleoyl-protein carboxylesterase 
Nr1h4 1.06 1.59E-02 nuclear receptor subfamily 1 group H member 4 
P2rx6 -1.10 3.07E-02 purinergic receptor P2X 6 
Pigr -1.04 3.27E-02 polymeric immunoglobulin receptor 
Prame -1.09 2.86E-02 preferentially expressed antigen in melanoma 
Prlr -1.57 1.72E-03 prolactin receptor 
Prr16 1.07 3.19E-02 proline rich 16 
Rassf9 1.07 4.98E-03 Ras association domain family member 9 
Rnf17 -1.41 5.39E-03 ring finger protein 17 
Scnn1g -1.09 3.02E-02 sodium channel epithelial 1 gamma subunit 
Scrg1 1.02 4.28E-02 stimulator of chondrogenesis 1 
Sema3e 1.10 3.00E-02 semaphorin 3E 
Slc1a2 1.03 4.06E-02 solute carrier family 1 member 2 
Slc44a5 1.07 3.48E-02 solute carrier family 44 member 5 
Slc4a9 1.32 7.66E-03 solute carrier family 4 member 9 
Snord41 -1.27 1.26E-02 small nucleolar RNA, C/D box 41 
Tlr1 1.09 1.14E-02 toll like receptor 1 
Tsga10 1.10 2.24E-03 testis specific 10 
Wdr87 1.02 4.22E-02 WD repeat domain 87 
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Table A-3 Differentially expressed genes identified by DESeq2 in MSC1opp ovaries 
versus Vopp ovaries.  
 
ID log2FC P-value Gene Description 
7sk 1.05 2.17E-02  
Abcg5 1.12 2.58E-02 ATP binding cassette subfamily G member 5 
Acp5 1.21 1.67E-02 acid phosphatase 5, tartrate resistant 
Adad1 1.30 6.27E-03 adenosine deaminase domain containing 1 
Adamts9 -1.02 3.87E-02 ADAM metallopeptidase with thrombospondin type 1 motif 9 
Adcy1 -1.28 4.29E-03 adenylate cyclase 1 
Ankrd34b 1.03 4.10E-02 ankyrin repeat domain 34B 
Ankrd55 -1.20 1.81E-02 ankyrin repeat domain 55 
Anln -1.17 1.91E-02 anillin actin binding protein 
Ano9 -1.52 2.42E-03 anoctamin 9 
Ap1m2 -1.02 1.28E-02 adaptor related protein complex 1 mu 2 subunit 
Aqp5 -1.03 3.99E-02 aquaporin 5 
Arid5a 1.29 9.87E-03 AT-rich interaction domain 5A 
Armc3 -1.20 1.19E-02 armadillo repeat containing 3 
Asb11 1.12 2.03E-02 ankyrin repeat and SOCS box containing 11 
Asgr2 -1.10 3.04E-02 asialoglycoprotein receptor 2 
Atp13a4 -1.26 4.81E-03 ATPase 13A4 
Atp13a5 -1.15 3.33E-03 ATPase 13A5 
Atp2c2 -1.37 6.64E-03 ATPase secretory pathway Ca2+ transporting 2 
Bmp7 -1.52 2.11E-03 bone morphogenetic protein 7 
Bnc1 -1.15 1.31E-03 basonuclin 1 
Bub1 -1.01 4.20E-02 BUB1 mitotic checkpoint serine/threonine kinase 
Bub1b -1.15 2.26E-02 BUB1 mitotic checkpoint serine/threonine kinase B 
C17orf72 -1.39 6.13E-03 chromosome 18 open reading frame 63 
C18orf63 -1.00 2.85E-02 chromosome 22 open reading frame 31 
C22orf31 -1.48 2.24E-03 chromosome 2 open reading frame 54 
C2orf54 -1.43 1.85E-03 chromosome 4 open reading frame 22 
C4orf22 -1.15 1.49E-02 chromosome 6 open reading frame 118 
C6orf118 -1.50 1.03E-03 calcium dependent secretion activator 
C9orf9 -1.54 2.02E-03 calmodulin regulated spectrin associated protein family member 3 
Cadps -1.07 3.40E-02 coiled-coil domain containing 113 
Camsap3 -1.49 3.37E-03 coiled-coil domain containing 116 
Ccdc113 -1.14 1.78E-02 cyclin B2 
Ccdc116 1.02 2.30E-02 cyclin B3 
Ccnb2 -1.27 1.13E-02 CD36 molecule 
Ccnb3 -1.45 3.51E-03 CD8b molecule 
Cd36 1.29 8.92E-03 cell division cycle 20 
Cd8b 1.18 1.93E-02 cell division cycle associated 5 
Cdc20 -1.02 2.72E-02 cadherin 1 
Cdca5 -1.16 2.24E-02 cadherin related family member 2 
Cdh1 -1.41 3.38E-03 cadherin related family member 4 
Cdhr2 -1.39 4.98E-03 cyclin dependent kinase inhibitor 3 
Cdhr4 -1.02 4.31E-02 centromere protein F 
Cdkn3 -1.07 3.17E-02 centrosomal protein 55 
 224 
 
Table A-3 continued 
 
ID log2FC P-value Gene Description 
Cenpf -1.13 2.55E-02 choline dehydrogenase 
Cep55 -1.13 2.49E-02 cartilage intermediate layer protein 
Chdh -1.01 3.12E-02 Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 1 
Cilp -1.73 4.62E-04 cytoskeleton associated protein 2 
Cited1 -2.09 1.38E-05 claudin 2 
Ckap2 -1.02 3.91E-02 claudin 7 
Cldn2 -1.26 1.22E-02 contactin 2 
Cldn7 -1.62 1.32E-03 contactin 4 
Cntn2 -1.31 9.01E-03 collagen type I alpha 1 chain 
Cntn4 -1.05 3.66E-02 collagen type XXI alpha 1 chain 
Col1a1 -1.09 3.20E-02 collagen type III alpha 1 chain 
Col21a1 -1.07 1.23E-02 collagen type VI alpha 6 chain 
Col3a1 -1.00 4.51E-02 copine 7 
Col6a6 -1.50 3.11E-03 chondroitin sulfate proteoglycan 5 
Cpne7 1.01 3.95E-02 C-X3-C motif chemokine receptor 1 
Cspg5 -1.22 9.46E-03 coxsackie virus and adenovirus receptor 
Cx3cr1 -1.05 2.68E-02 cytochrome P450 family 17 subfamily A member 1 
Cxadr -1.03 3.52E-02 dynein assembly factor with WD repeats 1 
Cyp17a1 -1.50 2.30E-03 DEP domain containing 4 
Daw1 -1.56 1.07E-03 dickkopf WNT signaling pathway inhibitor 2 
Depdc4 1.18 1.81E-02 dynein axonemal heavy chain 6 
Dkk2 -1.41 4.77E-03 dynein axonemal intermediate chain 1 
Dnah6 -1.80 6.54E-05 dipeptidyl peptidase 4 
Dnai1 -1.45 4.37E-03 desmocollin 1 
Dpp4 -1.32 9.54E-03 desmoplakin 
Dsc1 -1.16 1.44E-02 dual oxidase 1 
Dsp -1.48 3.31E-03 dual oxidase maturation factor 1 
Duox1 -1.15 2.09E-02 E2F transcription factor 1 
Duoxa1 -1.22 9.52E-03 ATP binding cassette subfamily G member 5 
E2f1 -1.05 3.60E-02 acid phosphatase 5, tartrate resistant 
Eca-Mir-492-1 -1.84 1.87E-04  
Ehf -1.35 5.20E-03 ETS homologous factor 
Elovl3 -1.24 6.73E-03 ELOVL fatty acid elongase 3 
Ensecag00000000778 -1.15 2.15E-02  
Ensecag00000000799 -1.11 2.95E-02  
Ensecag00000000929 -1.35 7.80E-03  
Ensecag00000001091 1.05 3.49E-02  
Ensecag00000001271 -1.42 5.01E-03  
Ensecag00000001639 -1.26 1.28E-02  
Ensecag00000002139 -1.18 1.95E-02  
Ensecag00000002196 1.09 2.81E-02  
Ensecag00000002402 -1.28 1.05E-02  
Ensecag00000004041 1.52 2.47E-03  
Ensecag00000004126 -1.26 7.35E-03  
Ensecag00000004696 -1.47 1.12E-03  
Ensecag00000005122 -1.14 7.96E-03  
Ensecag00000006099 -1.05 3.11E-02  
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Table A-3 continued 
    
ID log2FC P-value Gene Description 
Ensecag00000006291 -1.37 5.77E-03  
Ensecag00000006785 1.06 1.91E-02  
Ensecag00000006816 -1.58 1.39E-03  
Ensecag00000007832 -1.01 2.31E-02  
Ensecag00000008432 -1.02 3.69E-02  
Ensecag00000008785 -1.14 2.14E-02  
Ensecag00000009152 -1.68 6.31E-04  
Ensecag00000010934 1.28 9.75E-03  
Ensecag00000011121 1.21 1.57E-02  
Ensecag00000011256 -1.05 2.47E-02  
Ensecag00000011685 -1.05 3.29E-02  
Ensecag00000012503 -1.54 3.11E-04  
Ensecag00000013193 -1.02 4.31E-02  
Ensecag00000014165 1.03 1.50E-02  
Ensecag00000015137 -1.08 2.94E-02  
Ensecag00000016395 1.03 3.57E-02  
Ensecag00000016799 1.07 1.27E-02  
Ensecag00000016992 -1.25 6.50E-03  
Ensecag00000017155 -1.70 7.83E-04  
Ensecag00000018391 1.10 2.58E-02  
Ensecag00000018753 -1.23 1.49E-02  
Ensecag00000019052 1.28 1.07E-02  
Ensecag00000020268 -1.19 1.90E-02  
Ensecag00000020734 -1.21 9.99E-04  
Ensecag00000020802 1.26 1.16E-02  
Ensecag00000021531 -1.39 2.96E-03  
Ensecag00000021775 -1.24 1.28E-02  
Ensecag00000021806 1.11 2.30E-02  
Ensecag00000022318 -1.03 1.57E-02  
Ensecag00000022324 -1.34 2.26E-03  
Ensecag00000022656 1.14 2.31E-02  
Ensecag00000022921 -1.00 2.72E-02  
Ensecag00000023653 1.87 1.16E-04  
Ensecag00000023710 -1.28 1.55E-03  
Ensecag00000024557 1.09 3.00E-02  
Ensecag00000026387 1.01 3.41E-02  
Ensecag00000026830 -1.11 2.92E-02  
Ensecag00000027051 1.24 1.18E-02  
Ensecag00000027105 1.15 1.05E-02  
Ensecag00000027132 1.05 3.53E-02  
Ensecag00000027336 1.61 1.25E-03  
Ensecag00000027466 1.09 2.32E-02  
Ensecag00000027547 2.78 1.28E-08  
Ensecag00000027634 1.23 9.95E-03  
Epha1 -1.18 1.79E-02 EPH receptor A1 
Epha8 -1.27 1.22E-02 EPH receptor A8 
Esrp1 -1.11 9.75E-03 epithelial splicing regulatory protein 1 
Esrp2 -1.03 1.15E-03 epithelial splicing regulatory protein 2 
Exo1 -1.10 2.46E-02 exonuclease 1 
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Table A-3 continued 
    
ID log2FC P-value Gene Description 
Fabp7 1.10 1.37E-02 fatty acid binding protein 7 
Fads3 -1.18 1.79E-02 fatty acid desaturase 3 
Faim3 1.16 2.17E-02 family with sequence similarity 216 member B 
Fam216b -1.26 2.11E-03 family with sequence similarity 92 member B 
Fam92b -1.49 2.72E-03 fatty acyl-CoA reductase 2 
Far2 -1.16 2.08E-02 FAT atypical cadherin 2 
Fat2 -1.33 7.10E-03 F-box protein 47 
Fbxo47 -1.65 1.11E-03 Fc fragment of IgM receptor 
Fgf5 -1.12 1.76E-02 fibroblast growth factor 5 
Fgl1 1.10 1.96E-02 fibrinogen like 1 
Fibin 1.05 1.97E-02 fin bud initiation factor homolog (zebrafish) 
Foxc2 1.19 1.30E-02 forkhead box C2 
Foxj1 -1.17 2.14E-02 forkhead box J1 
Foxm1 -1.02 3.92E-02 forkhead box M1 
Fst -1.10 3.01E-02 follistatin 
Fstl4 -1.20 1.76E-02 follistatin like 4 
Ftcd -1.10 2.96E-02 formimidoyltransferase cyclodeaminase 
Fxyd2 -1.21 1.73E-02 FXYD domain containing ion transport regulator 2 
Gabrp -1.05 1.15E-02 gamma-aminobutyric acid type A receptor pi subunit 
Gcnt3 -1.13 1.83E-02 glucosaminyl (N-acetyl) transferase 3, mucin type 
Gdap1l1 -1.23 1.34E-02 ganglioside induced differentiation associated protein 1 like 1 
Ggt1 -1.17 1.98E-02 gamma-glutamyltransferase 1 
Gpr84 1.04 3.40E-02 G protein-coupled receptor 84 
Grhl2 -1.32 1.63E-03 grainyhead like transcription factor 2 
Grin3a -1.06 3.27E-02 glutamate ionotropic receptor NMDA type subunit 3A 
Gzmh 1.41 2.82E-03 granzyme H 
Hjurp -1.04 3.03E-02 Holliday junction recognition protein 
Hmmr -1.12 2.66E-02 hyaluronan mediated motility receptor 
Hpn -1.30 8.96E-03 hepsin 
Hsf4 1.11 1.84E-02 heat shock transcription factor 4 
Hspa6 1.35 7.53E-03 heat shock protein family A (Hsp70) member 6 
Htr1e -1.45 3.12E-03 5-hydroxytryptamine receptor 1E 
Igj -1.07 2.79E-02 interleukin 22 receptor subunit alpha 1 
Il22ra1 -1.31 1.02E-02 interleukin 22 receptor subunit alpha 2 
Il22ra2 1.28 1.01E-02 interleukin 2 receptor subunit gamma 
Il2rg 1.03 3.84E-03 interleukin 33 
Il33 1.02 3.97E-02 inhibin alpha subunit 
Inha -1.34 8.41E-03 inhibin beta B subunit 
Inhbb -1.14 2.10E-02 insulin like 3 
Insl3 -1.65 1.72E-04 inter-alpha-trypsin inhibitor heavy chain 2 
Itih2 -1.12 1.24E-02 inter-alpha-trypsin inhibitor heavy chain family member 4 
Itih4 1.14 2.19E-02 joining chain of multimeric IgA and IgM 
Kiaa0101 -1.28 7.78E-03 kinesin family member 11 
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Table A-3 continued 
    
ID log2FC P-value Gene Description 
Kif11 -1.12 2.46E-02 kinesin family member 20A 
Kif20a -1.14 2.21E-02 keratin 77 
Krt77 -1.02 1.72E-02 laminin subunit gamma 2 
Lamc2 -1.46 1.37E-03 leucine rich repeat LGI family member 4 
Lgi4 1.07 2.84E-02 lysophosphatidic acid receptor 3 
Lpar3 -1.28 6.68E-03 LDL receptor related protein 8 
Lrp8 -1.02 3.15E-02 leucine rich repeat containing 43 
Lrrc43 -1.20 1.56E-02 leucine rich repeat containing 56 
Lrrc56 -1.26 1.29E-02 leucine rich repeat neuronal 4 
Lrrn4 -1.74 4.25E-04 lymphotoxin beta 
Ltb 1.13 5.70E-03 MACRO domain containing 1 
Macrod1 1.03 1.15E-02 mediator complex subunit 12 like 
Med12l -1.06 1.21E-02 methyltransferase like 11B 
Mettl11b -1.27 4.33E-03 EPH receptor A1 
Mhc-1 -1.03 4.01E-02  
Mip-2beta 1.01 4.60E-02  
Mis18a -1.02 4.36E-02 MIS18 kinetochore protein A 
Mmp7 -1.90 4.47E-05 matrix metallopeptidase 7 
Mpo 1.12 1.29E-02 myeloperoxidase 
Ms4a1 1.29 1.01E-02 membrane spanning 4-domains A1 
Muc16 -1.55 2.37E-04 mucin 16, cell surface associated 
Muc20 -1.02 1.06E-02 mucin 20, cell surface associated 
Muc4 -1.53 8.22E-04 mucin 4, cell surface associated 
Muc5b 1.08 3.19E-02 mucin 5B, oligomeric mucus/gel-forming 
Mybphl 1.21 3.75E-03 myosin binding protein H like 
Myhc-Alpha -1.67 8.89E-04  
Myoc 1.08 3.37E-02 myocilin 
Myt1l -1.20 1.75E-02 myelin transcription factor 1 like 
Napsa 1.01 4.16E-02 napsin A aspartic peptidase 
Nefh -1.11 2.33E-02 neurofilament heavy 
Nov 1.09 3.05E-02 nephroblastoma overexpressed 
Nr0b2 -1.18 2.03E-02 nuclear receptor subfamily 0 group B member 2 
Nrcam -1.03 3.50E-02 neuronal cell adhesion molecule 
Oprk1 -1.33 6.76E-04 opioid receptor kappa 1 
Paqr5 -1.35 7.44E-03 progestin and adipoQ receptor family member 5 
Pax8 -1.07 1.27E-02 paired box 8 
Pde4c 1.12 1.47E-02 PCNA clamp associated factor 
Pi16 1.05 3.66E-02 phosphodiesterase 4C 
Pigr -1.65 7.58E-04 peptidase inhibitor 16 
Pinlyp -1.04 3.08E-02 polymeric immunoglobulin receptor 
Pkmyt1 -1.04 1.86E-02 phospholipase A2 inhibitor and LY6/PLAUR domain containing 
Pkp3 -1.01 1.04E-02 protein kinase, membrane associated tyrosine/threonine 1 
Ppp1r1b -1.39 5.52E-03 plakophilin 3 
Prc1 -1.06 3.48E-02 protein phosphatase 1 regulatory inhibitor subunit 1B 
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ID log2FC P-value Gene Description 
Prkg2 1.26 1.00E-02 protein regulator of cytokinesis 1 
Prkrir -1.30 1.04E-03 protein kinase, cGMP-dependent, type II 
Prlr -1.60 1.46E-03 prolactin receptor 
Prom2 -1.16 7.44E-03 prominin 2 
Prr11 -1.10 2.80E-02 proline rich 11 
Prss54 -1.08 3.23E-02 proline rich 29 
Ptpn5 -1.75 2.91E-04 protease, serine 54 
Ptprq -1.16 1.95E-02 protein tyrosine phosphatase, non-receptor type 5 
Qpct -1.05 3.41E-02 protein tyrosine phosphatase, receptor type Q 
Rab25 -1.40 3.20E-03 glutaminyl-peptide cyclotransferase 
Rbm47 -1.35 7.46E-03 RAB25, member RAS oncogene family 
Rgs8 -1.03 4.26E-02 RNA binding motif protein 47 
Rgs9 -1.04 3.20E-02 regulator of G-protein signaling 8 
Rnase_MRP 1.47 2.96E-03  
Rnasep_Nuc 1.32 7.76E-03  
Rnf43 -1.40 5.72E-03 ring finger protein 43 
Ropn1l -1.12 2.51E-02 rhophilin associated tail protein 1 like 
S100a14 -1.24 1.40E-02 S100 calcium binding protein A14 
Scarna17 1.08 3.12E-02 small Cajal body-specific RNA 17 
Scarna2 1.35 1.99E-03 small Cajal body-specific RNA 2 
Scnn1g -1.01 4.47E-02 sodium channel epithelial 1 gamma subunit 
Serinc2 -1.68 9.80E-04 serine incorporator 2 
Slc13a2 -1.21 8.57E-03 solute carrier family 13 member 2 
Slc22a16 -1.23 4.65E-03 solute carrier family 22 member 16 
Slc2a2 -1.49 1.45E-03 solute carrier family 2 member 2 
Slc35g1 -1.33 8.39E-03 solute carrier family 35 member G1 
Slc4a4 -1.07 1.87E-02 solute carrier family 4 member 4 
Slc8a2 1.16 1.93E-02 solute carrier family 8 member A2 
Snora43 -1.19 9.46E-03 small nucleolar RNA, H/ACA box 17B 
Snord74 1.09 2.16E-02 small nucleolar RNA, C/D box 74 
Snou2-30 1.01 4.45E-02  
Sp6 -1.20 1.44E-02 Sp6 transcription factor 
Spint1 -1.20 1.70E-02 serine peptidase inhibitor, Kunitz type 1 
Spla2 -1.67 4.19E-04  
Spta1 -1.51 2.62E-03 spectrin alpha, erythrocytic 1 
Sptbn2 -1.19 2.74E-03 spectrin beta, non-erythrocytic 2 
St14 -1.38 4.30E-03 suppression of tumorigenicity 14 
Svopl -1.09 7.19E-03 SVOP like 
Syce1l 1.48 3.19E-03 synaptonemal complex central element protein 1 like 
Tepp 1.11 1.92E-02 testis, prostate and placenta expressed 
Thsd7b -1.06 3.40E-02 THAP domain containing 12 
Tmem200a -1.05 3.80E-02 thrombospondin type 1 domain containing 7B 
Tmem54 -1.05 3.04E-02 transmembrane protein 200A 
Tnc -1.44 2.98E-03 transmembrane protein 54 
Top2a -1.03 3.35E-02 tenascin C 
Ttc21a -1.29 2.75E-03 topoisomerase (DNA) II alpha 
Tubb2b -1.07 1.57E-02 tetratricopeptide repeat domain 21A 
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Table A-3 continued 
    
ID log2FC P-value Gene Description 
U6atac 1.25 1.22E-02  
Ubd 1.21 1.39E-02 ubiquitin D 
Unc45b -1.72 6.69E-04 unc-45 myosin chaperone B 
Upk1b -1.73 5.85E-05 uroplakin 1B 
Upk3b -1.46 2.53E-03 uroplakin 3B 
Vwa3a -1.14 1.96E-02 von Willebrand factor A domain containing 3A 
Vwa3b -1.39 6.02E-03 von Willebrand factor A domain containing 3B 
Wfdc2 -1.05 2.26E-02 WAP four-disulfide core domain 2 
Wwc1 -1.38 6.37E-03 WW and C2 domain containing 1 
Xg 1.03 2.47E-02 Xg blood group 
Zdhhc23 -1.09 1.98E-02 zinc finger DHHC-type containing 23 
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Table A-4 Differentially expressed genes identified by DESeq2 in ovaries injected 
twice with MSCs (MSC2) versus ovaries injected once with MSCs (MSC1).  
 
ID log2FC P-value Gene Description 
ABCD2 -1.57 1.92E-03 ATP binding cassette subfamily D member 2 
ACP5 1.37 6.46E-03 acid phosphatase 5, tartrate resistant 
ACSBG2 1.07 2.07E-02 acyl-CoA synthetase bubblegum family member 2 
ADCY1 1.15 7.05E-03 adenylate cyclase 1 
AGBL4 -1.03 2.28E-02 adhesion G protein-coupled receptor E3 
AIM2 1.03 3.38E-02 ATP/GTP binding protein like 4 
ALOX5 1.31 5.78E-03 absent in melanoma 2 
ASB15 1.22 1.65E-02 arachidonate 5-lipoxygenase 
ASGR1 1.24 1.49E-02 ankyrin repeat and SOCS box containing 15 
BATF 1.13 1.98E-02 asialoglycoprotein receptor 1 
BCL2A1 1.14 2.29E-02 basic leucine zipper ATF-like transcription factor 
BCL2L14 1.32 8.73E-03 BCL2 related protein A1 
BPIFC 1.26 9.18E-03 BCL2 like 14 
BRINP2 -1.04 3.15E-02 BPI fold containing family C 
BTBD16 -1.00 4.86E-02 BMP/retinoic acid inducible neural specific 2 
BTLA 1.15 2.19E-02 BTB domain containing 16 
C1QA 1.17 6.38E-03 B and T lymphocyte associated 
C1QB 1.20 7.23E-03 complement C1q A chain 
C1QC 1.34 3.39E-03 complement C1q B chain 
C21orf62 -1.41 2.52E-03 complement C1q C chain 
C3AR1 1.04 4.97E-03 chromosome 21 open reading frame 62 
C5AR1 1.08 1.04E-02 complement C3a receptor 1 
CA8 1.09 1.80E-02 complement C5a receptor 1 
CACNA1B 1.38 6.55E-03 carbonic anhydrase 8 
CASP1 1.20 1.87E-03 calcium voltage-gated channel subunit alpha1 B 
CAV3 -1.05 3.67E-02 caspase 1 
CCL2 1.03 4.33E-02 caveolin 3 
CCL20 1.08 1.15E-02 C-C motif chemokine ligand 2 
CCR3 1.44 4.50E-03 C-C motif chemokine ligand 20 
CD163 1.52 9.80E-04 C-C motif chemokine receptor 3 
CD163L1 1.03 3.91E-02 CD163 molecule 
CD180 1.49 3.45E-03 CD163 molecule like 1 
CD300LB 1.69 8.95E-04 CD180 molecule 
CD48 1.50 2.85E-03 CD300 molecule like family member b 
CD53 1.11 1.15E-02 CD48 molecule 
CD68 1.13 1.60E-02 CD53 molecule 
CD84 1.09 1.59E-02 CD68 molecule 
CD86 1.47 1.23E-03 CD84 molecule 
CEBPE 1.04 1.54E-02 CD86 molecule 
CECR1 1.31 5.84E-03 CCAAT/enhancer binding protein epsilon 
CHI3L1 1.32 5.69E-03 cat eye syndrome chromosome region, candidate 1 
CHRM3 -1.31 9.61E-03 chitinase 3 like 1 
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Table A-4 continued 
    
ID log2FC P-value Gene Description 
CLDN20 1.00 4.70E-02 cholinergic receptor muscarinic 3 
CLEC6A 1.47 3.55E-03 claudin 20 
CLEC7A 1.30 8.72E-03 C-type lectin domain family 6 member A 
CNTN5 -1.09 2.47E-02 C-type lectin domain family 7 member A 
CP 1.01 1.72E-02 contactin 5 
CRABP1 -1.08 3.05E-02 ceruloplasmin 
CRADD -1.05 1.30E-03 cellular retinoic acid binding protein 1 
CRHBP 1.51 2.88E-03 CASP2 and RIPK1 domain containing adaptor with death domain 
CSF1R 1.17 3.60E-03 corticotropin releasing hormone binding protein 
CTSS 1.01 1.73E-02 colony stimulating factor 1 receptor 
CX3CR1 1.04 2.15E-02 cathepsin S 
CXCL11 1.21 1.60E-02 C-X3-C motif chemokine receptor 1 
CXCL9 1.50 1.77E-03 C-X-C motif chemokine ligand 11 
CYBB 1.50 1.51E-03 C-X-C motif chemokine ligand 9 
CYTH4 1.22 2.70E-03 cytochrome b-245 beta chain 
DENND1C 1.10 3.62E-03 cytohesin 4 
DEPDC4 -1.01 4.76E-02 DENN domain containing 1C 
DPEP2 1.22 1.07E-02 DEP domain containing 4 
EEF1A2 1.03 3.03E-02 dipeptidase 2 
EIF4E1B 1.22 1.09E-02 eukaryotic translation elongation factor 1 alpha 2 
EMR3 1.37 6.64E-03  
ENSECAG00000000339 1.31 6.80E-03  
ENSECAG00000000422 -1.04 2.73E-02  
ENSECAG00000000649 -1.06 3.43E-02  
ENSECAG00000001489 -1.15 1.67E-02  
ENSECAG00000001649 1.61 6.69E-04  
ENSECAG00000003088 1.34 7.35E-03  
ENSECAG00000003180 1.07 2.69E-02  
ENSECAG00000003446 1.02 2.90E-02  
ENSECAG00000003447 1.22 1.55E-02  
ENSECAG00000003466 1.07 1.56E-02  
ENSECAG00000004548 -1.05 3.89E-02  
ENSECAG00000004863 1.46 3.96E-03  
ENSECAG00000005231 1.62 4.84E-04  
ENSECAG00000005400 1.02 4.26E-02  
ENSECAG00000005562 1.23 9.90E-03  
ENSECAG00000006200 -1.04 3.98E-02  
ENSECAG00000006663 1.52 3.19E-04  
ENSECAG00000006701 1.08 2.65E-02  
ENSECAG00000006708 -1.11 1.74E-02  
ENSECAG00000007937 1.35 3.86E-03  
ENSECAG00000007943 1.08 5.09E-03  
ENSECAG00000008615 1.43 3.11E-03  
ENSECAG00000009228 -1.10 4.67E-03  
ENSECAG00000009271 1.60 1.06E-03  
ENSECAG00000009404 1.29 8.76E-03  
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Table A-4 continued 
    
ID log2FC P-value Gene Description 
ENSECAG00000009816 1.13 2.23E-02  
ENSECAG00000009954 -1.18 1.60E-02  
ENSECAG00000010357 1.46 3.16E-03  
ENSECAG00000011121 -1.18 1.69E-02  
ENSECAG00000011772 -1.13 1.84E-02  
ENSECAG00000012199 1.30 3.13E-03  
ENSECAG00000012204 -1.32 5.62E-03  
ENSECAG00000012222 1.22 1.13E-02  
ENSECAG00000012909 1.42 4.63E-03  
ENSECAG00000013056 1.08 2.18E-02  
ENSECAG00000014250 1.26 1.22E-02  
ENSECAG00000014546 1.98 4.79E-08  
ENSECAG00000014585 1.20 1.00E-03  
ENSECAG00000015201 -1.30 8.84E-03  
ENSECAG00000015451 -1.08 3.32E-02  
ENSECAG00000015462 -1.09 1.92E-02  
ENSECAG00000016000 -1.05 1.85E-02  
ENSECAG00000016712 1.01 2.61E-02  
ENSECAG00000016970 1.95 1.13E-04  
ENSECAG00000017969 1.17 2.08E-02  
ENSECAG00000018516 1.44 2.95E-03  
ENSECAG00000018574 1.69 5.16E-04  
ENSECAG00000018848 -1.05 3.84E-02  
ENSECAG00000019100 1.18 1.80E-02  
ENSECAG00000019352 1.24 1.05E-02  
ENSECAG00000019488 1.13 1.58E-02  
ENSECAG00000020136 1.29 1.02E-02  
ENSECAG00000020640 1.23 1.50E-02  
ENSECAG00000020862 -1.21 1.47E-02  
ENSECAG00000021110 1.52 5.49E-05  
ENSECAG00000021202 1.74 3.10E-04  
ENSECAG00000021713 1.02 4.37E-02  
ENSECAG00000022087 1.01 4.45E-02  
ENSECAG00000022716 1.23 1.44E-02  
ENSECAG00000022781 -1.16 2.04E-02  
ENSECAG00000023091 -1.06 3.68E-02  
ENSECAG00000023126 1.04 3.29E-02  
ENSECAG00000023214 1.02 3.21E-02  
ENSECAG00000023307 -1.05 3.83E-02  
ENSECAG00000023653 -1.19 1.22E-02  
ENSECAG00000024765 -1.30 5.07E-03  
ENSECAG00000024790 1.16 1.35E-02  
ENSECAG00000024882 1.31 1.45E-03  
ENSECAG00000024996 1.04 4.09E-02  
ENSECAG00000025064 -1.13 1.99E-02  
EQMHCC1 -1.05 3.44E-02  
ETV7 1.44 2.59E-03 ETS variant 7 
FAT2 1.01 3.40E-02 FAT atypical cadherin 2 
FCER1G 1.28 4.18E-03 Fc fragment of IgE receptor Ig 
 233 
 
Table A-4 continued 
    
ID log2FC P-value Gene Description 
FLT3 1.07 2.38E-03 fms related tyrosine kinase 3 
FOXC2 -1.00 2.91E-02 forkhead box C2 
FTCDNL1 1.00 4.21E-02 formiminotransferase cyclodeaminase N-terminal like 
GALNTL6 -1.08 3.33E-02 polypeptide N-acetylgalactosaminyltransferase-like 6 
GBP6 1.05 2.74E-02 guanylate binding protein family member 6 
GFRA3 -1.20 7.32E-03 GDNF family receptor alpha 3 
GFRA4 1.07 3.07E-02 GDNF family receptor alpha 4 
GHSR 1.18 1.50E-02 growth hormone secretagogue receptor 
GPR141 1.02 9.22E-03 G protein-coupled receptor 141 
GPR151 1.22 1.19E-03 G protein-coupled receptor 151 
GPR31 1.45 8.08E-04 G protein-coupled receptor 31 
GPR65 1.22 4.68E-03 G protein-coupled receptor 65 
GRIA4 1.07 2.78E-02 glutamate ionotropic receptor AMPA type subunit 4 
HCK 1.20 1.41E-02 HCK proto-oncogene, Src family tyrosine kinase 
HCLS1 1.08 5.80E-03 hematopoietic cell-specific Lyn substrate 1 
HIST1H2BB -1.11 1.96E-02 histone cluster 1 H2B family member b 
HIST1H2BN -1.10 2.36E-02 histone cluster 1 H2B family member n 
HIST2H2BE 1.08 1.14E-02 histone cluster 2 H2B family member e 
HMGA1 1.48 2.55E-03 high mobility group AT-hook 1 
HNF4A 1.03 4.23E-02 hepatocyte nuclear factor 4 alpha 
HPSE 1.23 1.45E-02 heparanase 
HPSE2 -1.08 3.29E-02 heparanase 2 (inactive) 
HS6ST3 1.28 6.07E-03 heparan sulfate 6-O-sulfotransferase 3 
HSPA6 1.43 4.96E-03 heat shock protein family A (Hsp70) member 6 
IFI30 1.11 1.65E-03 IFI30, lysosomal thiol reductase 
IGF2BP2 1.29 8.41E-03 insulin like growth factor 2 mRNA binding protein 2 
IGFBPL1 1.30 9.66E-03 insulin like growth factor binding protein like 1 
IL10RA 1.19 5.67E-03 interleukin 10 receptor subunit alpha 
IL1A 1.10 2.99E-02 interleukin 1 alpha 
IL1RN 1.37 6.37E-03 interleukin 1 receptor antagonist 
IL2 -1.15 2.29E-02 interleukin 2 
IL27 1.16 2.21E-02 interleukin 27 
IL33 -1.33 5.83E-03 interleukin 33 
ILT11A 1.29 9.93E-03  
IRF5 1.20 2.61E-03 interferon regulatory factor 5 
IRF8 1.49 3.00E-04 interferon regulatory factor 8 
ISG20 1.32 7.63E-03 interferon stimulated exonuclease gene 20 
ITGAX 1.27 7.82E-03 integrin subunit alpha X 
ITGB2 1.19 3.08E-03 integrin subunit beta 2 
JPH2 -1.07 1.51E-02 junctophilin 2 
KCNMA1 -1.17 1.30E-02 potassium calcium-activated channel subfamily M alpha 1 
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Table A-4 continued 
    
ID log2FC P-value Gene Description 
KCTD19 1.33 7.56E-03 potassium channel tetramerization domain containing 19 
KISS1 -1.06 2.79E-02 KiSS-1 metastasis-suppressor 
KLC3 -1.18 1.87E-02 kinesin light chain 3 
KRT26 1.18 1.90E-02 keratin 26 
KYNU 1.00 3.58E-02 kynureninase 
LAT2 1.20 7.23E-04 linker for activation of T-cells family member 2 
LCP1 1.13 1.41E-02 lymphocyte cytosolic protein 1 
LGALS4 -1.80 4.12E-04 galectin 4 
LRRC10B -1.03 2.84E-02 leucine rich repeat containing 10B 
LTF 1.24 7.24E-03 lactotransferrin 
LY86 1.17 1.15E-02 lymphocyte antigen 86 
LY9 1.05 2.85E-02 lymphocyte antigen 9 
MCOLN2 1.02 4.31E-02 mucolipin 2 
MEOX2 -1.21 1.62E-02 mesenchyme homeobox 2 
MNDA 1.02 1.41E-02 myeloid cell nuclear differentiation antigen 
MPEG1 1.35 7.60E-03 macrophage expressed 1 
MPZ -1.09 3.13E-02 myelin protein zero 
MS4A7 1.80 4.52E-05 membrane spanning 4-domains A7 
MSLN -1.20 1.75E-02 mesothelin 
MUC2 1.51 2.80E-03 mucin 2, oligomeric mucus/gel-forming 
MUSK 1.07 3.57E-02 muscle associated receptor tyrosine kinase 
MX2 1.08 2.72E-02 MX dynamin like GTPase 2 
NAT16 1.07 3.53E-02 N-acetyltransferase 16 (putative) 
NCF4 1.35 1.72E-03 neutrophil cytosolic factor 4 
NCKAP1L 1.32 2.56E-03 NCK associated protein 1 like 
NFAM1 1.19 1.26E-02 NFAT activating protein with ITAM motif 1 
NUP210 1.10 4.86E-03 nucleoporin 210 
NXPE4 1.43 2.81E-03 neurexophilin and PC-esterase domain family member 4 
NYAP2 1.23 1.09E-02 neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 2 
OVOL1 1.08 2.85E-02 ovo like transcriptional repressor 1 
P2RX2 1.10 3.09E-02 purinergic receptor P2X 2 
P2RY12 1.38 4.52E-03 purinergic receptor P2Y12 
PDE6A 1.84 7.89E-05 phosphodiesterase 6A 
PIK3AP1 1.27 3.80E-03 phosphoinositide-3-kinase adaptor protein 1 
PLA2G2D 1.18 2.63E-03 phospholipase A2 group IID 
PLD4 1.48 6.53E-04 phospholipase D family member 4 
POU2AF1 1.44 3.54E-03 POU class 2 associating factor 1 
PPFIA2 -1.11 7.82E-03 PTPRF interacting protein alpha 2 
PPP1R3C -1.14 1.04E-02 protein phosphatase 1 regulatory subunit 3C 
RAC2 1.20 3.67E-03 
ras-related C3 botulinum toxin substrate 2 
(rho family, small GTP binding protein 
Rac2) 
RASGRP4 1.01 3.43E-02 RAS guanyl releasing protein 4 
RASSF9 -1.13 1.40E-03 Ras association domain family member 9 
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Table A-4 continued 
    
ID log2FC P-value Gene Description 
RBM44 -1.05 7.11E-03 RNA binding motif protein 44 
RGS1 1.14 1.57E-02 regulator of G-protein signaling 1 
RHBG 1.63 1.08E-03 Rh family B glycoprotein (gene/pseudogene) 
SBSPON -1.23 1.49E-02 somatomedin B and thrombospondin type 1 domain containing 
SELL 1.01 4.66E-02 selectin L 
SEMA3E -1.16 2.19E-02 semaphorin 3E 
SERPINB1 1.01 4.50E-02 serpin family B member 1 
SEZ6L2 1.06 3.20E-02 seizure related 6 homolog like 2 
SIGLEC1 1.38 6.34E-04 sialic acid binding Ig like lectin 1 
SLAMF6 1.06 3.42E-02 SLAM family member 6 
SLAMF7 1.58 1.32E-03 SLAM family member 7 
SLAMF8 1.13 1.61E-02 SLAM family member 8 
SLAMF9 2.01 6.82E-05 SLAM family member 9 
SLC46A2 1.09 1.08E-02 solute carrier family 46 member 2 
SLCO4C1 1.12 2.61E-02 solute carrier organic anion transporter family member 4C1 
SPI1/PU.1 1.15 1.09E-02  
SPNS3 1.29 3.97E-03 sphingolipid transporter 3 (putative) 
ST14 1.13 1.62E-02 suppression of tumorigenicity 14 
SYT17 -1.15 5.95E-03 synaptotagmin 17 
TAC1 4.36 7.79E-18 tachykinin precursor 1 
TFEC 1.40 5.95E-03 transcription factor EC 
THBS1 1.15 1.56E-02 thrombospondin 1 
TIGIT 1.08 3.25E-02 T-cell immunoreceptor with Ig and ITIM domains 
TLR2 1.28 5.25E-03 toll like receptor 2 
TLR7 1.30 3.43E-03 toll like receptor 7 
TLR8 1.03 4.07E-02 toll like receptor 8 
TMEM82 1.05 2.38E-02 transmembrane protein 82 
TNFSF15 1.04 4.10E-02 tumor necrosis factor superfamily member 15 
TNFSF8 1.23 8.12E-03 tumor necrosis factor superfamily member 8 
TNFSF9 1.02 3.54E-02 tumor necrosis factor superfamily member 9 
TREM2 1.44 4.01E-03 triggering receptor expressed on myeloid cells 2 
TRPM2 1.34 3.01E-03 transient receptor potential cation channel subfamily M member 2 
TYROBP 1.24 4.47E-03 TYRO protein tyrosine kinase binding protein 
U4 1.03 3.31E-02  
UCP2 1.13 1.02E-02 uncoupling protein 2 
VAV1 1.44 8.60E-04 vav guanine nucleotide exchange factor 1 
VDR 1.32 7.76E-03 vitamin D (1,25- dihydroxyvitamin D3) receptor 
XCR1 1.15 2.05E-02 X-C motif chemokine receptor 1 
XPNPEP2 -1.16 1.69E-02 X-prolyl aminopeptidase 2 
ZMAT4 -1.07 3.62E-02 zinc finger matrin-type 4 
 
